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!The new face of heart transplantation: the need of 
improving outcomes both after transplant and on 
the waiting list 
The aim of the Research Project of this Ph D is to improve the medical management after surgery 
for advanced heart failure, both after left ventricular assist devices (LVAD) implantation, and after 
heart transplantation in the long-term. Regarding heart transplantation (HTx), the Research Project 
is focused on diagnostics, classification, prevention and treatment of cardiac allograft vasculopathy 
(CAV), and on treatment of post-HTx cancers; the results are presented in the first part of this 
Thesis. 
Regarding LVAD, the main focus is on the role of transthoracic echocardiography in the 
management of patients with a continuous-flow, centrifugal, intrapericardial pump (HVAD, 
Heartware); this section is reported in the second part of this Thesis. 
 
 
 
Heart transplantation (HTx) is actually the best available therapy for end-stage heart failure 
patients. According to International Society of Heart and Lung Transplantation (ISHLT) Registry1, 
taking in account all heart transplants made in the U.S., survival rates are very good, with a 
reported 1-year survival of 85 %, and of 70 % at 5 years. Survival rates are similar also in Europe. 
Besides these beautiful data, the overall success of HTx is impaired by the dramatic drop in the 
number of donations in last years, particularly in Europe, and by several comorbidities still 
influencing the late outcome, that has remained unchanged in the last years. The most frequent 
cause of death long-term after HTx is graft failure, that can be related to cardiac allograft 
vasculopathy (CAV), rejection (both in the form of cellular-mediated rejection, CMR, or antibody-
mediated rejection, AMR, or a mixed form). Post-transplant malignancies are the second more 
common cause of death, followed by renal insufficiency, and infections. These and other 
comorbidities may arise as a consequence of long-term immunosuppression. The early causes of 
death are surgical-related mortality, acute cellular rejection and infections. In the following 
paragraphs the main aspects of the pathophysiology of these complications as well as their 
management will be described.  
Beside these problems after transplant, the profile of donor hearts has changed in the last ten 
years, both in Europe and in the U.S., with a decrease in the number of donations, leading to an 
increase of the waiting time in the HTx list, and to a higher rate of deterioration of the patients. In 
order to maintain an acceptable survival rate while waiting for a HTx, several medical and surgical 
options are actually used as “bridge” to HTX, like a widely use of a left ventricular assist device 
(LVAD), or percutaneous treatments of valvulopathies, especially of mitral regurgitation. Moreover, 
the quality of donors worsened in the last years, with a higher donor age and longer ischemic time. 
As can be easily understood, the overall success of a heart transplant program is related to the 
careful and strict selection of patients and to the experience of the clinicians in managing both 
post-transplant complications and the patient on the waiting list, through the use of left ventricular 
assist devices (LVAD). Thus, there is an actuarial need of improving outcomes both after heart 
transplantation, through facing long-term comorbidities, and on the waiting list. 
 
 
 
 
 
 
!PART ONE 
 
 
 
 
MAJOR CHALLENGES IN THE LONG-
TERM COMPLICATIONS IN HEART 
TRANSPLANT RECIPIENTS 
 
 
 
 
 
 
 
 
 
 
 
!Chapter 1.  
Background on long-term complications and on 
mTOR inhibitors 
 
1.1 Cardiac allograft vasculopathy (CAV): 
pathophysiology, the role of CMV and unsolved 
problems on diagnosis and prevention  
Pathophysiology 
Cardiac allograft vasculopathy is main graft-related cause of death after HTx. It is characterized by 
a diffuse intimal thickening, arising from the small vessels (microvasculopathy) and then spreading 
to the great vessels, leading to lumen narrowing without focal eccentric stenosis (Figure 1). For this 
reason, coronary angiography underestimates real CAV incidence, that has been reported as 10% 
at 1 year and 40-50% at 5 years from HTx, whereas real incidence is higher (80% at 5 years) . Not 
only progressive increase in intimal area in coronary arteries, but also complex phenomena of 
vessel remodelling (vessel shrinkage) seem also to contribute to progressive lumen loss, that can 
lead, especially in the long term, to pruning of distal vessels. Given the involvement of 
microvessels and the denervation of the transplanted heart, CAV is often asymptomatic. In a 
frequent scenario, CAV is found in asymptomatic patients; in some cases, asthenia or hypotension 
are the only symptoms. Most of myocardial infarctions are silent. In other cases, CAV leads to a 
chronic graft failure, that must be differentiated in clinical diagnosis from chronic rejection, 
especially AMR. 
CAD 
CAV 
•  Focal lesions 
•  Lipid core  
•  Lamina elastica disruption 
•  Inflammatory infiltrate 
•  Diffuse luminal narrowing 
•  Myointimal hyperplasia 
•  Intact lamina elastica 
•  Inflammatory infiltrate 
 
Figure 1. Main morphological differences between “native” coronary artery disease (CAD) and 
post-transplant vasculopathy (CAV) 
!Risk factors for CAV are both immunologic and non immunologic, as shown in the below Figure 2. 
Among the first ones, a key role is played by frequent rejection episodes (especially in the first 
years) and CMV infection, whereas among the second ones metabolic syndrome, diabetes, 
hypertriglyceridemia and hypercholesterolemia are the main triggers, especially late in the long 
term; the role of obesity is less certain. Often an interplay between the various factors coexists, 
leading to mixed scenarios, especially in the long term, characterized by both intimal thickening 
(more prevalent in the first years after HTx)  and focal stenosis (more frequent in the long term). 
All these factors can contribute to inflammation, endothelial damage and intimal hyperplasia, the 
main morphological features of CAV. 
 
 
 
Figure 2. Main pathophysiological mechanisms of CAV 
 
The role of CMV 
Given the high prevalence of Cytomegalovirus (CMV) positivity in the general population, CMV 
reactivation frequently occurs after HTx, favoured by immunosuppression. The risk of virus 
reactivation or infection is higher in positive recipients (R+), and in negative patients receiving the 
heart from positive subjects (CMV mismatch, R-/D+).  For this reason, the CMV serologic status of 
the donor and recipient is used to stratify the patient’s risk for developing a CMV infection. 
Prophylaxis is usually started within 24 to 48 hours after HT with valganciclovir. 
CMV infection can be completely asymptomatic, especially when viral load is low; when symptoms 
manifest, are influenza-like, with asthenia, fever, diarrhea (CMV disease); laboratory exams can 
show leukopenia and anemia. More severe clinical scenarios can manifest with organ involvement: 
hepatitis, gastroenteritis, pneumonia can occur. Beside the systemic symptoms and effects, CMV 
infection must be treated because it has an impact on graft function; it has been demonstrated that 
even subclinical low-grade CMV infection can be a trigger for endothelial damage, and thus for 
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!cardiac allograft vasculopathy (Figure 2). The impact of CMV on the graft appears to be mediated 
by the action of innate and adaptive immune systems, rather than by a direct viral cytotoxic effect 
in situ. It has been showed that the more aggressively CMV infection is treated and prophylaxed, 
the less amount of intimal hyperplasia develops. 
By using specific anti-CMV agents such as ganciclovir and valganciclovir, two strategies are 
recommended for prevention of CMV infection and disease: universal prophylaxis and preemptive 
therapy. While prophylaxis consists in the universal administration of the antiviral agent to all the 
patients at risk, in the pre-emptive strategy only patients who develop a “certain” threshold of 
subclinical infection receive treatment. Their rationales are different: prophylaxis almost abolishes 
viral replication during the first weeks/months after transplant, when the burden of 
immunosuppression is higher, thereby delaying the eventual appearance of the infection until a 
later phase of follow-up, by which time the immunosuppressive burden and risk of rejection should 
be lower. The pre-emptive strategy permits early low-grade viral replication in the belief that it may 
stimulate host’s own immune response against the virus and will reduce the needing of anti-CMV 
drugs. Disadvantages are: considerable cost, risk of late CMV disease and ganciclovir resistance 
for prophylactic therapy; requiring of good logistic organization for preemptive therapy. In addition 
to specific anti-viral drugs, immunosuppressive agents may also influence occurrence of CMV 
infection. Inhibitors of the mammalian target of rapamycin (mTOR), tested for prevention of acute 
rejection in solid organ transplant recipients, appear to have anti-CMV properties and to reduce 
CAV progression when started early after HTx6.  
 
Unsolved problems in diagnosis  
IVUS is the technique with the best diagnostic sensitivity, allowing the visualization of intimal 
thickening, the typical feature of CAV; however, due to the economical costs related to IVUS and to 
the limitation to its performance in case of severe stenosis on left descending artery, actually the 
widest technique used for diagnosis is coronary angiography. Given the use of iodate contrast 
agents, kidney function must be taken in account before deciding to perform an angiography; 
generally, a serum creatinine > 2.5 mg/dl or a GFR > 35 ml/kg/min are contraindications to 
coronary angiography. The most frequent finding is absence of stenosis at angiography and a 
diffuse intimal thickening at IVUS (see Fig. 3); however, especially years after HTx, a mixed 
scenario, with eccentric stenosis, similar to the ones typical of native atherosclerosis, can be found 
at angiography, especially in patients with metabolic syndrome. 
! 
Fig. 3 Typical feature of CAV: normal angiogram with progressive intimal thickening at IVUS , 
becoming more severe proceeding to distal vessels. 
Until some years ago, there was a lack of standardized classification system for CAV. Recently, 
ISHLT has pointed out a new classification system, taking in account even mild stenosis, in the 
believe that they could affect post-transplant outcome. The purposed classification system is 
reported in Table 1 below. However, it is not known if this system can predict cardiovascular 
prognosis, and it is not known if it can be useful when used both for assess for CAV diagnosis and 
CAV progression . 
suggested that moderate or severe proximal or mid-vessel
CAV at angiography (! 40% stenosis) predicted an overall
mortality rate of ! 50% at 2 years.
The initial description of angiographic CAV by Gao et
al6 coded anatomic abnormalities into type A, B1, B2, and
C lesions. Type A was discrete or tubular stenosis and
multiple stenoses in the proximal, middle, or distal segment
branches; type B1 was a proximal vessel maintaining nor-
mal diameter with abrupt onset of distal concentric narrow-
ing and obliteration; type B2 was a gradual transition from
the normal proximal vessel with tapering, concentric nar-
rowing progressively increasing in severity distally; and
type C was a diseased vessel, diffusely irregular that lost
small branches with terminations often non-tapered,
squared off, and ending abruptly (Figure 1). Many clinicians
used this anatomic coding for descriptive purposes, but it
did not have prognostic value.
The largest assessment of CAV by coronary angiography
was a multi-institutional study of 4637 postoperative angio-
grams at 39 centers from Costanzo and the Cardiac Trans-
plant Research Database (CTRD).7 CAV was categorized as
normal (n " 3821, 82%), mild (n " 574, 12%), moderate
(n " 181, 4%), or severe (n " 61, 1%). Mild CAV was
defined as left main (LM) # 50%, or primary vessel with
maximum lesion # 70%, or isolated single-branch stenosis
! 70%, or any branch stenosis # 70% (including diffuse
narrowing). Moderate CAV included LM 50% to 69%, or a
single primary vessel ! 70%, or isolated branch stenosis !
70% in branches of 2 systems. Severe CAV included LM!
70%, or ! 2 primary vessels ! 70%, or isolated branch
stenosis! 70% in all 3 systems. The term “primary vessels”
refers to the proximal or middle 33% of the left anterior
descending, left circumflex, and dominant or codominant
right coronary artery. “Branch vessels” refer to the diagonal
branches, obtuse marginal branches, or the distal 33% of a
primary vessel or any part of a non-dominant right coronary
artery.
The overall likelihood of death or retransplantation (as
result of CAV) at 5-year follow-up was 7%. In patients with
severe CAV, 50% experienced these end points. Therefore,
this CAV classification scheme appears to have prognostic
significance, and we hope that use of the ISHLT CAV
classification will allow for more refined prospective and
contemporary validation.
CAV has protean presentations. It can occur early after
heart transplant (# 1 to 2 years), and this is more likely to
represent an inflammatory vasculitis, with distinctly bad
outcomes.2 CAV may also present later (! 2 years) after
transplant and have an indolent course with relatively good
prognosis. Rapidly progressive or fulminant CAV, defined
as a lesion ! 70% within 1 year of a benign angiogram (#
30% previously) may occur after transplant and can portend
a poor prognosis. Thus, the speed of CAV development and
the time after transplant are the primary determinants of
adverse outcomes.8
Figure 1 Anatomic abnormalities in transplant coronary vascu-
lar disease.6 Type A lesion: discrete, tubular or multiple stenoses.
Type B1 lesion: abrupt onset with distal diffuse concentric nar-
rowing and obliterated vessels. Type B2 lesion: gradual, concentric
tapering with distal portion having some residual lumen. Type C
lesion: narrowed irregular distal branches with terminations that
are often non-tapered and squared off, ending abruptly.
Table 2 Recommended Nomenclature For Cardiac Allograft Vasculopathy
ISHLT CAV0 (Not significant): No detectable angiographic lesion
ISHLT CAV1 (Mild ): Angiographic left main (LM) #50%, or primary vessel with maximum lesion of #70%, or any branch
stenosis #70% (including diffuse narrowing) without allograft dysfunction
ISHLT CAV2 (Moderate): Angiographic LM #50%; a single primary vessel !70%, or isolated branch stenosis !70% in branches
of 2 systems, without allograft dysfunction
ISHLT CAV3 (Severe): Angiographic LM !50%, or two or more primary vessels !70% stenosis, or isolated branch stenosis !70%
in all 3 systems; or ISHLT CAV1 or CAV2 with allograft dysfunction (defined as LVEF "45% usually in the presence of regional
wall motion abnormalities) or evidence of significant restrictive physiology (which is common but not specific; see text for
definitions)
Definitions
a). A “Primary Vessel” denotes the proximal and Middle 33% of the left anterior descending artery, the left circumflex, the ramus
and the dominant or co-dominant right coronary artery with the posterior descending and posterolateral branches.
b). A “Secondary Branch Vessel” includes the distal 33% of the primary vessels or any segment within a large septal perforator,
diagonals and obtuse marginal branches or any portion of a non-dominant right coronary artery.
c). Restrictive cardiac allograft physiology is defined as symptomatic heart failure with echocardiographic E to A velocity ratio !2
(!1.5 in children), shortened isovolumetric relaxation time (#60 msec), shortened deceleration time (#150 msec), or
restrictive hemodynamic values (Right Atrial Pressure !12mmHg, Pulmonary Capillary Wedge Pressure !25 mmHg, Cardiac
Index #2 l/min/m2)
719Mehra et al. ISHLT Cardiac Allograft Vasculopathy Nomenclature
 
Table 1. ISHLT CAV Classification System 
 
The protocol of CAV assessment varies am ng different Centers and is typically constituted by an 
angiogr phy one year after HTx and then periodically, with a timeline different among the various 
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!Centers (usually every 2 -5 years). 
IVUS is the technique with the highest sensitivity in CAV diagnosis; it allows the identification of 
changes in maximal intimal thickness (MIT), and the calculations of plaque volume, intimal volume 
and lumen volumes, as well as of complex remodelling systems in the coronary vessels. Previous 
studies showed that an increase in MIT >0.5 mm in the first year after HTx is a marker of 
subsequent poor cardiovascular outcome. Thus, this cutoff has been used to assess for the 
efficacy of different prevention and/or therapeutic strategies for CAV in subsequent studies. 
However, CAV is a continuous process, that develops also beyond the first year from HTx, and it is 
no known if IVUS-detected changes still retain a prognostic role also after the first year. 
Moreover, even if IVUS is more accurate in diagnosing CAV, it is not known if it can add more 
prognostic information than angiography alone. 
Coronary tomography (CT) is a non-invasive screening method for CAD; recently, it has been 
purposed also fro CAV monitoring, especially in patients with low probability of vasculopathy, 
performing a subsequent angiography if CT result is uncertain or positive, or in patients who don’t 
want to undergo to coronary angiography. However, it is not known if CT can provide useful 
prognostic information to assess cardiovascular risk, neither its sensititvity compared to coronary 
angiography. 
Unsolved problems in therapy and prevention 
Given the diffuse hyperplasia, percutaneous coronary intervention (PCI) is not possible in the 
majority of cases; however, in cases in which some focal critical stenosis coexists, similar to the 
ones of native atherosclerosis, PCI with or without stenting can be made. Globally, the role of PCI 
in CAV is limited, with high rates of restenosis, even with drug eluting stents, and the real 
prognostic benefit is uncertain. Moreover, the feasibility of performing an angiography decreases 
among time, when the probability of finding a stenosis similar to native atherosclerosis is higher, 
but renal function is worse. The use of coronary by pass is anecdotal and with high rates of 
mortality in transplanted patients; re-transplantation can be an option in selected cases, but its real 
feasibility is rare, given the shortage of donations. Medical therapy of CAV is substantially absent. 
The role of introducing an mTOR inhibitor after an established diagnosis of CAV has been tested, 
but with uncertain results; anti-platelets agents, if not already started before, are initiated, 
particularly acetylsalicylic acid, often in association with clopidogrel, the latter suggested in models 
in vitro to have a slight effect. Statins are also continued 
Given the substantial absence of therapy, medical approach to CAV is rather based on prevention 
strategies. In this context, drugs agent against the various possible trigger of CAV are given (see 
Fig 5). CMV infection is aggressively prophylaxed and treated, anti-hypertensive agents are given. 
It has been shown that aggressive prevention of even subclinical CMV infection can reduce IVUS-
detected CAV prevention, being universal prophylaxis probably more effective than pre-emptive 
strategy.  
Anti-lipid agents (statins) are a cornerstone in CAV prevention, as it has been shown that they 
reduce CAV incidence and plaque progression, as assessed by intravascular ultrasound (IVUS) 
with a class - effect; moreover, they improve prognosis after HTx, with an effect dependent not only 
by the lipid-lowering effect, but also by anti-inflammatory and anti-rejection properties. For this 
reason, statins are given to all transplanted patients, regardless of their cholesterol levels; a 
possible adverse effect can be elevation in creatine kinase (CK), leading to myalgias and even 
rhabdomyolysis, with acute renal failure. CK elevation is frequent in transplanted patents, given the 
interaction of some statins with CNI and mTOR inhibitors through P450 cytochrome, often requiring 
statins temporary suspension or switch from one statin to another one. A target of cholesterol LDL 
has not yet been well established, but generally a target LDL<100 mg/dl is reasonable. 
Hypertriglyceridemia is also treated conventionally, and has been suggested to be a strong CAV 
risk factor. Even if paucity of data exists, acetylsalicylic acid is usually given to prevent CAV. As 
!written above, in high-risk patients, a more strict angiographic follow-up can be considered. 
As explained in Section 1.3 , mTOR inhibitors (PSI: everolimus, sirolimus) have been investigated 
in CAV prevention, and have been shown to be more effective than mycophenolate mofetil (MMF)  
in CAV prevention in the first year after HTx 
However, it is not known if PSI can have a different prevention effect when combined with different 
anti-CMV prevention strategies (prophylaxis vs pre-emptive) neither if PSI can be useful in CAV 
treatment.  
 
1.2 Solid-organ cancers  
Malignancies are the first non graft-related cause of death after HTx. The incidence of 
malignancies in HTx is 3 folds-higher than the general population, and higher than in kidney or liver 
transplantation, probably because of the higher rates of immunosuppression. According to ISHLT 
registry, malignancy incidence is 14.2% at 5-years and 27.7% at 10 years, being older age at 
transplantation the most powerful risk factor. Beside the most frequent malignancies that can be 
found also in general population, some rare cancers are tipically seen almost only in the 
transplanted setting like in other cohorts of immunosuppressed patients (i.e. HIV+), like Kaposi’s 
sarcoma. Generally, the clinical course for malignancies after HTx is more aggressive than in the 
general population, because of immunosuppression, with a subsequent higher mortality rate. Skin 
cancers are the most frequent malignancies (5-years incidence: 9.4%, 10-years: 19.6%), especially 
squamocellular cancers (the most frequent ones) and basaliomas, and seem to be related partially 
to azathioprine. An aggressive dermatological screening, surgical treatment and follow-up is made 
in these patients, together with the recommendation, especially in the mediterranean countries, to 
avoid high exposition to UV and sun light. Some patients experience repeated skin cancers, with 
multiple surgical treatments, and sometimes lymphonodal involvement. Melanoma is also quite 
frequent, especially in young people. 
Among solid cancers, the most frequent are: prostate, colon, lung, kidney, bladder, pancreas, 
breast, sarcomas, but all organs can be involved14. In more than 30% of patients, cancer is 
diagnosed when already at an advanced stage; overall outcome is poor, with a reported overall 
survival of <50% 5 years after diagnosis. Aggressive screening protocols are used, but with 
uncertain results. Once a cancer is found, it must be surgically treated when possible. 
Chemotherapies and radiotherapy is also possible; during chemotherapeutic treatments, 
immunosuppressive drugs potentially causing leukopenia are usually reduced or even interrupted. 
In some selected cases (i.e. kidney, bladder, Kaposi’s sarcoma) a switch to an mTOR inhibitor can 
be considered, especially in those cancers in which these drugs (even if at higher doses than in 
HTx) are registered as chemotherapeutic agents. 
PTLD are also relatively frequent after HTX, especially in young people and women; the most 
frequent ones are non-Hodgkin lymphomas and sometimes MALT, developing frequently even 
early after HTx (incidence: 0.5% at 1 year, 1.1% at 5 years, 1.7% at 10 years). These diseases are 
treated as conventionally, but with a significant poorer outcome (20% survival at 5 years); bone 
marrow transplantation and even autologous stem cells transplantation are possible when 
appropriated, with even good results. 
Kaposi’ sarcoma, a disease exclusive of immunocompromised patients in the developed countries, 
is not rare after HTx. in these cases, mTOR inhibitors are introduced, given their known effect on 
this disease, with the potential to achieve a complete remission. 
 
!1.3  mTOR inhibitors: properties for potential use in 
CAV prevention and in oncological patients  
The triple combination of steroids, a calcineurin inhibitor (cyclosporine/tacrolimus, CSA/TAC) and 
an antiproliferative drug (mycophenolate mofetil or everolimus ,MMF/EVE) is actually the most 
frequent scheme used for long-term immunosupression. Their mechanism of action is depicted in 
Figure 4. 
MMF is a noncompetitive inhibitor of inosine monophosphate dehydrogenase. Proliferating 
lymphocytes are dependent on this pathway because it is the only pathway for the purine synthesis 
and DNA replication, whereas other cells use also other salvage pathways for purine synthesis. 
Therefore, MMF selectively inhibits lymphocyte proliferation in response to allogeneic stimulation 
without inhibiting other cell lines. MMF is given orally, usually twice a day, and it has been shown in 
a prospective randomized trial to be superior to AZA on graft survival and in preventing rejection, 
also when used with reduced CSA doses. It is actually the standard antiproliferative drug. Major 
side effects are: nausea, vomiting, and diarrhea, which usually are dose-dependent.  
52.8% in the everolimus 1.5 mg/day, everolimus 3.0
mg/day and Aza 50 –100 mg/day groups, respectively.6
The efficacy of everolimus and low-dose CsA i heart
transplantation has been rep rted from single-center
studies and from cli ical exp rience.7–10 Th  efficacy of
everolimus and low-dose CsA is currently being as-
sessed in a pilot clinical trial in maintenance heart
transplant recipients,11 and is also being compared with
MMF and conventional CsA in a large, randomized
clinical trial in de novo cardiac allograft recipients.12 In
addition, there is growing clinical experience with
everolimus and low-dose tacrolimus, with preliminary
data suggesting improvement of long-term renal func-
tion after substantial CNI reduction.13
RENAL FUNCTION
Chronic renal failure is common after cardiac transplan-
tation and is associated with an increased risk of
Figure 1. Sirolimus is a macrocyclic lactone produced by Streptomy-
ces hygroscopicus. Everolimus, a more recent addition to the class,
differs from sirolimus by one hydroxyl group located at position 40 of
the molecule.58
Figure 2. PSI/mTOR inhibitors have a distinct mode of action compared with other immunosuppressive agents. mAb, monoclonal antibody; MHC,
major histocompatibility complex; TCR, T-cell antigen receptor; MAP, mitogen-activated protein; IKK, I!kinase; NFAT, nuclear factor of activated
T cells; AP-1, activated protein 1; NF-!B, nuclear factor !B; PI-3, phosphatidylinositol 3-phosphate; mTOR, mammalian target of rapamycin; PSI,
proliferation signal inhibitor; MMF, mycophenolate mofetil.
Table 1. PSI Pharmacokinetics
PSI/mTOR inhibitors: sirolimus and everolimus
●  Significant  inter- and  intra-subject variation4,61
●  Pharmacokinetics not dependent on age, weight or gender4,61
●  Metabolized by cytochrome enzymes 3A4, 3A5 and 2C818,62
●  Substrate  for P-glycoprotein18,62
Sirolimus
●  Half-life of 62 hours18,28
●  Less polarity  than everolimus4
● Affinity for FKBP 12a approximately 3-fold stronger than that of
everolimus  in vitro64
Everolimus
●  Half-life of 28 hours18,55
●  Greater polarity  than sirolimus4
● Affinity for FKBP 12a approximately 3-fold weaker than that of
sirolimus  in vitro63
aFKBP12 ! FK 506 (tacrolimus)-binding protein.
142 Zuckermann et al. The Journal of Heart and Lung Transplantation
February 2008
 
Figure 4. Mechanisms of action of different immunosuppressive drugs 
Everolimus (EVE) and its analogue sirolimus (SIR), first isolated in soil samples from Rapa-Nui 
(Easter Island), is a natural product of the actinomycetes Streptomyces hygroscopicus. These 
drugs bind to the same family of immunophilins as TAC, but rather than blocking calcineurin- 
dependent T-cell activation, inhibit the target of rapamycin (TOR), a kinase phosphorylating 
proteins involved in the regulation of the cell cycle, playing a critical role in signals from the growth 
factor receptors to the cell nucleus for stimulation of growth and proliferation of T and B 
lymphocyte, smooth muscle cells and endothelial cells.  
The frequent involvement of mTOR system in various biological pathways (endothelial cells and 
smooth muscle cells proliferation, cancerogenesis, healing repair) explains both the adverse 
effects of this drug and its potential positive effect in various pathological processes. In particular, 
!mTOR inhibitors have been studied in preventing CAV development (smooth muscle cells 
proliferation is the basis of intimal thickening, the pathological marker of CAV), in oncology or in 
transplanted patients developing a tumor. On the same basis, these drugs can lead to a slower 
wound healing repair process, and to a higher susceptibility to infections, particularly bacterial. The 
synergic effect with CSA allows a reduction in CSA dose, with the aim to reduce the CNI-related 
nephrotoxic effect. 
Drug concentration in blood is also used for deciding mTOR inhibitors dosing; these drugs are the 
most complex to use among the various immunosuppressors, because of a narrow therapeutic 
index and frequent, often dose-related, side effects (about 25% of patients interrupt the treatment). 
The synergic effect with CSA allows a reduction in CSA dose, with the aim to reduce the CNI-
related nephrotoxic effect. The effect of EVE introduction to reduce or at least to delay renal failure 
is slightly more evident in the earlier stages of kidney disease and in the first years after HTx, 
especially when pathological proteinuria still has not occurred, and may be is mainly related to the 
ability of reducing CSA; EVE seems to have a slightly more benefit than MMF in preventing renal 
insufficiency10. The results of randomized and non randomized trials showed that EVE is superior 
to MMF in preventing rejection and CAV development in the first years after HTx, whereas the real 
benefit when CAV is already present is less clear and still debated11.  
The prospective randomized trials focusing on comparison between MMF and EVE in de novo use 
after HTx are reported in Table 2. 
2. Methodology
Multiple searches of the PubMed database were performed with
no time or language restrictions using different combinations of the
terms ‘everolimus’, ‘heart’, ‘cardiac’, ‘transplantation’, ‘randomized’
and ‘mTOR’. The proceedings of the International Society for Heart and
Lung Transplantation, the American Transplant Congress and the
European Society for Organ Transplantation congresses during 2010–
2012 were searched for ‘everolimus’ or ‘mTOR’.
3. Efﬁcacy of everolimus in de novo heart transplant recipients
The immunosuppressive potency of everolimus in de novo heart
transplant recipients was ﬁrst demonstrated in a randomized study by
Eisen et al., in which everolimus at a ﬁxed dose of 1.5 mg or 3.0 mg
was associated with signiﬁcantly superior efﬁcacy outcomes to
azathioprine, both in combination with standard-dose CsA [30]
(Table 1). Since then, following evidence from kidney [6,31] and
heart [4] transplantation showing that everolimus with reduced-
exposure CsA offers equivalent efﬁcacy to everolimus with standard-
exposure CsA, and the advantage of therapeutic drug monitoring of
everolimus [32], two randomized trials have assessed the use of
everolimus with reduced-exposure CsA versus mycophenolate mofe-
til (MMF) with standard-exposure CsA [3,5] in de novo heart
transplant populations. Both studies adjusted everolimus trough
concentration according to pre-speciﬁed target ranges, as is now
standard practice. Using an everolimus target range of 3–8 ng/mL, the
primary composite efﬁcacy endpoint and the incidence of biopsy-
proven acute rejection (BPAR) were similar in the everolimus and
MMF treatment arms at 12 months post-transplant in each study
(Table 1). Retrospective, single-center analyses using everolimus (3–
8 ng/mL)with reduced CsA have also reported similar efﬁcacy toMMF
with standard CsA [25,26] or tacrolimus [27,29], including one series
of 49 patients followed up for ﬁve years post-transplant [26]. Higher
everolimus exposure levels in CNI-treated patients may be inadvis-
able in view of an increased rate of early (b3 months) deaths in the
recent A2310 study among pati nts randomiz d to a target concen-
tration range of 6–12 ng/mL [3]. Use of IL-2 receptor antibody
induction in this setting does not appear to be associated with safety
concerns [28].
Only one trial has investigated the use of mTOR inhibition within a
CNI-free regimen for de novo heart transplant patients, in a series of
20 patients with poor kidney function at time of transplant (GFR
b30 mL/min per 1.73 m2) [33]. All patients received steroids, six
received everolimus and 14 received sirolimus; nine received
induction therapy. Within the mean follow-up of 500 days, by the
end of follow-up 11 patients (55%) had experienced rejection. Such an
Table 1
Efﬁcacy outcomes in prospective trials of everolimus in de novo heart transplant recipients.
Study Study design Follow-up Treatment N Primary efﬁcacy endpoint BPAR
Endpoint % p value % p value
Eisen 2012a [3] Randomized
Multicenter
Open Label
12 months EVR 1.5 mg (3–8 ng/mL)
Reduced CsA
Steroids
± Induction
282 ISHLT grade ≥3A (2R) BPAR,
acute rejection associated with
hemodynamic compromise,
graft loss/retransplant, death,
or loss to follow-up
35.1 0.705 22.3b n.s.
MMF
Standard CsA
Steroids
± Induction
271 33.6 24.7b
Zuckermann 2011 [4] Randomized
Multicenter
Open Label
6 months EVR (3–8 ng/mL)
Reduced CsA
± Induction
99 ISHLT grade ≥3A (2R) BPAR,
acute rejection associated with
hemodynamic compromise,
graft loss/retransplant, death,
or loss to follow-up
26.3 n.s. 16.2b n.s.
EVR
Standard CsA
± Induction
100 25.0 21.0b
Lehmkuhl 2009 [5] Randomized
Multicenter
Open Label
12 months EVR (3–8 ng/mL)
Reduced CsA
Steroids
± Induction
92 ISHLT grade ≥3A (2R) BPAR,
acute rejection associated with
hemodynamic compromise,
graft loss/retransplant, death,
or loss to follow-up
32.6 Statistically
non-inferior
(10% NI)
22.8b 0.005 for
non-inferiority
(10% NI margin)
MMF
Standard CsA
Steroids
± Induction
84 41.7 29.8b
Eisen 2003 [30] Randomized
Multicenter
Double blind
12 months EVR 1.5 mg
(ﬁxed dose)
CsA
Steroids
± Induction
209 ISHLT grade ≥3A (2R) BPAR,
acute rejection associated with
hemodynamic compromise,
graft loss/retransplant, death,
or loss to follow-up
36.4c 0.03 vs Aza 30.6b,d 0.001 vs Aza
EVR 3.0 mg
CsA
Steroids
± Induction
211 27.0c 0.001 vs Aza 21.3b,d 0.001 vs Aza
Aza
Standard CsA
Steroids
± Induction
214 46.7c – 45.8b,d –
Aza, azathioprine; BPAR, biopsy-proven acute rejection; CsA, cyclosporine; EVR, everolimus; ISHLT, International Society for Heart & Lung Transplant; MMF, mycophenolate mofetil;
NI, non-inferiority.
a Data from a discontinued third treatment arm (everolimus 3.0 mg) are not shown.
b ISHLT grade ≥3A (2R).
c Primary efﬁcacy endpoint was at 6 months; proportion of patients reaching composite endpoint at 12 months was 41.6% in the EVR 1.5 mg group (p = 0.02), 32.2% in the EVR
3.0 mg group (p b 0.001) vs 52.8% in the azathioprine group.
d At 12 months.
77A. Zuckermann et al. / Transplantation Reviews 27 (2013) 76–84
 
 
Table 2. Efficacy outcomes of prospective trials on everolimus in de novo heart transplant 
recipients (from Zuckermann A. Transplantation Reviews 2013; 27: 3: 76-84.) 
EVE is the immunosuppressant with the highest anti-CMV activity, regardless of the type of anti-
CMV prophylaxis used. Some registries have reported a decreased incidence of de novo cancers 
in patients continuously treated with EVE, and this drug seems to be at least partially effective in 
some kinds of cancer developed after HTx. 
!However,  the real clinical benefit of this drug is still matter of debate and must face with problems 
in tolerability: more than 25% of patients must interrupt the treatment, regardless of the post-HTx 
phase in which EVE is initiated 
The most frequent reasons for interruption in the first months after HTx or after every surgical 
procedure are problems in wound healing repair and pericardial effusions, often requiring 
pericardiocentesis, whereas when the drug is started later after transplant, lower limb edema, 
bacterial infections (especially pneumonia) and dyslipidemia are the most frequent causes of drug 
interruption. Hyperlipidemia, hypertriglyceridemia, thrombocytopenia, neutropenia, and anemia can 
occur in every phase after HTx while on mTOR inhibitors therapy. For these reasons, the use of 
mTOR inhibitors is very individualized and requires an assessment of potential benefits and side 
effects. 
Summary of unclear points and their development in this Research 
Thesis 
 
CAV diagnosis: 
- Is ISHLT classification system for angiographic detected CAV useful for 
assessing prognosis? (Chapter 2.1) 
- Is ISHLT classification system for angiographic detected CAV useful 
also when used to assess for disease progression? Is even mild CAV 
progression a marker of worse cardiovascular outcome? (Chapter 2.1) 
- Do IVUS detected changes observed after the first year from HTx have 
a prognostic effect? (Chapter 2.2) 
- Does IVUS add any more refined prognostic information compared to 
angiography? (Chapter 2.2) 
- Is coronary tomography  (CT) useful in predicting cardiovascular 
outcome? (Chapter 2.3) 
- What is the sensitivity of CT for CAV assessment when compared to 
angiography? (Chapter 2.3) 
 
 
CAV prevention/treatment: 
- do mTOR inhibitor have a different role in preventing early vs late CAV 
development? (Chapter 3.1) 
- What is the role of the interplay between different anti-CMV prevention 
strategies and mTOR inhibitors in CAV prevention? (Chapter 3.2) 
 
 
Post-transplant cancers: 
- What are factors influencing survival after post-transplant cancer 
diagnosis? (Chapter 4.1) 
- What is the role of mTOR inhibitors? (Chapter 4.1) 
 
mTOR related clinical benefit: 
- Do mTOR inhibitors matter for long-term outcomes? (Chapter 5) 
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Chapter 2.  
Cardiac allograft vasculopathy: trying to 
improve diagnosis 
2.1  Static versus dynamic angiographic CAV 
evaluation: prognostic stratification beyond ISHLT 
grading  
Introduction: 
ISHLT grading of coronary allograft vasculopathy (CAV) provides a static definition of CAV severity 
that has recently been correlated with adverse outcome. Although the grading system classifies 
emphasizes even mild stenoses, as they may represent a marker of adverse cardiovascular (CV) 
outcome, it may not detect the progression of subcritical lesions. Herein we aimed to analyze the 
prognostic implication of progressing vs. static angiographic lesions within ISHLT classification.  
 
Methods: 
All patients receiving heart transplant in 2 large centers (Bologna and Vienna) between 2001-08, 
surviving >1 year, having undergone 2 coronary angiographies, entered this study.  
Angiographic progression (assessed by an operator blinded to the exam report) was defined as 
any stenosis increase or any new stenosis in any vessel.  
 
Study endpoints were :  
- freedom from  cardiovascular death and  
- freedom from MACE combined occurrence (CV death, PCI, admissions for heart failure, re-
HT) during 5 yrs after the second angiography.   
 
Results: 
161 patients (85% males, 16-70 yrs) were included. The 2 angiographies  were performed 
respectively 13 and 61 months (median time) after HTx.  
As depicted in Figure 1, CAV occurred in 22.9% of the first angiography (21.1% grade 1; 1.8% 
grade 2; 0% grade 3), and in 41.5% of the second (34.1% grade 1; 6.2% grade 2; 1.2% grade 3). 
As represented in Figure 2 and 3 , ISHLT grading of both angiographies predicted MACE 
(p<=0.001). 
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Fig. 1 CAV prevalence 
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Fig. 2 Effect of ISHLT grading for first angiography on MACE 
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Figure 3. Effect of ISHLT grading for second angiography on MACE  
 
24.8% of patients had an ISHLT-grading progression (75% from 0 to 1, 15% 1 to 2, 5% 0 to 2, 5% 
1 to 3), 33.5% of patients had an angiographic progression (Figure 4). 
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Figure 4. Dynamic CAV assessment: progression in ISHLT grading versus angiographic 
progression 
 
Grade progression predicted the combined MACE (88.0±4.0% vs. 65.4±10.0%, p<0.01) but not CV 
death (91.3 ± 3.3% vs. 91.7 ± 4.6% vs. p=0.42), see Fig. 5 and 6.  
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Figure 5. Effect of progression in ISHLT grading on cardiovascular death 
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Figure 6. Effect of progression in ISHLT grading on MACE 
 
Any angiographic  progression predicted both CV death (95.8±2.6% vs. 82.6±6.3%, p<=0.0108) 
and MACE (93.9±6.1% vs 59.4±9.2%, p<0.0001), as represented in Figures 7 and 8.  
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Figure 7. Effect of angiographic progression on cardiovascular death 
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Figure 8. Effect of angiographic progression on MACE 
 
Of note, patients (8.9%) with an angiographic progression within the same ISHLT grade, had a 
higher incidence of CV death and MACE as compared to the non-progression group (95.8%±2.6% 
vs. 52.8±19.1%, p<0.001; 93.9%±3.2% vs. 40.3±19.2%, p<=0.0012). These results are 
represented in Figures 9 and 10. 
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Figure 9. Effect of angiographic progression within the same ISHLT grade on cardiovascular 
death 
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Figure 10. Effect of angiographic progression within the same ISHLT grade on MACE 
 
Entering both static and dynamic features in a multivariate model, static assessment of CAV 
according to ISHLT grading was able to predict independently MACE. However, ISHLT grading 
progression appeared to be more sensitive in predicting MACE. (Table 2). 
!OR# 95%##CI# P#
“sta%c”(ISHLT(grading(at(2°(angio( 18.3#(range,#
non#unità)#
2.5<107# 0.005(
ISHLT#grading#progression# 1.2# 0.4<3.5# 0.74#
Distance#from#HTx# 3.2# 0.1<57.1# 0.47#
OR# 95%##CI# P#
“staMc”#ISHLT#grading#at#2°#angio# 3.6#(range,#non#
unità)#
0.2<32.7# 0.32#
Angiographic(progression( 4.8# 1.4<20.4# 0.01(
Distance#from#HTx# 2.0# 0.06<39.2# 0.65#
 
Table 2. Static versus dynamic CAV assessment on MACE prediction at multivariate analysis 
 
Conclusion: 
 
Both static and dynamic ISHLT CAV grading stratifies CV prognosis after HT. However, analysis of 
progression of mild lesions not captured by changes in ISHLT grading appears to improve 
angiographic accuracy in stratify prognosis long term after HT, underlining CAV dynamic features 
and its negative prognostic impact. These data support the inclusion of the concept of 
“progression” in CAV grading system, identifying mild progressing lesions as potential therapeutic 
targets to improve prognosis after HTx.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2  Interplay of coronary angiography and 
intravascular ultrasound in predicting long-term 
outcomes after heart transplantation  
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Introduction*
Although!modern!immunosuppressive!strategies!have!led!to!a!marked!reduction!of!acute!rejection!rates!in!
heart!transplant!(HT)!recipients,!cardiac!allograft!vasculopathy!(CAV),!the!major!manifestation!of!chronic!
rejection,!still!remains!the!leading!cause!of!death!in!the!longVterm.!(1)!
Longitudinal!studies!based!on!intravascular!ultrasound!imaging!(IVUS)!revealed!that!early!changes!in!
coronary!artery!geometry,!such!as!increase!in!maximal!intimal!thickness!(MIT),!are!clearly!related!to!
adverse!prognosis,!identifying!early!MIT!change!as!a!potential!therapeutic!target!(2V4).!Among!the!several!
drugs!used!in!the!transplant!setting,!convincing!data!indicate!a!drugVrelated!benefit!on!early!CAV!
development!from!statins!(5,!6)!and!inhibitors!of!mammalian!target!of!rapamycin!(mTOR)!(7,!8).!While!
statins!are!widely!used!after!HT,!and!observational!registries!confirmed!their!benefit!in!clinical!practice!(9,!
10),!a!suboptimal!safety!profile!limited!the!use!of!mTOR!inhibitors!in!the!early!postVHT!phase!out!of!the!
context!of!randomized!clinical!trials,!and!their!effect!on!CAV!development!in!clinical!practice!is!unknown.!
Late!after!the!first!postVHT!year,!CAV!morphological!features!and!risk!factors!appear!to!differ!from!the!early!
pattern!(11V13).!However,!the!effect!of!pharmacologic!interventions!on!late!CAV!development!has!been!
investigated!by!a!few!studies!that!provided!contradictory!results!(14,!15).!
Herein!we!aimed!to!explore!how!therapeutic!strategies!could!affect!early!and!late!changes!in!coronary!
morphology.!In!particular,!we!focused!our!analysis!on!the!effect!of!the!mTOR!inhibitor!everolimus!on!early!
(year!1)!and!late!(year!1!to!5)!changes!in!coronary!morphology!after!HT,!as!detected!by!IVUS,!and!using!
patients!receiving!mycophenolate!mofetil!(MMF)!as!a!standard!comparative!cohort.!!
*
Methods*
Study&design&&
This!observational!study!is!a!retrospective!analysis!of!data!prospectively!collected!in!our!institutional!
database,!involving!all!consecutive!HT!recipients!fulfilling!study!inclusion!criteria.!The!study!design!is!
depicted!in!figure!1.!!
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Introduction 
Cardiac allograft vasculopathy (CAV) remains the major cause of late graft dysfunction and death after 
heart transplantation (HT)1 : its prevalence steadily increases during post-transplant follow-up, with at least 
50% of patients affected within 10 years after transplant. 1  Nevertheless, according with international 
registry data, over 50% of long term mortality related to graft failure is not ascribed to CAV: it can be 
reasonably speculated that a consistent fraction of those deaths may be related to underestimated CAV, 
underlining the need for improving CAV diagnosis long term after transplant.  
Typical CAV features 2, 3 reduce the diagnostic sensitivity of coronary angiography; 4however, current 
guidelines indicate angiography, coupled with the assessment of graft function, as the imaging procedure 
of choice for CAV diagnosis and classification, and to predict long-term prognosis. 5  Despite intravascular 
ultrasound (IVUS) imaging allows detection of angiographically silent early CAV, not enough data support 
this technique for routine CAV diagnosis, in particular in the long-term follow-up. 5 While IVUS-detected 
increase in intimal thickness during the first year post-transplant is a marker for CAV development, and 
predicts cardiovascular prognosis, whether IVUS performed subsequently to year 1 after transplant bears 
any additional prognostic information is unknown. 6, 7 Moreover, therapeutic interventions designed to 
reduce CAV development traditionally focused on the first post-transplant year, using IVUS findings as 
surrogate endpoint, 8-10 leaving unexplored the effect of therapies and risk factors management on late 
progression of IVUS and angiographic lesions. 
The scopes of this study are: 1) analyze the role of serial coronary imaging in improving the stratification of 
cardiovascular prognosis late after transplantation, focusing angiography classification on the grades 
proposed by current ISHLT guidelines 5; 2) explore the hypothesis that IVUS imaging performed later than 
the first year of follow-up may provide further information to serial coronary angiography in predicting long 
term prognosis.  
 
Methods 
Study design 
 4 
This is a single-center observational analysis, aiming to analyze the impact of coronary imaging on the long-
term outcome of recipients surviving at least 5 years after transplant. The sole inclusion criteria comprised 
availability of IVUS performed at 1 (study baseline) and 5 years after transplant, carried out as part of our 
standard CAV surveillance protocol, since 1998. 11 Severe comorbidities, moderate to severe renal 
dysfunction, and unwillingness to undergo invasive procedures were the main reasons to withdraw IVUS 
and angiography performance in our routine clinical practice.  
Patient demography, therapies and clinical events were retrieved from a prospectively filed web-based 
secured database including all transplant recipients ever followed at our Center since 1985, and from the 
Hospital electronic repository.  
This study was approved by local ethical committee and is in compliance with local laws and regulations.  
 
Coronary angiography and IVUS 
Coronary angiography was performed with standard technique with at least two planes for right coronary 
artery and three for left coronary artery examined and digitally recorded for off-line analysis. Angiogram 
reports were reviewed and classified according with ISHLT guidelines 5 and graded (from CAV 0 to CAV 
grade 3) blinded to clinical events and IVUS findings. Angiographic progression was evaluated by comparing 
year 1 and year 5 angiograms and was identified either as ISHLT grade progression, or as any worsening of 
disease severity within the same grade (e.g. change from mild single vessel disease to mild multiple vessel 
disease is a progression of CAV extension, although in both cases ISHLT grading remains 1)  
IVUS procedure was performed on LAD, after excluding stenoses 70%, as detailed previously. 12 Analyzed 
vascular segments from year 1 and 5 studies were accurately matched, using side-by-side longitudinal 
reconstruction of the LAD and left main. 13 Our Institutional IVUS Core laboratory performed 2-dimensional 
and 3-dimensional IVUS analysis by a semi-automated method using Qivus® Clinical Edition software (Medis 
medical imaging systems BV, Leiden, NL). Changes in maximal intimal thickness (MIT), intimal, lumen and 
whole vessel volumes were evaluated to describe variability in coronary geometry potentially associated to 
clinical outcomes. To minimize measurements variability 14 only one individual (V.P.) blinded to the 
patients’  outcome  performed  all  the  software  assisted  measurements  reported  in  this  study.   
 5 
 
Study endpoints and data analysis 
Study outcome was the occurrence of the composite endpoint of fatal and non-fatal major cardiovascular 
events (MACE) including: myocardial infarction, myocardial revascularization, and admission for acute heart 
failure (HF). Sudden death, in absence of known potentially fatal non-cardiovascular comorbidities, was 
considered of cardiovascular (CV) etiology. For descriptive purposes we additionally analyzed separately 
the  occurrence  of  CV  death,  but  the  limited  number  of  this  event  prevented  multivariate  analyses.  Patients’  
follow-up was recorded up to 10 years after year-5 coronary imaging (i.e. 15 years after transplantation).   
Continuous variables are expressed as means  standard deviation or as medians (25th to 75th percentile), if 
skewed distributed. Differences among groups were assessed by ANOVA, Chi square tests as appropriate. 
Receiver-operating curve (ROC) was used to identify the cut-off in IVUS measurements best predictive of 
study outcomes. Person-time and incidence rates were calculated and 95% confidence interval was 
reported. Composite MACE and CV death-free survivals were estimated with Kaplan-Meier method, and 
differences between groups were assessed with log-rank test. Contribution of clinical and laboratory data 
to  outcomes  was  identified  by  Cox’s  univariate  and  multivariate  regression  analysis.  The  goodness  of  fit  of  
multivariate Cox regression models including clinical and imaging data was compared by the likelihood ratio 
test. P <0.05 was considered as significant. 
 
Results 
Study population and events 
One hundred thirty-one patients, receiving HT between July 1998 and October 2007 were included in the 
study. A study flow-chart is depicted in the supplementary figure 1. As shown in table 1, between year 1 
and 5 a limited number of patients was converted to an mTOR inhibitor and steroid weaning was poor, with 
still 80% of patients on prednisone at year 5, although average daily dose significantly decreased (P<0.01). 
Statins were widely used, with 91% on medication at year 5, and metabolic parameters, including renal 
function, remained stable.  
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Year-5 IVUS was performed between June 2003 and July 2012 and patients were followed for the 
subsequent 1 to 10 years (689 total patient-years). During the follow-up period, at least one MACE 
occurred in 21 (16%) patients: 5 admissions for HF, 2 percutaneous coronary revascularization, 2 ST-
elevation myocardial infarction, and 12 CV deaths (6 sudden deaths, 6 chronic graft failures). Incidence rate 
of MACE was 31.8 (95% CI: 20.7 to 48.8) and of CV death was 17.4 (9.9 to 30.6) per 1,000 person-years.  
 
Coronary angiography and prognosis 
Figure 1A details progression of angiographic grading between year 1 and 5. Of the 21 patients with 
angiographic progression, in four cases lesions progressed within the same ISHLT CAV grade. This was the 
case of mild disease in one vessel (grade 1 CAV), which progressed to mild disease in two to three vessels 
(still CAV grade 1, but clear angiographic progression). Of note, two of these four patients presented CV 
death during follow-up. On the other hand, only one of the ten patients with stable CAV 1 had a non-fatal 
MACE.  
As shown in Figure 1B, patients with angiographic progression suffered a significantly greater incidence of 
MACE as compared with those with stable angiography, either CAV 0 or stable CAV 1 (103 vs. 22 events per 
1,000 person-years; incidence rate ratio 4.6: 95% CI: 1.6 to 11.9, P<0.01). Restricting the analysis to CV 
death only, the ability of angiographic progression in identifying patients at risk only approached statistical 
significance (44 vs. 13 deaths per 1,000 person-years; incidence rate ratio: 3.3; 95% CI: 0.73 to 12.3; 
P=0.07).    
 
IVUS measurements and prognosis 
Coronary geometry markedly changed between year 1 and year 5, with significant increase in intimal 
volume and MIT, and in loss of lumen volume. Of note, at year 5, only five (4%) patients showed a normal 
MIT (i.e. <0.5mm) 15, 16. Vessel volume did not changed significantly overall (Table 2), but varied widely 
across study population, with 54% of patients showing positive vascular remodeling. 
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As shown in Table 3, MIT increase predicted both MACE and cardiovascular death risk. Vessel volume and 
intimal volume increase, but not lumen loss, were associated with MACE risk only, suggesting a prognostic 
relevance of vascular wall remodeling.  
By building a ROC curve, we identify a MIT change 0.35mm as the most accurate cutoff to predict MACE. 
In patients with MIT change  ≥0.35  mm,  MACE  incidence  was  80  per  1,000  patients-year, while in those with 
MIT change <0.35 mm, MACE occurred in 13 per 1,000 patients/year (incidence rate ratio 6.3; 95% CI: 2.3 
to 19.7, P<0.01). Similarly, this cutoff allowed detecting the subgroup of patients with higher incidence of 
CV death (38 vs. 8 CV deaths per 1,000 person-years; incidence rate ratio 4.5; 95% CI: 1.2 to 20.5; P=0.01). 
These differences are depicted in the Kaplan-Meier estimates of events shown in Figure 2.  
 
Interplay between IVUS and angiographic progressions in predicting MACE.  
Patients with progressing angiographic lesions showed worsening IVUS measurements, in terms of greater 
increase in MIT (0.39 [0.10-0.95] vs. 0.18 [0.04-0.37] mm; P=0.03) and in intimal volume (77 [10-147] vs. 14 
[-19 to 54] mm3; P<0.01), greater loss in lumen volume (-62[-109 to -6] vs. -13[-64 to 21] mm3; P=0.03), and 
higher  likelihood  of  MIT  change  ≥0.35mm  (52  vs.  28%;  P=0.03).   
To elucidate whether IVUS-detected changes were adding any prognostic information to what could be 
gained by angiography alone, we stratified the effect of MIT change by angiographic progression. In the 
small group of 21 high-risk patients with any lesion progression, MIT increase 0.35mm did not stratify the 
estimated incidence of MACE (154 vs. 51 events per 1,000 patients-year respectively; P=0.2). On the other 
hand, in the subgroup of 110 patients with stable angiographic lesions, MIT increase  ≥0.35mm  identified  
those with a significantly greater incidence of MACE (60 vs. 9 events per 1,000 patients-year; incidence rate 
ratio 6.5; 95% CI: 1.6 to 20.7; P<0.01). Kaplan-Meier analysis shown in Figure 3, highlights that while 
angiographic progression identified patients with the earliest incidence of MACE, IVUS-detected changes in 
patients without angiographic progression of the disease discriminates between patients with very low and 
those with intermediate-late MACE incidence.   
In addition to imaging data, clinical and laboratory characteristics at year 5 were analyzed as potential 
confounders of MACE prediction by IVUS and angiography (Supplementary Table). Using a stepwise 
 8 
approach, MACE-associated variables with a P value<0.1 were factored in a multivariate model including 
angiographic progression (Table 4 – Model 1).  In this model angiographic progression independently 
predicts MACE risk, together with age and renal function, while hyperglycemia dropped out of the analysis. 
After adding MIT change (Model 2), both imaging variables persisted significant, and the Likelihood-ratio 
test comparing the two multivariate models showed that Chi square of model 2 increased significantly 
(P<0.01), suggesting that the information added by IVUS to clinical risk factors and angiography evaluation 
improved prognosis prediction. 
 
Risk factors for angiographic and IVUS progression 
In table 5 we analyzed the association of demographic, clinical and laboratory parameters at year 1 after 
transplant (time of baseline IVUS), with the degrees of CAV progression during the subsequent 4 years.  
Male gender, pre-transplant ischemic heart disease, fasting hyperglycemia, triglycerides and metabolic 
syndrome were significantly associated with CAV development, in a proportional fashion to the severity of 
the disease. Of note, we were unable to find any association with cellular rejection, or with 
immunosuppressive strategy. Use of anti CMV prophylaxis, on the other hand, was associated with less 
IVUS-detected progression.  
 
Discussion 
By analyzing angiographic and IVUS-detected changes over a 4-year time period, this study provides a first 
suggestive evidence of the association of late progressing angiographic and IVUS coronary lesions with 
long-term cardiovascular prognosis, and supports the concept that IVUS imaging may improve prognostic 
stratification even long term after transplant.  
Several observational studies 17-19 clearly show that the severity of angiographic lesions is proportional to 
the risk of graft loss and MACE. Our results expand these concepts beyond the first years after transplant, 
focusing on longitudinal lesion progression. In particular, we found that even mildly changing angiographic 
lesions (i.e. progressing lesions within ISHLT grade 1), are associated with poorer outcome as compared 
with stable or absent coronary lesions (Figure 1). Although serial evaluation of angiograms may improve 
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prognostic stratification, a vast majority of patients (76%) presented normal coronary angiography at year 
5. On the other hand, at year 5, only 4% of patients showed a MIT below the 0.5 mm threshold, considered 
as  “normal”  in  the  historical  IVUS  studies,  and  over  50%  showed  “severe”  intimal  thickening.  16, 20 This 
finding is in line with pivotal IVUS studies showing that at year 1 about 20 to 40% of patients presented 
with pathological MIT, 6, 7, 15, 16 and that MIT continues to steadily increase after the first year. 21, 22 In this 
setting, a central question was to ascertain whether in this context of advanced abnormalities 16 IVUS could 
retain any long-term prognostic information. As previously observed in native atherosclerosis, 23 we found 
that vessel enlargement in response to plaque increase was predictive of cardiovascular events, regardless 
of lumen loss (Table X). In addition, MIT change predicted both MACE and CV death and it was possible to 
derive a cutoff improving the stratification of cardiovascular prognosis obtained by angiography and clinical 
assessments  alone.  MIT  change  ≥0.35mm  was  found  associated  with  higher  incidence  of  MACE  and  CV  
death (Figure 2), identified patients at risk for MACE among those without angiographic progression, 
(Figure 3) and improved MACE risk prediction (Table 4). Not surprisingly we found a threshold for 
prognostic MIT change lower than that reported in studies focusing on early follow-up (0.5mm): intimal 
growth has been reported to be largest during the first year and smaller afterwards 22, 24, and the 
proportion of patients treated with statins in this cohort is much higher than what reported in earlier 
studies, (i.e. 30% vs. 90%) further supporting the concept of a strong protective effect of statins on CAV. 6-9, 
15, 16, 25 
In addition, the results of this study underscore the importance of the metabolic syndrome milieu (e.g. high 
fasting glucose, high triglycerides, renal insufficiency) as relevant risk factors for late CAV and for adverse 
long-term prognosis. 26-28 While the widespread use of statins may explain the lack of association between 
cholesterol and CAV in this series, 29 low rate of steroid weaning, on the other hand, may at least partially 
support the relevant contribution of altered glucose metabolism in CAV development (Table 5).  
Regarding immune-mediated risk factors, we were unable to detect any effect of cellular rejection on CAV 
or on subsequent prognosis (Table 3), whereas data regarding antibody mediated rejection, or even 
subclinical detection of circulating donor specific antibodies, were unavailable in the majority of patients 
and could not be analyzed. Anti CMV prophylaxis was associated with lower IVUS-defined progression, 
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(Table 5) confirming on the long term our previous findings focusing on first post transplant year. 12 We 
cannot exclude however that this observation may be biased by an era effect because anti CMV prophylaxis 
was used only in patients receiving HT after 2005.  
Study limitations 
This is a single center retrospective analysis, therefore these results should not be considered as definitive 
but hypothesis generating. However, by using a sample size comparable to that of previous studies we 
were able to replicate in long-term survivors the same concept of IVUS-detected CAV demonstrated in the 
first post-transplant year IVUS. 6, 7 In this study, we used grayscale IVUS analysis with volumetric 
reconstruction of proximal LAD. This approach bears several limitations including that LAD morphology is 
used as a surrogate for the entire coronary tree and that gray scale analysis does not allow analysis of 
intimal thickness composition. IVUS with virtual histology and coronary angioscopy, on the other hand, 
allowed demonstrating that CAV is characterized by heterogeneous plaque morphologies bearing specific 
prognostic information. 30, 31  Nevertheless, our approach represent a standard, simple and reproducible 
method that is accepted and validated in early CAV monitoring: our findings support its validity in 
combination with serial coronary angiography to stratify graft prognosis beyond year 5 after 
transplantation, despite lacking data on specific plaque composition. Finally, the MIT threshold has been 
derived from the same cohort of patients which it has been applied on: we cannot exclude that in a 
validation cohort this threshold may provide different results.  
Conclusions 
While showing that assessment of late coronary lesion progression provides prognostic information beyond 
ISHLT CAV classification, we identified late MIT increase as an additional sensitive marker for late adverse 
CV prognosis. Moreover, this study provide further data supporting pathophysiological similarities between 
late CAV and native coronary atherosclerosis, 24 including the relevance of metabolic syndrome milieu as a 
key risk factor for disease progression, and of dilated coronary remodeling as a marker of subsequent 
cardiovascular events.  
Clinical implications 
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In the effort of achieving the most accurate prognostic stratification in long-term heart transplant 
recipients, these findings support the strategy of performing routine coronary angiography, with accurate 
serial match to identify progressing CAV, coupled with IVUS in patients with CV risk factors and normal or 
non-progressing angiograms. Although we do not provide data supporting specific interventions in patients 
with progressing CAV, it is reasonable to suggest aggressive management of metabolic abnormalities in the 
early years after transplant, in light of the prominent association between metabolic syndrome features 
and CAV progression. Nevertheless, the issue of prevention and treatment of long-term CAV development 
still remains unanswered: this study may provide the basis to design appropriately sized interventional 
studies, in which late MIT change may be used as surrogate prognostic endpoint.  
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Figure legends 
Figure 1.  
Panel A: Flow chart of CAV grades associated with angiographic progression 
Panel B: MACE cumulative incidence according with angiographic classification 
 
Figure 2.  
Panel A: MACE cumulative incidence according with IVUS progression 
Panel B: Cumulative incidence of cardiovascular death according with IVUS progression 
 
 Figure 3 
MACE cumulative incidence according with angiographic or IVUS only progression.  
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Table 1. Patient demography and clinical characteristics at year 1 (study baseline) and 5 
after HT  
 
* P<0.05 for paired analysis between Year 1 and Year 5 values; § Median (25th to 75th 
percentile);  †  According with NHLBI-AHA consensus published in Circulation. 2004; 109: 433-438 
 Study population n=131 
Demography 
Male gender, n (%) 112 (85%) 
Age at transplant, median  56.6 (15-67.5) 
Pre transplant diagnosis, n (%)  
Dilated cardiomyopathy 46 (35%) 
Ischemic 62 (47%) 
Other 23 (18%) 
 Year 1  Year 5 
Immunosuppressive strategy, n (%)  
Prednisone 128 (98%) 106 (81%) 
Average daily dose (mg/kg) 0.12±0.05 0.050.03* 
Micophenolate mofetil 52 (40%) 56 (43%) 
Azatioprine 60 (46%) 39 (30%) 
Everolimus 3 (2%) 24 (18%) 
Statins 111 (85%) 117 (91%) 
Metabolic parameters   
Serum creatinine (mg/dl) 1.53±0.46 1.53±0.43 
Serum glucose (mg/dl) § 91 (84-105) 93 (83-108) 
Total cholesterol (mg/dl) 196±36 185±37* 
HDL cholesterol (mg/dl) 58±15 56±18 
LDL cholesterol (mg/dl) 103 94* 
Triglycerides 171±77 160±70* 
Treated DM, n (%) 32 (24%) 44 (33%) 
Metabolic syndrome, n (%)† 50 (38%) 55 (42%) 
Table
Table 2. Changes in IVUS-related measurements 
 
 
 
 
 
 
 
 
 
 
 Year 1 Year 5 
Change between year 1-5  
(median, 25th to 75th percentile) P 
MIT (mm) 0.96 1.22 0.2 (0,05 to 0,41) <0.01 
Intimal volume (mm3) 149.9 174.9 18.6 (-11.9 to 61.6) <0.01 
Vessel volume (mm3) 533.9 531.9 8.8 (-44.3 to 57.3) 0.8 
Lumen volume (mm3) 383.4 354.3 -18 (-71 to 18) <0.01 
Table
Table 3 Univariate risk estimate for MACE and CV death according with IVUS parameters 
 Univariate risk estimate for MACE Univariate Risk estimate for CV death 
 RR 95% C.I. P RR 95% C.I. P 
Year 1 to year 5 changes       
MIT (per mm) 2.93 1.22 – 6.16 0.02 3.72 1.15 – 9.83 0.03 
Intimal volume (per 10 mm3) 1.06 0.99 – 1.11 0.06 1.06 0.99 – 1.13 0.09 
Vessel volume (per 10 mm3) 1.06 1.01 – 1.11 0.04 1.04 0.98 – 1.11 0.19 
Lumen volume (per 10 mm3) 1.02 0.96 – 1.09 0.47 0.99 0.92 – 1.08 0.94 
 
 
 
 
 
 
 
Table
 Table 4.  Multivariate  Cox’s  models  for  risk  of  MACE  including  imaging  and  clinical  variables   
 Model 1 Model 2 
 RR 95% C.I. P RR 95% C.I. P 
Angiographic progression 8.92 2.97 – 26.7 <0.01 8.09 2.71 – 24.1 <0.01 
Recipient age (per y) 1.08 1.00 – 1.16 0.04 1.08 1.01 – 1.16 0.02 
Serum glucose > 125 mg/dl  2.11 0.70 – 6.43 0.18 - - - 
Serum creatinine (per mg/dl) 7.42 2.67 – 20.6 <0.01 4.52 1.64 – 12.4 <0.01 
IVUS progression - - - 4.29 1.61 – 11.4 <0.01 
Likelihood Rank Chi 2  33.13   41.11 <0.01* 
* P value calculated by the likelihood-ratio test 
 
 
Table
Table 5. Clinical and laboratory variables at year 1 and subsequent CAV development 
 
 
IHD: ischemic heart disease; DM: diabetes mellitus 
* According with NHLBI-AHA consensus published in Circulation. 2004; 109: 433-438 
 
Characteristic  
CAV progression 
P 
Angiographic 
progression 
n=21 
MIT  change  ≥0.35  
only 
n=31 
Stable 
n=79 
Male gender (%) 20 (95%) 30 (96%) 62 (78%) <0.01 
Pre transplant IHD (%) 15 (71%) 18 (58%) 29 (37%) <0.01 
Recipient age (y) 53±11 56±9 54±10 0.5 
Donor age (y) 3311 3210 3412 0.6 
Glucose >125 mg/dl (%) 7 (33%) 5 (16%) 6 (8%) 0.01 
Treated diabetes (%) 9 (43%) 7 (22%) 16 (20%) 0.10 
Total cholesterol (mg/dl) 203±34 201±39 191±35 0.25 
LDL cholesterol (mg/dl) 106±29 103±25 101±25 0.36 
HDL cholesterol (mg/dl) 57±17 57±14 59±15 0.78 
Triglycerides (mg/dl) 208±87 187±70 156±73 <0.01 
Serum creatinine (mg/dl) 1.6±0.74 1.5±0.33 1.5±0.4 0.35 
Metabolic syndrome* (%) 14 (66%) 12 (39%) 24 (30%) 0.01 
Cellular rejection (%) 6 (28%) 9 (29%) 20 (25%) 0.89 
CMV prophylaxis (%) 6 (29%) 3 (10%) 24 (30%) 0.05 
Table
Figure 1
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Table S1. Patients characteristics and relationships to the risk of MACE 
 
 RR  95% CI p 
Recipient age (per y) 1.06  1.00 – 1.13 0.03 
Ischemic etiology 2.25  0.94 – 5.74 0.06 
Donor age (per y) 0.98 0.94 – 1.01 0.32 
Serum creatinine 4.41  1.87 – 10.3 <0.01 
Serum glucose >125mg/dl 2.97 1.06 – 8.30 0.04 
Total cholesterol (mg/dl) 0,96 † 0,85-1,08 0.6 
HDL cholesterol (mg/dl) 0.81  † 0.61 – 1.04 0.1 
LDL cholesterol (mg/dl) 0.99  †   0.84 – 1.14 0.9 
Tryglicerides (mg/dl) 1,01 † 0,96-1,07 0.5 
Metabolic syndrome* 2.03 0.85 – 4.85 0.1 
On everolimus at year 5 0.85 0.13 – 3.13 0.9 
On steroids at year 5 0.99 0.36 – 3.5 0.99 
Rejection  ≥2R  during  y  1  to  5 1.1 0.39-2.71 0.84 
 
 
RR: risk ratios; CI: confidence intervals 
* According with NHLBI-AHA consensus published in Circulation. 2004; 109: 433-438 
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. 2.3  Role of coronary CT in predicting prognosis     
after heart transplantation  
Introduction: 
Cardiac allograft vasculopathy (CAV) is the main long term cause of death after heart 
transplantation (HTx). The ISHLT guidelines for CAV assessment suggest a role for coronary 
tomography (CT); however, its prognostic predicting power is unknown, and few data are available 
about the significance of scoring calcified plaques. Our study’s aim was to investigate the role of 
coronary CT in predicting cardiovascular (CV) prognosis in HTx patients. 
 
Methods: 
 
In this retrospective study of prospective collected data, all patients transplanted in Vienna 
between 2001-08, with a CT assessment for CAV, were enrolled. A CAV positive CT was labeled 
as any detected irregularity (stenosis, vessel wall irregularity, calcifications) for better matching 
with the ISHLT CAV grading system; calcium score (CS) was collected. The primary endpoint was 
CV death, the secondary MACE (CV death, admission for HF, PCI, re-HTx), both expressed as 5-
yrs survival rates 
 
Results: 
155 patients entered into the study (81.2% males, 50.3+/-14.0 years at HTx). CT scan was made 
44±24 months after HTx; 34.8% of the patients had a CAV positive CT, 25% a positive (>0) CS. 
Any irregularity in the first CT scan predicted both the primary (98.9+/-0.1% vs. 89.0+/-4.7%, 
p=0.01) and the secondary endpoint (96.4+/-2.0% vs. 77.2+/_6.1%, p<0.0001), see Fig. 1 and 2. 
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Figure 1. Role of CT scan positive for CAV in predicting CV death 
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Figure 2. Role of CT scan positive for CAV in predicting MACE 
 
 
 
A positive CS predicted MACE (94.0+/-2.3% vs. 78.6+/-7.3%, p=0.01) but not CV death. (Fig. 3 
and 4) 
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Fig. 3 Effect of positive calcium score on MACE 
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Fig. 4 Effect of positive calcium score on cardiovascular death 
 
 
At multivariate analysis, only CT irregularity predicted MACE [OR 2.5 (95% CI 1.1-5.2), p<0.0002]. 
, Table 1. 
 
 OR 95% CI P 
CT positive for CAV 6.7 1.7-23.4 0.008 
Positive calcium score 0.93 0.32-3.33 0.90 
 
Table 1. Multivariate analysis on MACE prediction 
 
115 patients underwent a second CT, 22±12 months after the first one; 27.8% of them had a CAV 
progression (increase of a stenosis, new onset stenosis, higher CS), and this predicted outcome 
with a borderline statistical significance (Fig. 5) 
 
Among the 102 in which CS was calculated, the ones who experienced an increase in CS (28) had 
a higher rate of MACE (98.6+/-1.3% vs. 82.4+/-9.5%, p=0.03), Fig. 6.  
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Figure 5. Effect of CT progression on MACE 
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Fig. 6 Role of calcium score progression on MACE 
 
Among the 39 patients who had a coronary angiography within 6 months from the CT, the ones 
with CT-detected CAV had a higher rate of angiography detected CAV (88.9% vs. 47.6%,p=0.006); 
a CT negative for CAV predicted a negative angiography with a 84% sensitivity and a 62% 
specificity (AUC 0.73,p=0.004). 
 
Conclusion: 
 
CT –detected coronary irregularities can predict CV death and MACE. CS may be used only as a 
longitudinal parameter to predict CV prognosis in a subset of patients. Even if its sensitivity in CAV 
assessment is lower than angiography, our study suggests that CT could be used a non-invasive 
screening tool for predicting prognosis in selected HTx patients. 
 
 
N=160 
P = 0.006 
N=197 
P=0.09 
Chapter 3. Cardiac allograft vasculopathy: 
trying to improve prevention 
3.1 Differential effect of everolimus on progression 
of early and late cardiac allograft vasculopathy in 
current clinical practice 
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Introduction*
Although!modern!immunosuppressive!strategies!have!led!to!a!marked!reduction!of!acute!rejection!rates!in!
heart!transplant!(HT)!recipients,!cardiac!allograft!vasculopathy!(CAV),!the!major!manifestation!of!chronic!
rejection,!still!remains!the!leading!cause!of!death!in!the!longVterm.!(1)!
Longitudinal!studies!based!on!intravascular!ultrasound!imaging!(IVUS)!revealed!that!early!changes!in!
coronary!artery!geometry,!such!as!increase!in!maximal!intimal!thickness!(MIT),!are!clearly!related!to!
adverse!prognosis,!identifying!early!MIT!change!as!a!potential!therapeutic!target!(2V4).!Among!the!several!
drugs!used!in!the!transplant!setting,!convincing!data!indicate!a!drugVrelated!benefit!on!early!CAV!
development!from!statins!(5,!6)!and!inhibitors!of!mammalian!target!of!rapamycin!(mTOR)!(7,!8).!While!
statins!are!widely!used!after!HT,!and!observational!registries!confirmed!their!benefit!in!clinical!practice!(9,!
10),!a!suboptimal!safety!profile!limited!the!use!of!mTOR!inhibitors!in!the!early!postVHT!phase!out!of!the!
context!of!randomized!clinical!trials,!and!their!effect!on!CAV!development!in!clinical!practice!is!unknown.!
Late!after!the!first!postVHT!year,!CAV!morphological!features!and!risk!factors!appear!to!differ!from!the!early!
pattern!(11V13).!However,!the!effect!of!pharmacologic!interventions!on!late!CAV!development!has!been!
investigated!by!a!few!studies!that!provided!contradictory!results!(14,!15).!
Herein!we!aimed!to!explore!how!therapeutic!strategies!could!affect!early!and!late!changes!in!coronary!
morphology.!In!particular,!we!focused!our!analysis!on!the!effect!of!the!mTOR!inhibitor!everolimus!on!early!
(year!1)!and!late!(year!1!to!5)!changes!in!coronary!morphology!after!HT,!as!detected!by!IVUS,!and!using!
patients!receiving!mycophenolate!mofetil!(MMF)!as!a!standard!comparative!cohort.!!
*
Methods*
Study&design&&
This!observational!study!is!a!retrospective!analysis!of!data!prospectively!collected!in!our!institutional!
database,!involving!all!consecutive!HT!recipients!fulfilling!study!inclusion!criteria.!The!study!design!is!
depicted!in!figure!1.!!
! 5!
To!study!early!changes!in!coronary!morphology!we!analyzed!a!cohort!of!consecutive!adult!recipients!
transplanted!between!November!2004!and!June!2010!(early!cohort),!who!underwent!a!baseline!(within!6!
weeks!from!transplantation)!and!a!1Vyear!followVup!IVUS!study,!and!with!everolimus!(marketed!in!Europe!
as!Certican®!by!Novartis!Pharma,!Basel,!Switzerland,!since!2003)!or!MMF!(marketed!as!CellCept,!by!Roche,!
Basel,!Switzerland)!added!to!cyclosporine!as!maintenance!immunosuppression!during!the!first!month!after!
transplant.!!!
Late!changes!in!coronary!morphology!were!assessed!by!analyzing!IVUS!performed!at!years!1!and!5!after!HT!
in!a!cohort!of!patients!transplanted!between!1999!and!2006!(late!cohort).!In!this!cohort!of!patients,!year!1!
was!considered!as!“baseline”.!We!included!in!the!study!all!patients!taking!MMF!or!everolimus!for!at!least!3!
of!the!4!years!of!followVup,!with!complete!year!1!and!5!IVUS!data!available.!!
IVUS&procedure&
In!our!center,!we!routinely!perform!IVUS!for!CAV!progression!surveillance!at!baseline!(3!to!6!weeks!after!
transplant),!and!at!years!1!and!5!after!transplant,!except!when!contraindicated!by!renal!dysfunction!or!
other!severe!comorbidities.!The!IVUS!procedure!of!the!left!anterior!descending!artery!(LAD)!has!been!
detailed!previously!(16).!Briefly,!IVUS!is!performed!after!documentation!of!the!absence!of!coronary!artery!
stenosis!≥60%!based!on!angiography,!and!images!were!acquired!by!an!automatic!pullback!(0.5!mm/sec!
motorized!device)!of!the!probe,!for!offline!analysis!of!the!first!30!mm!of!the!LAD.!External!elastic!
membrane!and!lumen!crossVsectional!borders!were!identified!and!used!to!quantify!intimal,!vessel!and!
lumen!volumes.!(17)!Our!Institutional!IVUS!Core!laboratory!performed!2Vdimensional!and!3Vdimensional!
IVUS!analysis!by!a!semiVautomated!method!using!Qivus®!Clinical!Edition!software!(Medis!medical!imaging!
systems!bv,!Leiden,!NL)!(18).!One!individual!blinded!to!the!patients’!treatment!performed!all!the!
measurements!reported!in!this!study.!!
Immunosuppression&and&concomitant&therapy&
Standard!immunosuppressive!regimen!in!our!Center!consists!in!induction!with!thymoglobuline!or!
basiliximab,!followed!by!maintenance!with!cyclosporine,!an!antiproliferative!agent,!and!oral!steroids.!After!
2005,!in!de!novo!patients!MMF!(2!to!3!g/day)!or!everolimus!(3!to!8!ng/ml!trough!levels)!were!used!instead!
of!azathioprine.!According!to!the!choice!of!the!inVcharge!physicians,!everolimus!could!be!started!a!few!days!
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after!surgery!or!introduced!after!2!to!6!weeks!of!MMF!treatment.!Presence!of!cytomegalovirus!(CMV)!
serological!mismatch,!history!of!preVtransplant!neoplasm,!or!mere!preference!of!the!inVcharge!physician!
supported!the!choice!of!everolimus!introduction!(intentionVtoVtreat!basis).!!!
Late!after!transplant!(late!cohort!patients)!everolimus!introduction!associated!with!cyclosporine!
minimization!could!be!used!to!substitute!azathioprine!or!MMF!combined!with!standard!cyclosporine,!as!
rescue!strategy!in!patients!developing!renal!dysfunction,!(19)!cancer,!(20)!or!a!rapid!increase!in!maximal!
intimal!thickness!as!detected!at!year!1!IVUS!(14).!
Statin!therapy!was!prescribed!universally,!regardless!of!cholesterol!levels,!excluding!patients!with!known!or!
developed!intolerance.!Statin!type!and!dosage!was!chosen!by!the!inVcharge!physician!and!usually!started!
between!months!1!and!2!after!transplant.!Based!on!the!metaVanalysis!from!Law!and!coVworkers,!(21)!and!
on!studies!from!our!group,!(22V24)!we!defined!“high”!and!“low”!dose!statins!according!with!the!predicted!
LDL!cholesterol!reduction.!Table!1!reports!only!statins!type!and!dosage!actually!given!to!the!study!patients.!
Cytomegalovirus!(CMV)!disease!was!prevented!by!either!preVemptive!strategy!(before!2005),!or!by!
universal!prophylaxis!with!valganciclovir,!as!previously!described.!(16)!All!patients!were!monitored!for!CMV!
infection!with!pp65!antigenemia!or!whole!blood!DNA!PCR.!Patients!were!treated!for!CMV!infection!for!
antigenemia!levels!greater!than!30!pp65cells/200,000!neutrophils,!or!20,000!DNA!copies/ml!(16).!
&
Data&analysis&and&study&endpoints&
Early!and!late!cohorts!were!analyzed!separately.!The!main!outcome!measure!was!change!in!MIT,!which!was!
assessed!between!baseline!and!year!1!IVUS!for!the!early!cohort,!and!between!years!1!and!year!5!for!the!
late!cohort.!Study!endpoint,!for!both!cohorts,!was!a!change!in!MIT!>0.5mm,!which!for!study!purposes!only!
was!defined!as!“CAV!progression”.!Additional!IVUS!parameters!used!to!analyze!CAV!progression!comprised:!
baseline!to!followVup!changes!in!vessel,!lumen!and!intimal!volumes,!and!change!rate!of!intimal!index.!
Intimal!index!was!defined!as!the!rate!between!intimal!and!vessel!volume,!and!the!change!rate!as!the!rate!
between!change!in!intimal!index!and!baseline!intimal!index!(17).!For!descriptive!purposes!we!additionally!
report!angiographic!CAV!classification!based!on!ISHLT!nomenclature.!(25)!
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The!primary!aim!of!the!study!was!to!compare!IVUSVdefined!CAV!between!patients!receiving!everolimus!
with!those!receiving!MMF.!In!the!early!cohort,!we!performed!an!intentionVtoVtreat!(ITT)!analysis,!based!on!
the!drug!that!patients!were!taking!at!the!time!of!baseline!IVUS.!!To!account!for!crossVovers,!we!additionally!
performed!an!onVtreatment!analysis,!including!in!the!EVE!group!any!patients!who!took!at!least!one!dose!of!
the!drug!during!the!first!year!of!followVup.!!
In!the!late!cohort,!shortly!after!the!year!1!time!point,!the!immunosuppressive!agent!chosen!at!transplant!
was!changed!in!several!patients,!but!was!then!left!unchanged!until!the!end!of!the!year!5!followVup.!This!
allowed!us!to!compare!the!association!of!everolimus!and!MMF!with!late!MIT!changes,!without!the!possible!
confounding!effect!of!late!crossVovers.!(Figure!2B)!
Because!of!the!observational!design,!to!weigh!for!possible!confounders,!we!adjusted!for!differences!
between!study!groups!in!laboratory,!clinical,!and!therapeutic!variables!collected!at!months!1!and!12!after!
transplant!in!the!early!cohort,!and!at!years!1!and!5!after!transplant!in!the!late!cohort,!by!using!logistic!
multivariable!analysis.!In!addition,!baseline!variables!(i.e.!month!1!for!the!early!cohort!and!year!1!for!the!
late!cohort)!were!tested!in!univariate!logistic!models!where!MIT!change>0.5!mm!(defined!as!CAV!
progression)!was!the!outcome!variable.!Variables!associated!with!CAV!progression!with!a!P!≤!0.1!at!
univariate!analysis!were!challenged!one!at!a!time!in!multivariate!logistic!models!against!the!variable!of!
interest!(i.e.!everolimus!vs.!MMF)!to!identify!independent!predictors!of!early!and!late!CAV!progression.!!
Among!the!possible!confounders,!we!devoted!particular!attention!to!metabolic!variables,!statin!therapy,!
and!rejection!burden.!Because!the!vast!majority!of!our!patients!routinely!receive!statin!therapy,!to!analyze!
the!possible!role!of!statins!in!CAV!development!we!compared!patients!taking!high!dose!statins!vs.!those!
taking!low!dose!or!no!statin!(see!supplemental!material)!(21V24).!Rejection!burden!was!analyzed!by!
computing!average!rejection!score,!obtained!by!scoring!biopsy!grades!as!follows:!grade!0!=!0;!grade!1R!=!1;!
grade!2R!=!2;!grade!3R!=!3.!!
Statistical!analysis!was!performed!by!JMP®!9.0.1!software.!Continuous!variables!are!expressed!as!mean!±!
SD!if!normally!distributed!or!as!median!(25th!to!75th!percentile)!if!skewed,!categorical!variables!as!
percentages;!differences!between!study!groups!were!assessed!by!Student’s!T!test,!Mann!–!Whitney!or!chiV
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square!test,!as!appropriate.!The!odds!for!CAV!progression!associated!with!study!variables!were!estimated!
by!nominal!logistic!analysis,!and!a!p!value!<0.05!was!considered!as!significant!for!all!comparisons.!
*
Results!
Overall,!143!patients!entered!the!study,!of!which!91!were!included!in!the!early!cohort!and!52!in!the!late!
cohort!(Figure!2).!!
In!the!early!cohort,!20!patients!were!on!everolimus!and!71!on!MMF!at!baseline!(ITT!groups).!Median!(25thV
75th!percentile)!distance!from!transplant!of!everolimus!start!was!5!(3!to!18)!days.!
Three!patients!were!shifted!from!MMF!to!everolimus!six!to!nine!months!after!transplant,!because!of!
recurrent!CMV!infection,!Kaposi’s!sarcoma!and!CNIVminimizing!strategy!for!renal!failure.!One!patient!was!
shifted!from!EVE!to!MMF!for!an!adverse!event!related!to!the!drug!(lower!limb!edema).!Following!these!
crossVovers,!the!onVtreatment!groups!consisted!in!23!patients!on!everolimus!(i.e.!anyone!who!received!
everolimus!for!at!least!3!months)!and!68!on!MMF,!at!year!1!
As!can!be!noted!from!table!1,!MMF!and!everolimus!groups!were!largely!comparable!at!baseline,!except!for!
cyclosporine!trough!levels!that!were!lower!in!everolimus!patients.!One!year!after!transplantation,!
everolimus!patients!showed!higher!total!and!LDLVcholesterol!levels!(despite!a!wide!and!comparable!use!of!
high!dose!of!statins!in!both!groups),!higher!fasting!glucose,!less!steroid!dose,!and!fewer!treated!CMV!
infections!than!the!MMF!group.!Of!note,!calculated!GFR!(26)!was!not!significantly!different!between!study!
groups!at!year!1.!Regarding!major!adverse!events,!patients!in!the!everolimus!group!underwent!postV
operative!pericardial!drainage!significantly!more!often!than!patients!in!the!MMF!group!(36.8%!vs.!13.8%,!
P=0.02).!No!difference!in!severe!bacterial!infection!or!other!major!adverse!events!was!noted.!
In!the!late!cohort,!33!patients!received!MMF!and!19!everolimus,!for!at!least!3!of!the!4!years!of!followVup!
(Figure!2B!and!Table!2).!Seven!patients!were!on!everolimus!on!a!deVnovo!basis!since!after!surgery,!while!in!
the!remaining!12!everolimus!was!introduced!as!a!rescue!strategy!between!year!1!and!2!after!transplant!for!
renal!failure!(n=8),!CAV!at!1Vyear!IVUS!(n=2),!recurrent!CMV!infection!despite!antiviral!treatment!(n=1)!and!
recurrent!rejection!(n=1).!Median!(25thV75th!percentile)!duration!of!everolimus!treatment!was!41!(37!to!57)!
months!and!median!distance!from!transplant!of!everolimus!start!was!18!(0.5!to!23)!months.!At!baseline,!
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the!MMF!and!everolimus!groups!differed!for!statin!use!(P=0.01)!and!first!year!rejection!score.!During!the!4!
years!of!followVup,!patients!receiving!EVE!developed!a!worse!metabolic!profile!compared!to!MMF,!driven!
by!higher!total!cholesterol!(p<0.01),!LDL!(p=0.01),!and!triglycerides!(p<0.01),!despite!the!similar!use!of!
statins!at!5!years!in!both!groups!(86.3%!overall,!p=0.39!for!EVE!vs!MMF).!Levels!of!cyclosporine!were!lower!
in!EVEVtreated!patients,!as!expected.!Of!note,!GFR!improved!from!baseline!to!followVup!in!EVE!group,!while!
it!remained!stable!in!MMF!patients!(Table!4).!Regarding!safety,!in!the!EVE!group,!4/19!(21%)!experienced!
bacterial!infections!and!two!(10%)!lower!limb!edema;!however,!none!of!these!events!caused!drug!
withdrawal.!!
!
Predictors&of&early&CAV&progression&
At!year!1,!16!(17%)!patients!presented!mild!angiographic!CAV!(ISHLT!grade!1),!with!only!3!(3%)!patients!
showing!angiographic!progression!from!baseline.!Progression!of!IVUSVdefined!CAV!was!found!in!17!(19%)!
patients.!MMF!treatment!was!associated!with!higher!occurrence!of!early!CAV!than!everolimus,!both!by!ITT!
(22.8!vs.!5%;!P=0.04)!and!by!onVtreatment!(24.8!vs.!4.7%;!P=0.02)!analyses.!Accordingly,!the!MIT!change!
was!significantly!greater!in!the!MMF!than!in!everolimus!group!(0.37±0.29!vs.!0.23±0.15!mm,!P=0.05,!Figure!
3!A).!Volumetric!IVUS!analysis!revealed!that!in!patients!treated!with!MMF!lumen!volume!decreased!(V11%;!
P<0.01)!caused!both!by!a!significant!increase!in!intimal!volume!(+14%;!P=0.01)!and!shrinkage!in!vessel!
volume!(V5%;!P=0.03),!while!in!patients!receiving!everolimus,!vessel!volume!parameters!did!not!change!
significantly.!Consequently,!the!median!change!rate!in!intimal!index!was!significantly!higher!in!patients!
receiving!MMF!(3.2%[V5%!to!17%]!vs.!11%![0%!to!41%];!P=0.02;!Figure!3B).!
Among!all!the!other!variables!included!in!the!study,!CAV!occurrence!appeared!to!be!influenced!only!by!the!
use!of!high!doses!of!statins.!In!particular,!early!CAV!tended!to!develop!less!frequently!among!the!31!
patients!starting!aggressive!statin!therapy!at!the!time!of!baseline!IVUS,!than!in!those!with!no!or!lowVdose!
statins!(9.7!vs.!25%!P=0.06).!Of!note,!high!dose!statins!was!also!associated!with!significantly!lower!MIT!
increase!(0.23±0.19!vs.!0.38±0.29!mm;!P=0.01)!Multivariable!logistic!analysis!showed!that!both!everolimus!
treatment!(OR[95%CI]=0.14![0.01V0.78];!P=0.02),!and!high!doses!statins!(OR[95%CI]=!0.28![0.06V0.95];!
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P=0.04)!had!an!independent!protective!effect!on!early!CAV!development,!even!after!adjusting!for!other!
possible!confounders,!such!as!elevated!cholesterol!and!glucose,!and!steroid!use!at!year!1.!
!
IVUS&analysis&and&predictors&of&late&CAV&progression&
At!year!5,!14!(23%)!patients!presented!angiographic!CAV!(12!grade!1,!and!2!grade!2),!with!5!(9.6%)!patients!
showing!progression!from!year!1!to!year!5!(2!in!everolimus,!3!in!MMF!groups).!IVUSVdefined!CAV!
progression!was!observed!in!15!(29%)!patients.!Intimal!volume!increased!(from!157±87!to!196±97mm3;!
P<0.01),!causing!a!significant!lumen!loss!(from!363±118!to!398±110!mm3;!P<0.01),!accompanied!by!lack!of!
vessel!wall!remodeling!(from!556±138!to!560±164mm3;!P=0.8).!No!significant!differences!between!
everolimus!and!MMF!patients!were!observed!in!the!occurrence!of!late!CAV!(31.5%!vs.!27.2%,!respectively!
P=0.74),!average!MIT!change!(0.34±0.53!vs.!0.27±0.36mm;!p=0.57),!and!average!change!of!all!vascular!
volume!parameters!(Figure!4;!all!P!values!>0.5).!!
Univariate!analysis!revealed!that!high!doses!of!statins!at!year!1!were!associated!with!a!lower!occurrence!of!
late!CAV!(10%!vs.!39%;!P=0.02).!In!addition,!patients!with!late!CAV!also!had!higher!median![25thV75th!
percentile]!triglyceride!concentrations!at!baseline!(210[154V245]!vs.!153[110V199]!mg/dl;!P=0.01)!than!
those!without!CAV.!Of!note,!year!1!triglyceride!levels!showed!a!linear!correlation!with!increase!in!MIT,!
intimal!volume,!and!lumen!loss!(Figure!5).!!
At!multivariate!analysis,!levels!of!tryglicerides!(OR!per!10mg/dl!increase![95%CI]!=!1.11![1.02!–!1.21];!
P=0.01)!and!high!doses!of!statins!(OR[95%CI]=!0.08![0.01!–!0.47]!P<0.01)!independently!predicted!late!CAV!
progression,!even!after!adjusting!for!everolimus!or!MMF!based!strategy.!
DISCUSSION*
This!IVUSVbased!study!analyzes!early!and!late!CAV!development!in!two!patient!cohorts!receiving!everolimus!
or!MMF!in!a!clinical!practice!context.!We!found!that!everolimus!and!high!dose!statins!are!associated!with!a!
low!risk!for!early!markers!of!CAV!development.!While!statins!appear!to!protect!against!CAV!progression!
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also!later!after!transplant,!everolimus!treatment!does!not!seem!to!influence!changes!in!IVUS!parameters!
assessed!between!years!1!and!5!after!transplant.!!
IVUSVdetected!increase!in!MIT!during!the!first!year!after!HT!is!a!marker!for!early!CAV!development!and!has!
been!identified!as!a!surrogate!endpoint!for!longVterm!survival,!being!associated!with!high!risk!for!death!and!
nonVfatal!cardiovascular!events.!(2V4)!Although!MIT!progression!has!been!described!also!after!the!first!year!
following!transplant,!its!contribution!to!subsequent!prognosis!is!unknown,!and!late!MIT!increase!appears!to!
be!associated!with!different!remodeling!properties!of!the!vessel!wall!(12).!These!differences!between!early!
and!late!geometric!changes!of!graft!coronaries!support!the!hypothesis!that!different!pathophysiological!
mechanisms!may!be!implicated!in!early!and!late!CAV!progression.!(11,!13).!This!hypothesis!led!us!to!
separately!analyze!early!and!late!morphological!changes!of!graft!coronary!arteries!and!compare!the!effect!
of!everolimus!with!lowVdose!cyclosporine!to!MMF!with!standard!dose!cyclosporine!in!two!separate!cohorts!
of!patients.!!
In!the!early!cohort,!everolimus!was!chosen!as!first!choice!antiproliferative!agent!in!20!patients,!but!was!
started!during!a!wider!period!of!time!than!what!it!was!in!the!major!randomized!trials!(i.e.!median!(25th!–!
75th!percentile)!of!everolimus!start!was!5!(3!to!18)!days!after!HT,!instead!of!72!hours!after!surgery).!
Between!months!6!to!9!after!transplant,!three!additional!patients!were!converted!from!MMF!to!
everolimus,!and!one!discontinued!everolimus!because!of!drugVrelated!side!effects.!Everolimus!intake!was!
independently!associated!with!lower!early!CAV!development!both!in!an!ITT!analysis,!and!in!an!on!
treatment!analysis!(which!includes!all!patients!receiving!the!drug!at!any!time!during!the!followVup;!Figure!
2A),!by!reducing!the!likelihood!of!MIT!increase!≥0.5mm,!the!absolute!increase!in!MIT,!and!intimal!index.!
This!finding!extends!in!a!clinical!practice!context!the!finding!of!the!randomized!trials!of!everolimus!and!
sirolimus!against!azathioprine,!(7,!8)!and!of!the!preliminary!analysis!of!the!CRAD!2310!trial,!currently!
available!only!as!part!of!conference!proceedings!(27).!Our!data!additionally!suggest!that!the!protective!
effect!of!the!mTOR!inhibition!may!also!be!achieved!by!starting!the!drug!slightly!later!after!surgery.!This!
concept!may!be!of!particular!importance!because!a!delayed!start!of!everolimus!may!help!to!maintain!
efficacy!while!avoiding!some!of!the!side!effects!typical!in!the!postVoperative!period!(28V30).!!
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At!our!institution,!patients!not!presenting!contraindications,!and!accepting!the!procedure,!routinely!receive!
IVUS!examination!at!year!5!after!transplant.!We!were!thus!able!to!analyze!late!CAV!progression,!by!defining!
as!an!endpoint!an!MIT!change!≥0.5mm!between!years!1!and!5!after!transplant.!During!the!second!year!
after!transplant,!20!out!of!the!52!patients!in!the!late!cohort!were!shifted!from!the!antiproliferative!agent!
they!originally!received!after!surgery!(Figure!1).!We!thus!compared!IVUS!change!over!a!4Vyear!period!
between!groups!of!patients!treated!for!about!three!years!with!the!same!therapeutic!strategy.!In!particular,!
median!duration!of!everolimus!treatment!was!41!(37!to!57)!months.!We!were!unable!to!show!any!
difference!in!late!CAV!progression!between!patients!receiving!everolimus!or!MMF,!as!opposed!to!what!we!
found!in!the!patients!from!the!early!cohort.!This!finding!is!in!apparent!contradiction!with!the!results!of!a!
randomized!study!of!sirolimus,!in!which!clinical!endpoints!were!combined!with!morphological!ones!(14),!
but!are!in!line!with!a!recent!IVUSVbased!observational!study,!comparing!patients!receiving!sirolimus!and!
MMF/AZA!on!a!calcineurinVfree!regimen,!to!patients!on!cyclosporine!or!tacrolimus!and!MMF/AZA!(31),!in!
which!mTOR!inhibition!had!a!greater!effect!in!limiting!intimal!hyperplasia!in!early!converted!patients!than!
in!patients!converted!late!after!transplant.!This!concept!is!further!supported!by!the!recent!NOCTET!
substudies.!(15,!32)!In!patients!randomized!to!receive!everolimus!or!standard!immunosuppression!late!
after!HT,!NOCTET!investigators!analyzed!MIT!changes!and!plaque!composition!by!using!grayscale!IVUS!and!
virtual!histology!technique.!While!MIT!increase!was!unaffected!by!everolimus!therapy,!mTOR!inhibition!was!
found!to!be!associated!with!increased!calcified!and!necrotic!plaque!component!(known!to!predict!adverse!
coronary!outcomes!in!native!atherosclerosis),!in!particular!in!patients!with!more!than!5!years!of!postV
transplant!followVup.!
Taken!together,!all!these!findings!support!our!initial!working!hypothesis!that!early!and!late!CAV!
development!are!influenced!by!different!pathophysiological!mechanisms.!Everolimus!intake!during!the!first!
year!is!likely!to!reduce!coronary!intimal!hyperplasia!by!antagonizing!the!immunoVmediated!injury!leading!to!
endothelial!proliferation!(for!example!by!reducing!CMV!infection,!Table!2).!On!the!other!hand,!metabolic!
risk!factors!appear!to!play!a!more!relevant!role!in!favoring!late!intimal!proliferation!compared!with!what!
everolimus!could!antagonize.!Of!note,!late!metabolic!abnormalities!are!more!likely!to!be!associated!with!
local!inflammatory!milieu!and!with!plaque!composition,!as!showed!the!virtual!histology!study!from!
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NOCTET.!(32)!Remarkably,!we!found!that!triglycerides!concentrations!at!one!year!were!highly!correlated!
with!subsequent!increase!in!intimal!hyperplasia!and!loss!of!lumen!volume!(Figure!5).!In!this!context,!
therapy!with!high!dose!statins!appears!to!have!a!protective!effect,!both!on!early!and!late!CAV!
development,!confirming!and!extending!the!results!of!a!recent!randomized!study!by!our!group,!(23)!and!
supporting!the!concept!that!these!drugs!may!interact!with!immunoV!and!metabolicVmediated!vascular!
injury!in!HT!recipients.!(5,!9)!!
Our!results!additionally!shed!light!on!the!safety!profile!of!everolimus!in!a!clinical!practice!context,!when!
used!in!patients!with!a!lowVcomorbidity!profile.!While!noting!that!we!found!no!difference!in!graft!loss!or!
death!for!safety!reasons!in!the!study!groups,!we!confirm!most!of!known!everolimus!side!effects,!such!as!a!
trend!towards!a!worse!lipid!profile,!which!however!did!not!appear!to!influence!its!efficacy!on!early!
coronary!intimal!hyperplasia.!In!addition,!while!we!did!not!record!woundVhealing!or!early!renal!
insufficiency!issues,!it!must!be!noted!that!patients!receiving!everolimus!in!the!early!cohort!had!a!
significantly!higher!rate!of!pericardial!drainage!than!those!treated!with!MMF.!Overall!tolerability!was!
satisfactory,!with!only!one!patient!in!the!early!group!discontinuing!everolimus!for!drugVrelated!side!effects,!
and!none!who!discontinued!in!the!late!group,!over!a!4Vyear!period!of!followVup.!!
Study&limitations&
The!use!of!IVUSVdetected!increase!in!MIT!as!a!surrogate!endpoint!for!longVterm!graft!survival!has!been!
validated!only!in!patients!receiving!IVUS!during!the!first!postVtransplant!year!(e.g.!our!early!cohort)!and!not!
when!occurring!late!after!transplant!(e.g.!our!late!cohort).!Thus,!we!are!unaware!whether!our!MIT!change!
cutoff!of!0.5!mm!has!any!prognostic!relevance!when!measured!between!years!1!and!5!after!transplant.!In!
addition,!it!must!be!noted!that!recent!guidelines!do!not!consider!IVUS!changes!sufficient!to!properly!define!
CAV!(25),!and!that!we!used!the!term!“CAV!progression”!to!more!easily!indicate!meaningful!progression!of!
graft!vascular!disease.!However,!in!this!study!we!aimed!to!provide!a!descriptive!analysis!of!factors!
influencing!coronary!morphology!and!chose!established!linear!and!volumetric!parameters!that!clearly!
relate!to!CAV!pathophysiology.!With!this!approach,!we!were!able!to!provide!evidence!supporting!the!
hypothesis!that!drugs!and!risk!factors!have!a!timeVdependent!effect!on!early!and!late!changes!in!coronary!
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morphology.!In!this!study!we!included!only!patients!who!were!healthy!enough!to!undergo!two!IVUS!
examinations.!Thus,!patients!with!severe!comorbidities!or!with!worsening!kidney!failure!could!not!be!
analyzed!and!we!cannot!exclude!the!possibility!that!their!outcome!might!have!provided!a!different!picture!
to!our!results.!Observational!design!may!represent!a!further!limitation!to!the!study!results,!and!
multivariable!models!may!not!fully!account!for!uncontrolled!potential!confounders.!In!particular,!late!
cohort!patients!were!transplanted!during!a!wide!time!span!in!which!therapeutic!strategy!transitioned!from!
azathioprine!to!MMF!or!everolimus,!quite!a!few!years!before!early!cohort!patients,!and!thus!we!cannot!
exclude!that!other!uncontrolled!changes!in!clinical!practice!could!have!influenced!the!different!IVUS!
outcomes!in!the!two!study!eras.!However,!our!results!provide!a!realVlife!picture!of!everolimus!timing!of!use,!
tolerability,!and!effects!in!current!clinical!practice,!besides!the!protected!environment!of!a!multicenter!
randomized!trial,!which!may!often!be!far!from!the!complex!reality!of!standard!heart!transplant!recipients.!!
Conclusions&
In!a!clinical!practice!context,!we!found!that!mTOR!inhibition!by!everolimus!was!associated!with!a!reduced!
progression!of!coronary!intimal!hyperplasia!during!the!first!postVtransplant!year,!but!not!in!the!subsequent!
four!postVtransplant!years.!High!triglycerides,!on!the!other!hand,!did!not!appear!to!influence!early!CAV,!but!
were!highly!correlated!with!late!progression!of!coronary!intimal!hyperplasia,!while!highVdose!of!statins!
provided!beneficial!effects!on!both!sides!of!this!spectrum,!by!limiting!early!and!late!CAV!progression.!By!
highlighting!a!differential!effect!of!everolimus!and!metabolic!abnormalities!on!early!and!late!changes!of!
graft!coronary!morphology,!this!observational!study!confirms!the!evidence!that!CAV!progression!is!
influenced!by!risk!factors!acting!at!different!time!points!of!the!CAV!time!course.!Prospective!studies!are!
needed!to!test!the!hypothesis!that!timeVtailored!interventions!may!grant!a!major!benefit!in!limiting!CAV!
progression.!!
!
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!
Table*1.*Definition*of*high*and*lowCdose*statins**
!
See!articles!(21V24)!for!reference!
“High!dose”!statins!
(expected!35!to!45%!reduction!in!LDL!cholesterol) 
Fluvastatin!80mg!
Rosuvastatin!10mg!
Atorvastatin!20mg!
Simvastatin!40mg!
Ezetimibe!10mg!plus!Simvastatin!20mg!
“Low!dose”!statins!
(expected!20!to!35%!reduction!in!LDL)!
Fluvastatin!20V40!mg!
Atorvastatin!10mg!
Pravastatin!10V40mg!
Simvastatin!10V20mg!
Ezetimibe!10mg!plus!Simvastatin!10mg!
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Table*2.*Baseline*characteristics*of*the*early*cohort*according*with*ITT*therapy!
 
EVE!
(n=20) 
MMF!
(n=71) P 
Recipient!age!(yrs) 50.1!!±!9.2 51.7!!±!11.7 0.57 
Recipient!sex!(males!%) 16(80.0) 58(81.7) 0.86 
Donor!age!(yrs) 38.4!!±!13.8 35.0!!±!12.1 0.29 
Donor!sex!(males!%) 14!(73.7) 48!(67.6) 0.76 
PreVtransplant!CAD!(n,!%) 7!(36.8) 29!(42.6) 0.64 
Ischemic!time!(min) 198.1!!±!57.6 200.7!!±!45.4 0.82 
GFR!(ml/min) 62.4!!±!20.2 65.7!!±!25.4 0.59 
Glycemia!(mg/dl) 87.4!!±!33.6 84.5!!±!27.5 0.70 
Cholesterol!(mg/dl) 223.3!!±!38.8 216.3!!±!60.7 0.62 
HDL!(mg/dl) 64.3!!±!17.8 58.0!!±!16.0 0.13 
LDL!(mg/dl) 125.7!!±!37.1 117.9!!±!48.2 0.50 
Triglycerides!(mg/dl) 173.3!!±!61.4 207.8!!±!105.6 0.16 
Body!mass!index!(Kg/m2) 23.6!!±!3.4 24.0!!±!3.4 0.65 
Steroid!dose!(mg/Kg) 0.16!!±!0.04 0.18!!±!0.05 0.08 
Cyclosporine!trough!(ng/ml) 250.8!!±!85.9 303.3!!±!92.7 0.02 
Diabetes!(n,!%) 8!(40.0) 33!(46.4) 0.73 
Aspirin!(n,!%) 13!(65.0) 38!(53.5) 0.35 
Any!statin!(n,!%) 14!(70.0) 51!(71.8) 0.87 
High!dose!statins!(n,!%) 5!(25.0) 26!(36.6) 0.32 
Ejection!fraction!(%) 65.0!!±!4.5 65.6!!±!6.3 0.70 
CAD=!coronary!artery!disease;!GFR=!calculated!glomerular!filtration!rate!
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Table*3.*Baseline*characteristics*of*the*late*cohort*according*with*ITT*therapy*
 
EVE!
(n=19)!
MMF!
(n=33)! !!!!!P!
Recipient!age!(yrs)! 55.1!!±!10.7! 55.6!!±!8.8! 0.86!
Recipient!sex!(males!%)! 16!(84.2)! 28!(84.8)! 0.95!
Donor!age!(yrs)! 38.1!!±!12.6! 34.9!!±!10.7! 0.33!
Donor!sex!(males!%)! 11!(57.9)! 22!(66.7)! 0.83!
PreVtransplant!CAD!(n,!%)! 9!(47.3)! 15!(45.4)! 0.89!
Ischemic!time!(min)! 205.3!!±!57.7! 196.3!!±!51.0! 0.56!
Rejection!score!during!1st!yr! 0.68!±!0.29! 0.84!±!0.27! 0.05!
GFR!(ml/min)! 46.0!!±!16.3! 53.4!!±!15.9! 0.11!
Glycemia!(mg/dl)! 96.4!!±!27.3! 99.3!!±!28.7! 0.72!
Cholesterol!(mg/dl)! 215.3!!±!48.3! 192.9!!±!41.7! 0.08!
HDL!(mg/dl)! 60.4!!±!15.8! 57.2!!±!14.0! 0.45!
LDL!(mg/dl)! 110.4!!±!37.7! 97.8!!±!24.1! 0.14!
Triglycerides!(mg/dl)! 196.7!±!62.3! 189.1!!±!100.7! 0.76!
Body!mass!index!(Kg/m2) 25.7!!±!2.4! 26.7!!±!3.5! 0.24!
Steroid!dose!(mg/Kg)! 0.09!!±!0.06! 0.12!!±!0.05! 0.08!
Cyclosporine!trough!(ng/ml)! 188.6!!±!92.3! 224.5!!±!61.4! 0.09!
Diabetes!(n,!%)! 6!(31.6)! 15!(45.4)! 0.32!
Aspirin!(n,!%)! 8!(42.1)! 15!(45.4)! 0.81!
Any!statin!(n,!%)! 14!(73.7)! 32!(96.9)! 0.01!
High!dose!statins!(n,!%)! 7!(36.8)! 12!(36.3)! 0.97!
Ejection!fraction!(%)! 65.7!!±!4.4! 65.1!!±!5.2! 0.65!
CAD=!coronary!artery!disease;!GFR=!calculated!glomerular!filtration!rate!
*
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Table*4.*Early*cohort*characteristics*after*one*year*of*followCup*according*with*ITT*therapy*
 
EVE!
(n=20) 
MMF!
(n=71) P 
Rejection!score 0.72!±!0.34 0.84!±!0.32 0.16 
GFR!(ml/min) 55.0!!±!20.7 53.8!!±!18.5* 0.80 
Glycemia!(mg/dl) 111.6!!±!51.9* 94.2!!±!22.7* 0.03 
Cholesterol!(mg/dl) 211.6!!±!34.6 187.5!!±!45.3 0.03 
HDL!(mg/dl) 56.6!!±!19.5 52.6!!±!15.4 0.33 
LDL!(mg/dl) 111.4!!±!31.2 96.4!!±!30.8* 0.05 
Triglycerides!(mg/dl) 183.7!!±!60.2 192.9!!±!88.5 0.66 
Body!mass!index!(Kg/m2) 25.9!!±!3.9* 25.5!!±!3.4* 0.70 
Steroid!dose!(mg/Kg) 0.06!±!0.04* 0.09!±!0.05* 0.04 
Cyclosporinemia!(ng/ml) 78.1!±!34.7* 219.6!±!68.7* <0.01 
Diabetes!(n,!%) 7!(35.0)! 22!(30.9)! 0.73!
Aspirin!(n,!%) 15!(75.0)! 46!(64.8)! 0.38!
Any!statin!(n,!%) 17!(85.0)! 65!(91.5)! 0.40!
High!dose!statins(n,!%) 12!(60.0)! 30!(42.2)! 0.15!
Ejection!Fraction!(%) 67.4!!±!5.1 65.4!!±!6.3 0.19 
CMV!infection!(n,!%) 1!(5%) 33!(48%) <0.01 
!*!Significantly!different!from!baseline!by!paired!analysis!
!
!
!
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Table*5.*Late*cohort*characteristics*after*four*years*of*followCup*(year*5*after*transplant)*according*with*ITT*therapy!
 
EVE!
(n=19) 
MMF!
(n=33) !!!!P 
GFR!(ml/min) 55.8!!±!22.4* 54.1!!±!16.8 0.75 
Glycemia!(mg/dl) 108.3!!±!36.6 108.5!!±!69.3 0.99 
Cholesterol!(mg/dl) 212.6!!±!27.6 171.0!!±!35.9 <0.01 
HDL!(mg/dl) 61.2!!±!18.6 52.4!!±!16.6 0.08 
LDL!(mg/dl) 110.1!!±!33.0 87.3!!±!29.7 0.01 
Triglycerides!(mg/dl) 199.7!±!76.8 142.5!!±!64.3* <0.01 
Body!mass!index!(Kg/m2) 25.9!!±!2.3 27.5!!±!4.3 0.17 
Steroid!dose!(mg/Kg) 0.07!!±!0.05* 0.05!!±!0.03* 0.27 
Cyclosporine!trough!(ng/ml) 91.9!!±!84.8* 158.6!!±!62.4* 0.02 
Diabetes!(n,!%) 6!(33.3)! 12!(37.5)! 0.76!
Aspirin!(n,!%) 17!(89.4)! 27!(81.8)! 0.46!
Any!statin!(n,!%) 15!(78.9)! 29!(87.8)! 0.39!
High!dose!statins!(n,!%) 11!(57.9)! 13!(39.3)! 0.19!
Ejection!fraction!(%) 66.6!!±!5.0 65.2!!±!5.5 0.36 
*!Significantly!different!from!baseline!by!paired!analysis!
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Figure*legends!
Figure*1.***
Study!design.*ITT,!intention!to!treat;!CAV,!cardiac!allograft!vasculopathy;!IVUS,!intravascular!ultrasound;!
MMF,!mycophenolate!mofetil.!!
!
Figure*2.**
Study!flowVchart.!Panel!A:!Early!cohort;!Panel!B:!Late!cohort.!!
!
Figure*3.**
Change!in!IVUS!parameters!between!study!groups!of!the!early!cohort.!Panel!A:!mean!and!standard!
deviation!of!MIT!change.!Panel!B:!median!and!interquartile!range!of!the!change!rate!in!intimal!index.!!
Figure*4.*
Change!in!IVUS!parameters!between!study!groups!in!the!late!cohort.!.!Panel!A:!mean!and!standard!
deviation!of!MIT!change.!Panel!B:!median!and!interquartile!range!of!the!change!rate!in!intimal!index.!
Figure*5.*
Linear!correlations!between!triglycerides!at!year!1!and!change!in!maximal!intimal!thickness!(panel!A),!
lumen!volume!(panel!B),!and!intimal!index!(panel!C)!in!the!late!cohort!patients.!!
!3.2 Everolimus and valganciclovir prophylaxis: 
insights from PROTECT study 
 
Purpose: 
Cytomegalovirus (CMV) infection may influence the development of Cardiac Allograft Vasculopathy 
(CAV). In this prospective randomized study we aimed to analyze the interplay of 
immunosuppressive, anti-CMV strategies and CMV immunity on the risk for CMV infection and 
CAV during the first year after transplant  
Methods: 
By a 2x2 randomization process, CMV seropositive heart transplant (HT) recipients were 
randomized to receive 3 months of valganciclovir prophylaxis (PRO) or a pre- emptive based 
approach (PRE), and to receive mycophenolate (MMF) or everolimus (EVE) on top of a 
cyclosporine-based immunosuppressive therapy. All were monitored for CMV infection by whole 
blood PCR and CMV-immunity reconstitution by elispot assay. At month 1 and 12 after transplant 
eligible patients underwent intravascular ultrasound (IVUS). Occurrence of CMV infection and 
change in maximal intimal thickness (MIT) >0.5mm were study endpoints. 
Results:  
Forty-six patients were randomized: 22 to PRE vs. 24 to PRO, and 24 to EVE vs. 22 to MMF. Six 
(25%) patients discontinued EVE and 13 (54%) did not completed the 3-months period of PRO for 
adverse events (mainly effusions in EVE and leucopenia in PRO). Only 23 patients underwent 
IVUS both at month 1 and month 12. After adjusting for donor serology, PRO and EVE were 
associated with reduced risk of 70 and 54% respectively for CMV infection in the intention to treat 
(ITT) analysis (P<0.05). However, EVE discontinuation and lack of PRO completion were 
associated with increased risk for CMV infection. Only 4 (17%) patients developed the MIT 
endpoint, not allowing any conclusion about treatments efficacy. Nevertheless 100% of the patients 
who discontinued EVE developed the MIT endpoint. Recovery of CMV immunity at month 1 by 
Elispot analysis allowed stratifying the risk for CMV infection: patients with lack of immunity were at 
higher risk of infection, and most likely to benefit from PRO or EVE (P<0.01).  
Conclusion:  
EVE and PRO are protective from CMV infection, but a significant percentage of patients 
discontinued the treatments for intolerance and appear to be exposed to higher risk of events. 
Analysis of CMV immunity recovery may provide guidance in customizing therapeutic strategies, 
by identifying patients in whom aggressive anti-CMV strategies may have a favorable risk/benefit 
ratio. 
 
 
 
 
 
!Chapter 4.  
Solid organ cancers after heart transplantation: 
trying to improve the management 
4.1 Factors influencing survival of heart 
transplanted patients with a solid organ cancer: 
focusing on the role of immunosuppressive 
therapy, surgery and oncological status 
Introduction: 
 
Despite advances in oncology and in immunosuppression, solid organ cancers are still the main 
non graft-related cause of the death in the long-term for heart transplant (HTx) recipients. Whereas 
some risk factors for the development of post-transplant malignancies have been provided, like 
global immunosuppressive burden smoking, advanced age, previous malignancy and global. 
However, after a solid organ cancer has been found in a heart transplanted patient, the challenge 
for the Transplant Clinician is how to manage these patients, with regard to both 
immunosuppression and oncological treatment. In the literature, data about factors influencing 
survival after a cancer has occurred are lacking. 
About immunosuppression, in the last years, interest has grown up about mTOR inhibitors (i.e. 
everolimus or sirolimus), due to their known antiproliferative effect and to the frequent involvement 
of mTOR pathway disregulation in the pathogenesis of several cancers. Actually, these drugs are 
approved for chemoterapeutic use in some malignancies (i.e. Kaposi sarcoma, renal cell 
carcinoma). Basing on these properties, in some consensus conference, mainly based on case 
reports results, an introduction of an mTOR inhibitor has been suggested in solid organ 
transplanted patients developing a malignancy. However, it is not known if EVE introduction could 
influence subsequent outcome.  
About the general oncological treatment, it appears obvious that oncological surgery can impact 
the outcome, but still now no published data have been provided about the feasibility of surgical 
treatment and about cardiovascular risk and rate of complications for a surgical procedure in this 
subset of patients. 
 
The aim of this retrospective study is to investigate factors influencing survival after cancer 
occurrence in HTx patients. 
 
 
Matherials and methods: 
 
Study design 
We retrospectively collected data about cancers occurring in all patients transplanted at our 
Institution since the beginning of our Transplant Program (October 1988) until July 2011, who 
survived more than one year after HTx (n=500). Cancers were categorized in four groups: solid 
organ cancers, post-transplant lymphoproliferative disease (PTLD), non-melanoma skin cancers, 
Kaposi´s sarcoma. We decided to restrict our analysis to solid organ cancers. We collected 
oncological data at the moment of diagnosis: histology, organ involved, and stadiation of the tumor, 
with regards to the presence (M1) or not (M0) of metastases. With the intent to look for factors that 
could influence post-cancer outcome, we collected data about demographics (age at the moment 
of cancer occurrence, sex, pre-HTx heart disease, HTx era, induction therapy), oncological 
!management (surgery, chemotherapy or radiotherapy), immunosuppressive therapy after cancer 
diagnosis. Regarding this aspect, after recording all changes made in the immunosuppressive 
regimen after cancer diagnosis, we decided to focus the analysis on the therapy after the 
diagnosis; patients were divided in two groups for each drug, regardless of the immunosuppression 
regimen they had before cancer occurrence: steroids, cyclosporine yes/no, antiproliferative agent: 
azathioprine, AZA yes/no mycophenolate MMF yes/no, everolimus EVE yes/no. In particular, as 
second step, we focused our attention on the role played by everolimus after cancer diagnosis.: 
those who received EVE after the diagnosis of malignancy (EVE-group), and those who received 
an other kind of antiproliferative drug (or any at all) (non-EVE group). Of note, EVE group was 
comprehensive both of patients in which EVE was started after cancer diagnosis, both of patients 
who were already on that therapy before. We analyzed the occurrence of cancer-related mortality 
in the two groups, that included also complications of the malignant status (i.e. pulmonary 
embolism, sepsis due to severe neutropenia related to anti-cancer therapies) 
The primary endpoint was cancer-related mortality. The secondary endpoint was a combined one 
of cancer-related death and cancer recurrence. The safety profile of EVE after cancer diagnosis 
was also analyzed, by recording serious adverse events (i.e. severe neutropenia, serious 
infections, pleural or pericardial effusions, wound problems after cancer surgery), and the 
cardiovascular and non graft related complications of patients undergone to oncological surgery. 
 
Statistical analysis 
The incidence of solid organ cancer in the overall study population was expressed by survival 
curve (Kaplan-Meyer analysis). Due to the large heterogeneity of cancers observed, an organ- or 
histological- specific analysis was not possible. Prevalence of metastases at diagnosis was 
expressed as a percentage. The influence of surgical treatment, chemotherapy, radiotherapy and 
HTx era on cancer-related survival were analyzed by Cox´analysis (P<0.05 considered as 
significant, OR expressed using CI 5-95%) at univariate and multivariate analysis and expressed 
with Kaplan-Meyer curve as a 5-yrs survival rate. To analyze the impact of different eras of HTx, 
we choose to divide the patients before and after 2002  (year in which induction with 
Thymoglobuline was started in our Institution) EVE was entered in a step-wise model of 
multivariate analyses including the other variables significant. 
Subgroup analysis was performed when appropriate. Differences in categorical variables between 
EVE and non-EVE group were expressed with t-Student test (P<0.05 considered as significant) 
 
Results. 
 
Among 580 patients transplanted in our Center in the period of observation, 500 patients survived 
more than one year after HTx; 14 developed a PTLD; 7 Kaposi´s sarcoma, 70 non-melanoma skin 
cancer). 71 experienced a solid organ cancer (10-yrs incidence: 16.8 ± 2.2%). 
In Fig. 1 are represented cancers that occurred in the study population: as expected, there was a 
great heterogeneity. Most common cancers were localized respectively at prostate, colon, lung, 
kidney, but also less common cancers (i.e. central nervous system and sarcomas) were observed.  
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Figure 1. Incidence of cancers 
 
 
Estimated 5-yrs survival after solid organ cancer diagnosis was overall poor (43.4 ± 6.8%, Fig. 2); 
in 39.1% of the patients the disease had already reached a metastatic stage at diagnosis. 
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Figure 2. Cancer-related survival 
 
 
!In Table 1 characteristics of the patients at the time of diagnosis are summarized: whereas most of 
them were on steroid and CNI therapy at the moment of cancer detection, there was eterogeneity 
on the antiproliferative agent used, thus reflecting different era of HTx. 
  
Sex (%M) 83% (59) 
Age at diagnosis (yrs) 63.9 ± 6.9 
Transplant after 2002 29.5% (21) 
Time after HTx (yrs) 6.7± 4.4 
Metastasis at diagnosis (M1) 39.7% 
Prednison  (%)  88.7% (63) 
CNI  
   Cyclo 
   TAC) 
94.5%  (67), 
  90.1% (64) 
    4.2%  (3) 
 
AZA (%) 43.6% (31) 
MMF (%) 21.1% (15) 
EVE (%) 14% (10) 
 
Table 1. Characteristics of the patients at the time of cancer diagnosis 
 
 
By analyzing the impact of  different transplant eras on cancer-related death, we found that, 
whereas cancer incidence didn´t change significantly (P=0.18), cancer-survival significantly 
improved after 2002 (5-yrs estimated survival: 68.0 ± 13.2% vs 34.4 ± 7.4  5, P=0.02, Fig. 3a) 
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P=0.02 
!Figure 3A. Effect of era on post-cancer survival 
 
Of note, the percentage of patients with an M1-status at diagnosis was significantly lower 
(19% vs 47.9%, P=0.02) after vs. before 2002. 
At univariate analysis, the presence of metastases at the time of cancer detection (M1 
status) significantly affected survival (OR: 9.76 (95% C.I. 4.51-23.52), P<0.0001); median 
survival of M1-patients was  6 ± 3 months (Fig. 3b) 
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Figure 3 B. Role of metastasis (in blue) at diagnosis on cancer-related survival 
 
 
In 59.7% of the overall population, a surgical treatment of the tumor was offered, and this impacted 
cancer-related survival (OR: 0.41 (95% C.I. 0.20-0.81), P=0.01, Fig 3c). The possibility of surgically 
treating the malignancy was overall high and not different before vs after 2002 (P=0.19).  Of note, 
no graft-related complications as well as significant rejections (>2R) or life-threatening events 
occurred in the peri and post-operative period. Both chemotherapy and radiotherapy didn´t appear 
to influence cancer-related survival, as globally considered. 
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Figure 3 C. Effect of surgery (in blue) on cancer-related death 
 
P<0.0001 
P=0.01 
! 
Role of everolimus on cancer-related death 
139 patients who underwent to HTx in the study period were on EVE therapy: 82 of them received 
the drug as a manteinance therapy, 57 as a de novo therapy. 11/139 patients developed a 
malignancy during EVE treatment (8 in the manteinance group, 3 in the de novo group), with the 
following localization: prostate (n=4), colon (n=3), kidney (n=2), bladder (n=1), lung (n=1). In all of 
them EVE therapy was continued after diagnosis. Among patients (n=60) who developed a solid 
cancer during another antiproliferative treatment, immunosuppression management was quite 
different among various era from HTx; 9 of them were switched to an EVE-regimen; overall, EVE 
was introduced at a median time of 6.3 months after diagnosis, and at a median time of 8.5 months 
in patients undergone to surgery. Surgical treatment was offered in 70% of patients that were 
switched to EVE. In patients not shifted to EVE, global immunosuppression was reduced when 
possible. 
Overall, among the study population, 20 patients were on EVE therapy after cancer diagnosis 
(EVE-group), 11 of them were on EVE as a de novo therapy, 9 as a manteinance therapy after 
cancer diagnosis. 
Cancer-related death was significantly lower in EVE group when compared to non-EVE group (5-
yrs survival: 64.8 ± 13.5% vs 36.3 ± 7.6% P=0.01, Fig.4). The prevalence of metastatic disease at 
diagnosis was not different between the two groups (P=0.14), as well as the feasibility of a surgical 
treatment (P=0.30). 
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Figure 4. Effect of everolimus (in red) on cancer-related survival 
 
At multivariate analysis, oncological surgery and metastases at diagnosis were found to be 
indipendent predictor of cancer-related death (respectively OR 0.41 (CI. 95% 0.20-0.83), P=0.01 
and 8.92 (C.I. 95% 4.09-21.58), P<0.0001, Table 2), with metastases as the strongest predictor, 
whereas era of HTx lost of statistical significance. When EVE therapy was entered in a step-wise 
multivariate analysis model comprehensive of surgery, it showed to influence cancer-related 
outcome (OR 0.34 (C.I. 95% 0.11-0.81, P=0.01), whereas it reached a borderline statistical 
significance (P=0.06, OR 0.43, C.I. 95% 0.14-1.04) in a stepwise model with metastases. 
 
 
P=0.01 
! UNIVARIATE MULTIVARIATE 
 OR P OR P 
Metastasis at 
diagnosis (M1) 
9.76 (4.51-
23.52) 
<0.0001 8.92 (4.09-
21.58) 
<0.0001 
Surgery for cancer 0.41 (0.20-0.81) 0.01 0.41 (0.20-0.83) 0.01 
EVE after cancer 
diagnosis 
0.36 (0.12-0.86) 0.01 0.34 (0.11-0.81) 
0.43 (0.14-1.04) 
0.01• 
0.06† 
Transplant era (after 
2002) 
0.34 (0.11-0.88) 0.01 0.49 (0.15-1.35) 0.18 
 
Table 2. Predictors of cancer-related death at univariated and multivariate analysis 
 
 
By subgroup analysis (Fig. 5 A and B), we noticed that, in the EVE group, no one of the patients 
who developed a cancer during EVE-therapy (EVE as a de novo therapy) had metastases at 
diagnosis, and all of them survived until the end of the follow-up period (100%). The   prevalence of 
a metastatic disease at diagnosis was similar between patients among the EVE group who were 
switched to EVE and non-EVE group patients (55.5% vs 43.7 %). 5-yrs survival was 34.5 ± 18.3 % 
vs 36.3 ± 7.6 % respectively for EVE switched vs. non-EVE group patients.  
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Fig. 5 A. Subgroups analysis: effect of EVE (in red) on survival  in M0 patients 
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Fig. 5 B Subgroups analysis: effect of EVE (in red) on survival  in M1 patients 
 
Globally, therapy with EVE after cancer diagnosis appeared to influence the outcome in patients in 
M0 status (P=0.04), whereas it didn´t appear to influence the outcome of patients with metastases 
(P=0.18) 
 
Discussion: 
 
Whereas efficacy of EVE in the treatment of some types of cancers is known, the efficacy of its 
introduction after a cancer occurrence in solid organ transplantation has been poorly investigated 
and shown to be effective in some special cases, such as Kaposi´s sarcoma in renal transplanted 
patients. However, data about the role of EVE on subsequent outcome in HTx are lacking. 
In our institution, immunosuppression widely varied among last years: in the 90´s , AZA was the 
only antiproliferative agent used, subsequently replaced by MMF since 2003. EVE was used in our 
institution since 2007, both as a de novo and a rescue therapy. In our Center, EVE as a de novo 
therapy has been used in patients enrolled in multicentric or monocentric prospective randomized 
studies of comparison with MMF or AZA or, more recently, for clinician’s choice (i.e. patients with 
serological mismatch for CMV); even it was not the aim of the present study, overall incidence of 
cancer in patients on EVE de novo was low.  Even if the main indication for the introduction of EVE 
as a manteinance therapy in our Center is renal failure in the setting of a CNI-reducing strategy, in 
9 patients this drug was introduced after cancer. In the last years, after the development of a solid 
organ malignancy, the main strategy in our Center in patients who developed a solid organ cancer 
was to reduce overall immunosuppression and when possible to introduce EVE, in absence of 
controindication (i.e. severe proteinuria  or leucopenia). 
In this study, we observed a lower incidence of cancer-related death in patients on EVE after 
cancer diagnosis; of note, the prevalence of the two strongest predictors of survival (metastatic 
disease at diagnosis and the feasibility of a surgical approach) was not different in EVE vs non-
EVE group. However, at step-wise multivariate analysis , the effect of EVE was retained only in a 
model comprehensive of surgery, but not in the one with metastasis, even if with a borderline 
statistical significance. It must be noted that patients without metastasis at diagnosis had a 
benefical effect on survival by EVE therapy, whereas those with an M1 status did not. Moreover, in 
the EVE group, cancer-related death of patients in which EVE was introduced after the diagnosis 
of cancer was similar to the one that patients in the non-EVE group had, whereas no one of 
patients who developed a cancer during EVE-therapy died. It must be noted that no one of patients 
in the EVE-de novo group had metastases whereas M1-status prevalence in the patients that were 
subsequently switched to EVE was similar to the one of patients in the non-EVE group. However, it 
is also possible that EVE could have played an addictive role also in the EVE-de novo group, or 
P=0.18 
!especially in the subgroup of patients that didn’t undergo to surgery. This hypothesis is difficult to 
prove but also to exclude, due to the different pathobiology of the different types of tumors in all 
groups of the study, that is, undoubtly, an important study limitation. However, it gives a rationale 
to the introduction of EVE after a cancer diagnosis; of note, EVE was introduced regardless the 
presence o not of metastases (p= EVE vs non EVE).  
Surgery is an effective treatment of cancer, and it can improve survival when it’s possible to be 
offered in general oncological patients. The decision to offer a surgical treatment for cancer has to 
be balanced on one hand with the risk of cancer recurrence, and on the other with the peri- and 
post-operative risk and complications, of which  the cardiovascular one are the most threatening. In 
HTx  patients, these two topics are matter of an increased concern, because of the believed 
increased risk of cancer recurrence after surgery, due to overall immunosuppression, and because 
of the fear of graft-related (i.e. rejection, CAV) and non-graft related (i.e. infections) complications. 
In our study, surgery was performed in a great majority of patients, so very aggressive, appeared 
to add a benefit on cancer-related risk of death and to be safe. We didn’t experience any-graft 
related serious complication and only few, not life-threatening episodes of infection (XX). Of note, 
the feasibility of surgery was apparently not influenced by the presence of a metastatic status at 
the moment of cancer diagnosis.  
It has been shown that EVE may delay wound healing; for this reason, we waited a median time of 
8.5 months before to introduce it in the cohort of operated patients (70% of the overall cohort of 
patients switched to EVE after cancer diagnosis). The introduction of EVE after surgery appeared 
to be  safe: we didn’t observe any impaired wound healing neither significative adverse events (i.e. 
pleural or abdominal effusions, pneumonia or bacterial infections). The drug was well tolerated also 
in the overall EVE group. 
 
Study limits 
The sample size of this study was limited, but however regardable for a single-center study testing 
a long-term complication. Apart from the observational nature, the most important limit of our work 
is undoubtly the heterogeneity of the population due to the different cancers observed. It could be 
that the effect of EVE on cancer occurrence and prognosis was different in different subsets of 
tumors in our population. EVE was introduced in a cohort of people not affected by the same tumor 
and not all people affected by a certain kind of tumor were switched to EVE therapy; however, we 
can’t exclude that this drug was introduced on a subset of patients with a cancer biology favourable 
to respond to mTOR inhibition, thus introducing a biological-based bias in the evaluation of its 
effect. On the other hand, it has also to be said that the unselective mTOR inhibition played by 
EVE could have also mitigated the potential anti-proliferative effect of mTOR inhibition, 
paradoxically favouring the progression of cancer in certain hystobiological subtypes. 
These limitations are however difficult to contrast: ideally, a prospective randomized trial about the 
introduction of EVE after cancer should be made in a subset of patients affected by the same 
cancer, and should require a multicentric design due to the small number of cancer events, even in 
a long-experienced and large transplant program. 
However, an indagine about the biological effect of EVE was not the purpose of this study. Our aim 
was to obtain grossolani data that could provide a rationale for the clinicians to the use and 
introduction of EVE after a cancer has occurred. 
 
Conclusions: 
The efficacy of the introduction of an mTOR inhibitor after a cancer diagnosis occurring in a heart 
transplant patient has been poorly investigated, both on the safety and on the efficacy site. In our 
observational study including 500 HTx patients, the presence of metastasis at diagnosis and an 
highly-aggressive surgical treatment were the strongest outcome predictors. Surgical treatment of 
cancer in HTx patients, when possible, has a favourable efficacy-safety profile, without life-
threatening complications. 
EVE introduction was safe, and appeared to influence cancer-related survival even when 
compared to surgery, whereas its benefic effect was shown only in patients without metastasis at 
diagnosis. Despite the heterogeneity of its population, this study provides a strong rationale for the 
introduction of EVE after cancer for the clinicians taking care of long-term heart transplant 
recipients. 
!Chapter 5.  
Everolimus versus mycophenolate de novo 
after heart transplantation: does it matter for 
long-term outcomes? 
Background:  
 
Several large prospective randomized trials (RTs) compare EVE and MMF de novo after  HTx; 
however, long term comparison on clinically meaningful endpoints is lacking. 
 
Methods:  
 
In this study we included all patients enrolled in our Center in RTs about EVE de novo. We 
analyzed 5-years (yrs) incidence of fatal and non fatal major cardiovascular events (MACE), all-
cause mortality, rejection, CMV infection, cancers, GFR (by MDRD). Given the frequent cross-
overs between the two drugs, we performed both an Intention to treat (ITT) and an On-Treatment 
(OT) analysis, defined retrospectively as the drug taken for most of the time. 
 
Results:  
93 patients (80% males, 53±11 yrs, HTx 2005-14) were enrolled: 57 randomized to EVE, 36 to 
MMF. Study population characteristics are depicted in Table 1. 
 
 
Parameter Everolimus 
N=57 
Micofenolato 
N=36 
P  
Gender (M,%) 84,2%  72,2%  0,16  
Age at HTX (years)  52,7 ± 11,02 53,8 ± 11,31 0,62  
Donor age (years) 41,7 ± 12,48 38,8 ± 12,19 0,27  
Donor gender  
(M,%) 
80,7 %  75 %     
VFG base  
(mL/min) 
68,63 ± 30,42 66,49 ± 36,06 0,75  
Pre-HTx 
Cardiopathy (N) 
CAD 22 
DCM 22 
HCM 4 
RCM 3 
Valvular 2 
Others 4 
CAD 13 
DCM 9 
HCM 4  
RCM 4 
Valvular 3 
Others 3 
0,5  
 
Table 1. Study population characteristics 
 
29 underwent at least one cross over, 10 for clinical reasons (cancers, renal failure, rejection), 19 
for drug intolerance. Tolerability was lower in the EVE arm (p=0.05), see Figure 1 mostly due to 
!pericardial effusions, but comparable to MMF after 3 month from HTx (p=0.42). Causes of drug 
interruption due to intolerance are depicted in Figure 2. 
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Figure 1. Study drug interruption due to tolerance problems 
 
 
  
 
Figure 2. Causes of drug interruption 
 
At ITT analysis, we found no differences about MACE (Fig. 3), overall mortality (Fig. 4), rejection, 
CMV infection, cancers, (Figures 5 A, B, C), renal function (p all not significant).  
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Figure 3. Difference about MACE (ITT analysis) 
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Figure 4. Overall survival (ITT analysis) 
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Figure 5 A. Rejection (ITT analysis) 
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Figure 5B. CMV infection (ITT analysis) 
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Figure 5C. Difference on cancer incidence (ITT analysis) 
EVE 
MMF 
 
P=0.75 
EVE 
MMF 
 
P=0.86 
EVE 
MMF 
 
P=0.86 
! 
At OT analysis EVE group (42/93) had a lower incidence of MACE (2.6±2.5% vs 19.0±5.8%, 
p=0.01), (see Fig. 6) and CMV infection at one year (28.8±7.0% vs 44.0±7.3%,p=0.02), (Fig. 7), 
with similar mortality (p=0.53) and renal function (p=0.45) and a promising lower estimated 
incidence of cancers at 10 yrs (9.5±5.4% vs 38.7±16.2%, p=0.33). 
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Fig. 6 Difference on MACE incidence (on treatment analysis) 
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Fig. 7 Difference on CMV infection at one year (on treatment analysis) 
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Figure 8. Difference on cancers’ incidence (on treatment analysis) 
 
 
 
Conclusion:  
 
This is a single-center post-hoc analysis of long-term outcomes in patients initially 
randomized in trials with different endpoints. While confirming problems in maintaining 
EVE therapy in the early post-HTx period, we found suggestive evidence of potential long-
term benefits of EVE in reducing MACE, CMV infection and cancers. Although these data 
are only hypothesis generating, they suggest a delayed introduction of EVE to favour its 
tolerability, aiming to take better advantage of its possible long-term benefits. 
 
 
 
 
 
 
 
 
 
 
EVE 
 
 
MMF 
 
P=0.33 
!PART TWO 
 
 
 
 
LEFT VENTRICULAR ASSIST DEVICES (LVAD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!Chapter 1.  
Background on LVAD 
Among durable devices for mechanical circulatory support (MCS), the ones supporting left ventricle 
(left ventricular assist devices, LVAD) are the widest used in clinical practice, according to data 
from INTERMACS, the Registry of ISHLT for MCS. LVAD represent 95% of all MCS, being right 
ventricular assist devices (RVAD) and biventricular assist devices (BIVAD) respectively 4% and 
1%.  
 
1.1  Technology of the most used LVAD systems  
The first pumps available on the market provided pulsatile-flow through specific valves; however, 
despite a more physiologic flow, it was demonstrated that they were associated with a worse 
outcome than the second-generation pumps, that provide a continuous flow (CF).  
The widest used CF-LVAD is Heartmate II device, from Thoratec. It is an axial pump, usually 
positioned extrapericardial.  
The other largely implanted pump is HVAD, from Heartware; it’s a pump with a centrifugal design, 
implanted intrapericardially, bearingless, and providing a continuous flow; it has a magnetic 
levitation system. This pump has been approved by FDA for the use “bridge to transplant” in 2012, 
actually, it is used also as destination therapy (Fig.1) 
 Ventricular Assist Device Innovation 
1st Generation 
3rd Generation 
2nd Generation 
• Pulsatile Flow 
• Valves 
• Mechanical bearings 
• Continuous Flow 
• Axial Design 
• Bearing with mechanical 
pivot 
• Continuous Flow 
• Centrifugal Design 
• Noncontact bearing design 
භ Minaturization 
භ Durability 
FDA Approved 
BTT 1998 
DT   2002 
FDA Approved 
BTT 2008 
DT   2010 
FDA Approved 
BTT 2012 
DT Investigational 
Bearings 
Bearings with stator 
Bearingless with  
magnetic and  
hydrodynamic levitation 
 
Figure 1. Evolution of LVADs’ technology 
!Continuous Flow Rotary Pumps 
Axial versus Centrifugal Design 
Axial Flow Pump 
භ Flow along the axis of 
symmetry 
භ Mechanical pivot – 2nd 
Generation pumps 
 
Centrifugal Flow Pump 
භ Blood enters near to the 
rotating axis and flows radially 
outward  
භ Impeller suspended by 
hydrodynamic or magnetic 
forces – 3rd Generation pumps 
  
Figure 2. Differences between axial and centrifugal design 
Differently from axial flow pump, in a centrifugal flow pump , the blood enters near to pump rotating 
axis and flows radially outward. In the HVAD centrifugal pump, the impeller is suspended by 
hydrodynamic or magnetic forces. 
1.2 Physiology of LVAD systems  
Even if they provide flow continuously, CF LVAD do not carry the same output through cardiac 
cycle or in different physiologic conditions, and they are influenced in some degree by pulsatility of 
the heart, that is related to systolic performance of left ventricle. 
In particular, pump flow depends on : 
- Type of the pump (axial vs centrifugal) 
- pump speed 
- residual left ventricular function 
- the pressure gradient between pump head (left ventricular pressure) and after the pump 
(aortic pressure), that is : 
ΔP = aortic pressure- left ventricular pressure =P AO- P LV 
Pump speed is regulated externally. Thus, left ventricular function and the gradient between aortic 
pressure and left ventricular pressure are crucial in determining LVAD flow. Aortic pressure 
depends on overall fluid status and from systemic medications normally used for heart failure’s 
treatment, like ACE inhibitors or beta blockers. Left ventricular filling pressure is determined by left 
atrial pressure, that depends on left ventricle relaxation properties (diastolic function) and, in  
absence of mitral stenosis and/or significant pulmonary regurgitation, on right ventricular output. 
Thus, in these conditions, right ventricle determines the preload of the pump, whereas systemic 
aortic pressure is the afterload of the pump. From this assumption, one can understand that pump 
flow is different among the different phases of cardiac cycle and among different settings of pump 
speed. Flow curves have been built among different types of pumps, extrapolating the 
!haemodynamic features from animal models of isolated hearts. A different shape of flow curve 
corresponds to a different pump speed 
 
Most important to note is that most centrifugal pumps
have what is called a flat head curve, where they operate
over a very wide range of flows for a very small change in
delta P across the pump. The example in Figure 3 shows that
for 1 cardiac cycle in which pump delta P swings from 40 to
80 mm Hg, centrifugal pumps have a very large swing in
flow (0 to 10 liters/min), acting almost like a pulsatile pump
with high peak systolic flows and low, even negative,
diastolic flows. One can think of a centrifugal pump with a
flat head curve as an on/off CF pump cycling between high-
flow and low-flow as its output surges with the beating of
the ventricle. This creates inherent high pump flow pulsatility in
response to changing LV pressures (Figure 2D). In contrast, a
typical axial-flow pump has a steep head curve where there is a
linearly related increase and decrease in flow with decreasing
and increasing pump delta P.4 In this example, the 40- to 80-
mm Hg swing across the pump conduits produces less flow
pulsatility, ranging from 3 to 7 liters/min during a cardiac cycle.
As the text that follows explains, this difference in pump-flow
pulsatility affects the diagnostic and control feedback available
to the respective pump controllers. Figure 3B and C
demonstrate that the actual degree of flatness of centrifugal
pump head curves can vary with design, with the HeartWare
HVAD being less flat than the Terumo DuraHeart design.
Inlet cannula suction and control of pump
operating speed
The likelihood of high inlet cannula suction in axial vs
centrifugal CF pumps is related to the flow vs delta P
relationship described above. A CF pump is blind to the
absolute value of the pressures at the inlet and outlet ports
and responds only to the total differential pressure across the
pump. At any given pump speed, a CF pump would have
the same flow at inlet and outlet pressure values of 0/100,
100/200, and –50/50 mm Hg, because it sees only the delta
P of 100 mm Hg. This has clinical significance during a low
LV volume state in which pump flow decreases, such as one
might expect during conditions related to hypovolemia
associated with right ventricular (RV) failure or bleeding.
As can be seen from the head curves in Figure 2B, a
Figure 3 Comparison of head curves for axial vs centrifugal continuous flow (CF) pumps is shown for the (A) HeartMate II axial CF, the
(B) HeartWare HVAD! centrifugal CF,3 and the (C) Terumo DuraHeart centrifugal CF. Reprinted with permission from Frazier OH et al.
Optimization of axial-pump pressure sensitivity for a continuous flow total artificial heart. J Heart Lung Transplant 2010;29:687–91.r 2010
Elsevier Inc. and Alex Medvedev, Terumo Heart, Inc.!The HeartWare HVAD is an investigational device limited by Federal Law to
investigational use.
Moazami et al. Comparison of Axial vs Centrifugal Pumps 5
 
 
 
Figure 3. Pressure-flow curves: at left, axial pump, at right, centrifugal pump.  
Continuous Flow Rotary Pumps 
Pressure – Flow Relationship 
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Figure 4. Effect of different pump spe ds on pressure flow curve  
As depicted in Figure 4, at the same level of pressure difference across the pump, an increase in 
pump speed leads to an increase in pump flow.  
However, as represented in Figure 3, there is a substancial difference between axial and 
!centrifugal curves. Centrifugal pumps have a flat head curve, where they operate over a very wide 
range of flows for a very small change in ΔP across the pump. The example in Figure 5 shows that 
for one cardiac cycle in which ΔP swings from 40 to 80 mm Hg, centrifugal pumps have a very 
large swing in flow (0 to 10 liters/min), acting almost like a pulsatile pump; this creates inherent 
high pump flow pulsatility in response to changing LV pressures. In contrast, a typical axial-flow 
pump has a steep head curve where there is a linearly related increase and decrease in flow with 
decreasing and increasing pump ΔP; in this example, the 40- to 80- mm Hg swing across the pump 
conduits produces less flow pulsatility, ranging from 3 to 7 liters/min during a cardiac cycle. Thus, 
centrifugal pumps (like HVAD) are more sensitive to ΔP variations and therefore to afterload 
changes. 
 
Comparison of the Hydrodynamic Performance 
of Axial and Centrifugal Pumps 
 
Figure 5. Different behavior of centrifugal and axial pumps in respect to different ΔP 
(afterload) values 
Given the sensitivity of pump flow to ΔP, significant changes occur during cardiac cycle. During 
systole, when LV pressure is higher, ΔP decreases, leading to an increase in pump flow; during 
diastole, when aortic pressure increases, the increase in ΔP leads to a decrease in pump flow (Fig. 
6). Residual left ventricular systolic function influences also pump flow, by influencing the capacity 
of left ventricle of generating higher pressures in the systolic phase.  
!Continuous Flow Rotary Pumps 
Variation in Flow During the Cardiac Cycle 
Generation of Pulse 
represents ventricular diastole 
represents ventricular systole 
Flow  
Variability 
ȴP 
ȴP 
 
 
Figure 6. Pump flow during the different phases of cardiac cycle. 
Pre-load sensitivity, as it relates to mechanical circulatory assist devices, mimics the relationship 
between LV filling pressures and ventricular stroke volume defined by the Frank-Starling curves. 
As right ventricular output and volemia are the preload determinant, right ventricular failure or 
dysidratation can lead to decrease in LVAD flow, thus of the overall cardiac output.  
Data from Salamonsen et al on afterload sensitivity of CF rotary pumps support the general 
understanding that these pumps have higher after-load sensitivity than the human heart. This high 
after-load sensitivity creates the need to control systemic vascular resistance (SVR) in these 
patients to guarantee sustained outputs. Typically, the targeted mean systemic arterial pressures 
for CF pump patients is 70 to 90 mm Hg, with pressures exceeding 90 mm Hg to be avoided. If 
SVR were to increase (ΔP increase), this would produce an instantaneous drop in pump causing a 
lower flow condition. In contrast, the steeper head curve of axial pumps responds to an increase in 
SVR by increasing the pressure generated across the pump ports, limiting the decrease in flow by 
increasing outlet pressure. At low-flow conditions, this retains the capability to enforce high blood 
pressures with adequate LV volume. However, it also results in high inlet suction that in a low LV 
volume state can potentiate arrhythmias, create suction events, or lead to hemolysis. Thus, as 
depicted in Figure 5, the dependence of axial pumps and centrifugal pumps from preload and 
afterload is different, being centrifugal pumps more sensitive to afterload changes. 
Flow pulsatilty, that is related to the difference between the systolic and diastolic amount of flow,  is 
inversely related to the degree of LV unloading by the pump and directly proportional to the 
strength of LV contraction and as such can be used as a measure of the LV function under VAD 
support. Any significant decrease in pump flow pulsatility without a change in pump speed should 
be investigated clinically for causes of decreasing LV pressures during LVAD support. This 
typically includes decreasing LV contractility or low LV volume states caused by right heart failure 
or dehydration. Reasons for the flow PI to increase, without a change in pump speed, include an 
increase in LV contractility via inotropes, myocardial recovery, and exercise or increased pre-load 
Starling effects. 
Low flow occurring in the pump or a condition of excessive unloading is dangerous, as can lead to 
!contact between inflow cannula and interventricular septum, and ventricular tachycardias, thus 
leading to further low flow and to a loop of low flow, hypotension and ventricular arrhythmias. 
In the circulation assisted by LVAD, flow is directed from left ventricle (LV) into ascending aorta 
through LVAD, and no flow is observed through LV outflow tract (LVOT), thus remaining aortic 
valve closed during the entire cardiac cycle (Fig. 7A). However, if LV is not completely assisted by 
the LVAD, a certain amount of blood will reach ascending aorta through LVOT, thus allowing 
opening of aortic valve (AV) (Fig. 7 B).  
 When th  aortic valve does not open, the left ventricle (LV) functions in 
series with the LV assist device (LVAD). If the heart pumps strongly enough to 
open the valve, the ventricle is operating in parallel with the AD. LA, l ft 
atrium; RA, right atrium; RV, right ventricle 
 
Fig.7 A. Full support condition. B. Partial support condition 
 
Right ventricle receives the overall output carried by the LVAD and by LVOT. Therefore: 
RV output= systemic output =  LVAD output + output through LVOT 
In condition of full support, output through LVOT is = 0, becoming RV output= LVAD output 
In condition of partial support, RV output = LVAD output + output through LVOT 
Of course, these two conditions are the two extremes of a wide spectrum of haemodynamic 
situations, in whom different degrees of support are possible. thus, it has been suggested to 
consider AV opening as a marker of LV support by the LVAD, However, this sentence is not 
completely true, as, even if various studies showed the relationship between the extent of pump 
support and the opening time and area of the AV, other factors influence LV unloading conditions 
and AV opening. 
 
Factors influencing AV opening in a LVAD patients are: 
- preload and afterload pressures (right ventricular function, liquid intake and systemic aortic 
pressure) 
- LV unloading support by LVAD 
- LV residual function 
- Pump speed 
!A situation in whom LV is not completely assisted by the LVAD can occur in case of a low pump 
support (low speed settings) or of a strong LV function, such in case of myocardial recovery.in this 
case,  the ventricle is still able to generate pressures greater than the aortic pressure (AoP), and 
blood is ejected in parallel to the RBP via the AV. A condition of complete support can happen in 
case of a very weak ventricular function; in this case, the AV remains closed throughout the whole 
heart cycle, and the blood flow occurs entirely through the RBP. However, the AV opening is 
certainly affected by afterload and preload pressures: an decrease in preload, like right ventricular 
failure or a status of hypovolemia, can reduce LV filling pressures, thus reducing LVAD flow and 
changing aortic valve status from open to closed.  
However, at fixed afterload and preload conditions, AV opening status the evaluation of the AV 
opening provides information about the native heart function and the interaction with the LVAD. It 
has been reported that a fixed closure of AV can lead to aortic leaflets’ fusion, aortic insufficiency, 
and formations of  thrombi in the aortic root (see Chapter 1.4).  
The assessment of the opening state of the AV is currently performed with echocardiography. 
Echocardiography has a key role in the optimization of pump settings and in the management of 
these patients, because it has the potential to help to recognize some of LVAD-related 
complications and to differentiate between the different possible causes of fluctuations in pump 
flow, like right ventricular failure or aortic insufficiency. Moreover, it has been reported that it can 
provide information about the unloading status of LV. These aspects are illustrated later. 
In clinical as well as experimental animal data, it has been observed that the state of the AV (open 
or closed) is related to the shape of the systolic portion of the pump flow signal. In case of partial 
support (AV opens), the pump flow signal shows a flat plateau in the systolic portion of each 
heartbeat; in case of full support (AV always closed), the systolic peak is sharper (Fig. 8). This 
observation has a basic hemodynamic explanation: during full support, the almost sinusoidal shape 
of the left ventricular pressure (LVP) signal mainly affects the systolic shape of the pressure head 
waveform across the pump. Consequently, this results in an almost sinusoidal pump flow signal. 
On the contrary, if the AV opens, the pressure difference between the AoP and the LVP during 
ejection becomes slightly less than zero and does not change substantially as long as the AV 
remains open, which leads to the flat plateau in the pump flow signal. As shown from Granegger et 
al, the state of the AV can be automatically determined by quantifying the different shapes of the 
pump flow waveform during systole, as shown in Figure 8.  
Figure 9 shows pressure patterns (LVP and AoP) and pump flow waveforms during speed changes 
in an animal experiment. In Fig. 9, the changes in the systolic portion of the pump flow waveform 
as well as the shape change in the histograms at the different speeds can be clearly observed. The 
flat plateau of the pump flow wave- form vanishes when the AV remains closed during the whole 
heart cycle. Similarly, the peak in the right side of the histograms decreases with increasing pump 
speed and vanishes when the AV is closed. The peak in the systolic portion of the histogram plot is 
thus equivalent to the flat plateau in the time course, whereas the absence of a 
!improvement.Assuming that at a certain pump speed
setting and hemodynamic state a heart with low con-
tractility results in a closedAV, theAV might open at
the same speed setting and hemodynamic state as
soon as contractility improves.The time course ofAV
opening, especially evaluated together with arterial
blood pressure monitoring, carries information about
the native heart function.Therefore, the evaluation of
the AV opening provides information about the
native heart function and the interaction with the
RBP.
The assessment of the opening state of the AV is
currently performed with echocardiography, which is
both cumbersome as well as time demanding, and can
thus be done only infrequently. Therefore, a method
for frequent or even continuous evaluation of theAV
state would be highly desirable. The detection of the
AV condition might enable the development and
implementation of control algorithms for frequent
opening of the AV, which would in turn potentially
minimize the risk of aortic fusion, insufficiency, and
thromboembolic risk in the aortic root.We present a
new robust method, which accurately determines
the state of the AV based on the pump flow signal
only.
MATERIALS AND METHODS
Observations and hypothesis
In clinical as well as experimental animal data, it
has been observed that the state of the AV (open or
closed) is related to the shape of the systolic portion
of the pump flow signal. In case of partial support
(AV opens), the pump flow signal shows a flat plateau
in the systolic portion of each heartbeat; in case of
full support (AV always closed), the systolic peak
is sharper (Fig. 1). This observation has a basic
hemodynamic explanation: during full support, the
almost sinusoidal shape of the left ventricular pres-
sure (LVP) signal mainly affects the systolic shape of
the pressure head waveform across the pump. Con-
sequently, this results in an almost sinusoidal pump
flow signal. On the contrary, if the AV opens, the
pressure difference between the AoP and the LVP
during ejection becomes slightly less than zero and
does not change substantially as long as the AV
remains open, which leads to the flat plateau in the
pump flow signal.
We therefore hypothesized that the state of theAV
can be automatically determined by quantifying the
different shapes of the pump flow waveform during
systole. Features to quantify these shape differences
and classification algorithms for the AV state were
developed, tested, and validated in data derived from
a numerical model and from animal experiments.
Figure 2 shows pressure patterns (LVP and AoP)
and pump flow waveforms during speed changes in
an animal experiment. Additionally, histogram plots
calculated from the pump flow are presented. The
histograms were calculated as the number of occur-
rences of a certain value of the pump flow versus
that particular flow value. So, they provide another
useful representation of the pump flow shape
characteristics.
In Fig. 2, the changes in the systolic portion of the
pump flow waveform as well as the shape change in
the histograms at the different speeds can be clearly
observed. The flat plateau of the pump flow wave-
form vanishes when the AV remains closed during
the whole heart cycle. Similarly, the peak in the right
side of the histograms decreases with increasing
pump speed and vanishes when theAV is closed.The
peak in the systolic portion of the histogram plot is
thus equivalent to the flat plateau in the time course,
whereas the absence of a peak in the histogram plot
indicates the absence of a plateau.
Preprocessing algorithms
Because the flow waveform reflects the state of the
AV during systole, only this portion of the pump flow
signal was evaluated.To accurately detect the systolic
portion of the pump flow, the signal was high-pass
FIG. 1. In the case of partial support with an opening of the aortic
valve, the pump flow signal shows a flat plateau in the systolic
portion (black) of each heart beat (upper panel); in the case of full
support with a closed aortic valve throughout the whole heart
cycle, the systolic peak is sharper (lower panel). This figure
shows data from an animal experiment. Similar signal shapes
were observed in numerical models.
M. GRANEGGER ET AL.2
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Fig. 8  (from Granegger M et al, Artificial Orga s 2013) 
 
 
(cutoff frequency 0.7 Hz) and low-pass filtered
(cutoff frequency 20 Hz). Then, the zero crossings of
the rising and falling edges were detected, which
delimited the systolic portion. In data derived from
numerical models, a subtraction of 0.15 L/min before
the zero crossing detection ensured a better identifi-
cation of the systolic portion.The signal in between a
zero crossing of a rising edge and one of a falling edge
was considered to be one beat for further analysis.To
quantify the different patterns of the pump flow, each
beat was analyzed by employing three descriptive
features: two statistical parameters of the probability
distribution derived from the pump flow waveform,
the skewness and kurtosis, and the crest factor as a
shape measurement of the same waveform.
Features
The skewness is the third central moment of a
distribution, and it is a measure reflecting the
degree to which a distribution is asymmetrical (11)
(Fig. 3a). The probability distribution of the flow
waveform will be more left skewed for an open AV
FIG. 2. Left pan ls: examples of five second r cordings of LVP (black) and AoP (gray) signals at increasing pump speeds; middle panels:
resulting measured pump flow signals; right panels: the same flow signals plotted as histograms. Note the sharp peak in the systolic portion
of the flow signal histograms (inside the gray rectangle) at low speeds (top diagram), which decreases with increasing pump speed.
FIG. 3. Examples of shapes of probability distributions and their skewness (a) and kurtosis (b) values. (c) Examples of three different
signal shapes and their corresponding crest factors.
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!1.3 The impact of LVAD in the management of the 
waiting list and on post-transplant outcomes 
Indications for implantation 
Patients being considered for an LVAD are normally within NYHA III and IV classes. However, as 
shown in the literature, these two classes contain a wide spectrum of patients with different 
characteristics. More in detail, the Clinicians actually refer to 7 INTERMACS classes (Table) 
 
INTERMACS 
Profile Level 
Status  Time frame 
1 Critical cardiogenic shock „crash and burn“ hours 
2 Progressive decline „sliding fast on inotropes“ Days to weeks 
3 Stable but inotrope 
dependent 
„stable on inotropes“ weeks 
4 Recurrent advanced HF „fequent flyer“ Weeks to few 
months 
5 Exertion intolerant „housebound“ Weeks to months 
6 Exertion limited „walking wounded“ months 
7 Advanced NYHA class III   
 
 
Table 1. INTERMACS profiles within NYHA III and IV classes  
 
 
The main indications for LVAD implantation are classically 4: 
Bridge to transplant, bridge to candidacy, bridge to recovery, destination therapy. 
 " bridge to transplant (BTT): patients listed or suited to be listed for heart transplantation, 
having an high risk of clinical deterioration while on the waiting list; " bridge to candidacy (BTC): patients having a temporary and potentially reversible 
contraindication to HTx, such as high pulmonary vascular resistances, solid organ cancer 
within the previous 5 years, smoking status, mild obesity; " bridge to recovery (BTR): patients in a life-threatening condition, such as post-cardiotomy 
cardiogenic shock, acute myocarditis, in whom an LVAD is a potential life-saving procedure 
leading to an improvement in left ventricular function; " destination therapy: patients with a fixed, irreversible contraindication for HTx (older age 
(>70 yrs), COPD or renal function contraindicating transplantation, severe obesity), having 
a life expectancy < 2 years and no other comorbidities potentially limiting survival in the mid 
term.  
 
!However, this classification is not fixed, as a sustancial proportion of patients switch from a group 
to another (cit Teuteberg); for example, patients initially considered for heart transplantation and 
implanted with a BTT or BTC intention, can subsequently stay permanently with an LVAD, thus 
becoming DT patients, because of the development of a long term complication, or persistence of 
a previous temporary contraindication to heart transplantation, or because of a mild clinical 
improvement, so that HTx is no more necessary.  Conversely, patients implanted with a DT 
intention can be considered for heart transplantation, thus becoming a BTT group,  if improvement 
of a believed fixed contraindication for heart transplantation occurs; in some patients, indeed, the 
decrease of left ventricle filling pressures and the increase in cardiac output carried by the LVAD 
can lead to an improvement in pulmonary vascular resistances and in renal function, so that HTx 
become a more suitable option. 
According to INTERMACS data, about XX % of patients switch from BTT/BTC to DT and XX% 
from DT to BTT; at the end, as reported in Fig. 1, after 2 years from implantation, only 55% of 
patients in the BTT group remain effectively listed, in 20% of patients HTx is a probable option, 
whereas 20% of patients are in the DT group. In  DT group, about 5% of patients after 2 years are 
listed for HTx. In the “transplanted –likely groups” (BTT, BTC, BTR) are effectively listed, and XX% 
of the DT . 
 
might be inﬂuenced by device type, a substantial proportion
of patients in bridge trials are still supported beyond 1 year.
In the HeartMate II BTT trial, patients had to be listed 1A
or 1B to be included, but 20.6% of patients were still on
support at 18 months (7). The long duration of support for
many patients in the BTT and BTC: likely group is not
necessarily attributable to transplant ineligibility due to
development of contraindications after MCS or the failure of
pre-existing contraindications to resolve with MCS. When
device strategy over time was examined, 74.2% of BTT
patients were still BTT at 1 year, and only 6.3% had become
DT. For those still on support at 1 year in the BTC: likely
group, 67% of patients were still BTC: likely or were actively
listed for transplant, whereas the rate of DT in this group
was 11.1%. In contrast, by 1 year 24.1% of those still sup-
ported in the BTC: moderate group had already changed
to a strategy of DT.
Our data strongly suggest that the population of patients
who receive MCS have a continuum of risk as reﬂected
by their pre-implant strategies. Overall, the BTC patients
represent the transition in risk and outcomes between the
BTT and DT populations. Furthermore the initial implant
Figure 4 Device Strategies Over Time
(A) BTT; (B) BTC: likely; (C) BTC: moderate; (D) BTC: unlikely; (E) DT. Strategies have been grouped according to original intent. BTC: likely ¼ BTC and likely to be transplanted;
BTC: moderate ¼ BTC and moderately likely to be transplanted; BTC: unlikely ¼ BTC and unlikely to be transplanted; other abbreviations as in Figure 2.
Teuteberg et al. JACC: Heart Failure Vol. 1, No. 5, 2013
Implant Strategies for LVADs in the INTERMACS Registry October 2013:369–78
376
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Fig. 10 Changes in being considered for HTx within BTT class (A) and DT class (B). 
 
!1.4  The management of LVAD patients: short and 
long-term complications  
Main complications arising after LVAD implantation are: " driveline and/or pump pocket  infections " haemorragic or non haemorragic stroke " pump thrombus " aortic insufficiency " right ventricular failure " gastrointestinal bleeding " suction and arrhythmias  
Time course of these complications is different, being  respectively bleeding, RV failure and 
infections more frequent in the early phase , and cardiac problems and bleeding and thrombosis in 
the later one. 
The management of driveline infection is based on antibiogram-driven antibiotics; in extremely 
selected cases, pump pocket exchange can be necessary. Driveline infection is a significant risk 
factor for stroke, and can be a cause of change in waiting list status for patients with an LVAD as 
BTT. 
Haemorragic stroke and/or systemic bleeding is a frequent condition; patients with LVAD require a 
combined anticoagulant and antiplatelet therapy, that exposes the patient to a higher risk of 
bleeding. Moreover, colon angiodysplasias are believed to be more frequent in patients with a new 
generation pump, probably because of the continuous flow. Bleeding risk is high during overall 
support condition but is higher in the first post operative phase. On the other hand, driveline 
infections, problems in anticoagulation management and/or temporary anticoagulation reduction 
because of bleeding, are potential causes for ischemic stroke in these patients. Pump thrombosis 
is a dramatic event, that leads to a rapid increase in pump power (because of increased resistance 
forces) and to an erroneous higher estimated pump flow. Treatment of pump thrombosis is based 
on intravenous thrombolytic agents. 
Aortic insufficiency is a frequent long-term complication in LVAD patients; it has been reported that 
a permanently closed AV can have damage in aortic leaflets, leading to leaflets’ fusion, and to 
aortic regurgitation (AR). AR is deleterious for LVAD: if a moderate to severe AR occur, a 
consistent part of the blood carried by the LVAD returns in the LV, thus leading to a decrease in 
systemic output and to an increase in LV filling pressures. In the long term, this can worsen LV 
function, haemodynamic parameters and even RV function. For this reasons, aortic valve repair or 
substitution with a biological prosthesis is made preoperatively in patients with a more than mild 
AR. Of note, AR can be continuous through the entire cardiac cycle, thus being systodiastolic. 
Recently, it has been suggested an intermittent opening of AV to try to reduce AV damage, but the 
target of AV opening has not yet been established. High systemic blood pressure is avoided, as it 
can increase AR. 
Right ventricular failure is a frequent long term complication, but can occur also intraoperatively. 
After pump starting during the operation, a sudden increase in LV output occur, therefore causing 
an increase in right ventricular (RV) preload and output. If preoperative RV function is moderately 
reduced, RV could not be able to tolerate the sudden increase in volume, and this could lead to 
intraoperative RV failure, causing low-flow in the LVAD. This condition can happen also chronically 
because of the chronic RV volume overload carried by the LVAD. However, other factors not 
completely clear could contribute to its pathogenesis. RV failure is usually treated with 
levosimendan and with slight reduction in pump speed. 
!Suction can occur in all condition of too high support: this can happen either when pump speed is 
too high either when hypovolemia is present. Also arrhythmias, like atrial fibrillation or ventricular 
tachycardia, by reducing LV filling status, can lead to a relative too high condition of support by the 
pump, thus causing suction. When suction occurs, a contact between inflow cannula and 
interventricular septum or papillary muscles can occur, causing further arrhythmias, potentially life 
threatening, and leading to a loop of hypovolemia-arrythmias, that must be corrected by increase in 
fluid intake, antyarrithmic agents and reduction in pump speed. Typically, in these condition, 
interventricular septum is “sucked” towards LV cavity and has a more “left-oriented position”. 
Therefore, position of LV is considered another marker of LV unloading status and of interaction 
between the heart and the pump. 
1.5  The HVAD system and pump signal analysis  
HVAD system is constituted by HVAD pump, driveline, two external batteries, driveline, and a 
controller (Fig. 11) 
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Fig. 11 HVAD system (Heartware) 
 
On HVAD monitor the flowing information are displayed (Fig. 12): " pump flow (estimated by haematocrit values) " pump power 
!" pump speed  
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Fig. 12 HVAD monitor 
 
As shown by Moscato et al (Fig. 13), different information can be derived by the analysis of pump 
flow curves.  
Pulsatility index informs about LV contractility, the shape of the systolic portion pf pump flow about 
AV opening status, the diastolic part of the pump curve about suction events. 
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Fig. 13 Information derived from pump flow signal 
 
Time course variations in pump flow or power also give important information about volemic status, 
grade of support and potential life-threatening situations. HVAD monitor has different grades of 
alarms. The most important alarms are: low flow alarm, high watt alarms and batteries charge 
status (see Fig. 14-16) 
 
 
 
Fig. 14 Suction 
 
! 
Fig. 14 High watts 
 
 
 
 
Fig. 15 Hypovolemia and excessive pump speed   
 
 
HVAD monitor allows to achieve a lot of information, as already written.  
Transthoracic echocardiography (TTE) is the other method that allows to recognize most of LVAD 
related complications and to distinguish between the different causes of alarms, as reported in 
Table 2. LV diameters as assessed by M-Mode, the position of interventricular septum and aortic 
valve opening status are parameters indicative of the unloading status of left ventricle provided by 
the pump. Pump flow can be also measured by transthoracic echocardiography (TTE), through 
visualization of inflow and outflow cannula and Doppler analysis. 
!However, almost the totality of the echocardiographic data about LVAD are derived from 
Heartmate II device, whereas there is paucity of data in the literature about the feasibility of a TTE 
exam with HVAD 
 
 
 
Other LVAD dysfunction/related complications. In ad-
dition to thrombosis of the LVAD cannula, several
other complications may occur early and late after
implantation that can be detected by echo and are
listed in Table 3. Cannula malposition may cause
low-flow LVAD alarms, ventricular arrhythmias, or a
clinically low CO state. Increasingly, with newer
third-generation device shapes or because of specific
body habitus, the inflow cannula may be placed in an
inferior LV approach. This may necessitate modified
2-dimensional and Doppler imaging from the
parasternal views as opposed to the apical view. Can-
nula/graft malposition or dist rtion may also be sus-
pected on routine chest radiography or detected by
Figure 11. Echo Findings With Continuous-Flow Pump Failure
Left ventricular assist device on: Parasternal long-axis view with minimal mitral regurgitation (white arrow) and a normal apical inflow
velocity flow pattern (yellow arrows). Left ventricular assist device stopped: 2 months later, VentrAssist (Ventracor) pump failure with
regurgitant inflow (yellow *), increased mitral regurgitation (red arrow), and reversal of apical inflow (yellow arrows) using spectral
Doppler standard apical view. Abbreviations as in Figure 4.
Table 3. LVAD Dysfunction and Post-Implant Complications Detected by Echo
Pericardial effusion with or without cardiac tamponade
RV failure (increased RV size, decreased RV systolic function, increased right atrial pressure, and increased tricuspid regurgitation)
Inadequate LV filling (small LV dimensions)
LVAD-induced ventricular ectopy or tachycardia (underfilled LV and mechanical impact with septum)
LVAD-related continuous aortic insufficiency (aortic regurgitation throughout cardiac diastole and systole)
Intracardiac thrombus (including right and left atrial, LV apical, and aortic root thrombus)
Pulsatile pump inflow valve regurgitation (apical inflow cannula turbulent flow detected by color Doppler during LVAD ejection, dilated LV,
frequent opening of the AV, and reduced outflow graft flow !1.8 m/s)
Pulsatile pump apical inflow obstruction (intermittent interruption of usual laminar LVAD diastolic inflow using pulsed-wave Doppler with
inflow velocities "2.5 m/s and color flow aliasing at the cannula orifice)
Continuous pump apical inflow abnormality due to inflow cannula obstruction, malposition, or hyperdynamic apical LV function (color Doppler high-velocity
aliased flow at the cannula orifice with a peak Doppler velocity !2 m/s)
Cannula kinking or complete thrombosis (loss of Doppler signal in all echo views and loss of RV outflow tract stroke volume with speed change)
Hypertensive emergency, continuous flow pump (minimal AV opening, dilated LV, worsening MR, and peak outflow cannula velocity "2 m/s)
Impeller cessation, continuous flow pump (dilated LV, acute reversal of apical inflow flow direction using spectral or color Doppler, worsening MR,
and decreased RV outflow tract stroke volume)
AV # aortic valve; LV # left ventricle; MR # mitral regurgitation; RV # right ventricle; other abbreviations as in Table 1.
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Table 2. Information derived from transthoracic echocardiography 
 
 
Giving these considerations, it appears useful to integrate data derived from pump curves analysis 
and from TTE. However, it is not known if aortic valve opening status assessed by pump curves’ 
analysis is consistent with TTE, and what is the real feasibility of TTE in HVAD system, considering 
its intrapericardial position. 
 
 
 
 
Summary of unclear points and their development in this Research 
Thesis 
 " Is aortic valve opening status assessed by pump curves’ analysis 
consistent with TTE? (Chapter 2.1) " what is the real feasibility of TTE in HVAD system? (Chapter 2.2) 
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!Chapter 2.  
The combined role of echocardiography and of 
analysis of pump signals: trying to improve the 
management 
2.1 Continuous monitoring of aortic valve opening 
in rotary blood pump patients 
 
 
Introduction: 
In patients with end-stage heart failure, rotary blood pumps (RBPs) for left ventricular support have 
become the therapy of choice for bridging the patient to heart transplantation. More recently RBPs 
even emerged as an alternative to heart transplantation (1-4). However, especially during 
prolonged left ventricular support, adverse events such as aortic valve (AV) commissural fusion, 
aortic insufficiency and thrombus formation in the aortic root, which may cause neurologic events, 
were observed (5-8). These complications are most probably related to the diminished or absent 
opening of the AV in patients with a RBP: In case of high pump support or a weak ventricular 
function, blood flow occurs entirely through the RBP (9, 10) and the AV remains closed during the 
entire heart cycle. Consequently, a continuous back-pressure load is exerted on the AV, which 
does therefore not experience the physiologic cyclic load changes. To prevent these adverse 
events it might be of importance to allow - at least intermittently - the opening of the AV by 
appropriate periodic pump speed adjustments. To determine the duration and magnitude of these 
speed adjustments a continuous and simple monitoring of the AV opening would be required. 
Additionally, a continuous monitoring of the AV state would provide important information about the 
native heart function and the condition of the cardiovascular condition: a change of the AV state 
from closed to open at a given level of pump support could indicate an improvement of heart 
function and could be a first indicator of cardiac recovery.  
Currently, the clinical assessment of the AV condition is performed with echocardiography, which is 
conducted by experienced personnel and it is time-consuming and cumbersome. Therefore, it 
cannot be performed frequently especially because of the increasing number of patients with a 
RBP implanted and the limited hospital resources. In this framework, a method that allows 
monitoring of the AV state continuously from available pump data, without any required additional 
intervention, would represent a great benefit for the treatment of this patient population. In previous 
work a method was developed to discriminate between an open and closed AV using pump flow 
data from numerical and animal models, respectively (11). This algorithm is based on the fact that 
the state of the AV (open or closed) is related to the shape of the systolic portion of the pump flow 
signal: In case of partial support (AV opens) the pump flow signal shows a flat plateau in the 
systolic portion of each heartbeat, in case of full support (AV always closed) the systolic peak is 
sharper.  
The aim of the current study was to apply and validate the previously developed algorithm to detect 
AV opening in RBP recipients using the estimated pump flow signal from a centrifugal pump 
(HeartWare Ventricular Assist Device (HVAD), HeartWare, Inc., Miami Lakes, FL). 
 
Materials and Methods: 
A single-center, prospective clinical study was approved by the Review Board of the Medical 
University of Vienna. Fifteen hemodynamically stable patients with an implanted HVAD were 
enrolled into this study. Before each examination potential thrombus formations in the left ventricle 
and the aortic root were excluded by echocardiography. Pump speed was then reduced stepwise 
!reduced from baseline speed by 200, 400, 600, 800, 1000, 1200, 800 and 400 rpm but not below a 
minimum speed of 1800 rpm) in 20 second intervals. After each speed reduction speed was returned 
to baseline for a minimal interval of 60 seconds (Figure 1). Using M-mode echocardiography the 
AV state was assessed and a video was continuously acquired via the output of the ultrasound 
device (iE33 xMATRIX Ultrasound, Philips Medical Systems, Andover, MA, USA) for subsequent 
beat-to-beat offline analysis. Pump data (speed and current) were collected simultaneously by 
continuously recording the RS-232 datastream which is available from the HVAD pump controller.  
 
Classification of the AV state based on pump data 
Basically, the same algorithm for pump flow analysis as presented in (11) was used. This method is 
based on three features (skewness, kurtosis and crest factor) calculated from the systolic portion of 
the pump flow signal. In the following text the major differences to the algorithm described in (11) 
will be highlighted: 
• We made use of the previously reported flow estimator (12), which is able to estimate the 
pump flow signal based on the speed and current signal with a frequency content of up to 
15 Hz. This was necessary because the frequency content of the signal is of major 
importance to reflect the plateau in the systolic portion of the pump flow signal in partial 
support. 
• To detect accurately the systolic portion of the estimated pump flow signal and minimize the 
effect of noise, the signal was band-pass filtered (0.8 - 10 Hz). The frequency content was 
limited to 10 Hz, since this is sufficient to represent the plateau in the flow signal in the 
partial support condition and, at the same time, limits the amount of noise in the pump 
signal. However, in some cases the estimated pump flow signal was still affected by 
disturbances. For the beat-wise analysis a moving average filter for each of the three 
features (skewness, kurtosis and crest factor) over 10 beats was applied before 
classification to reduce the effects of noise. 
• After preliminary experience with clinical data, the detection of the systolic portion of the 
flow signal had to be slightly modified: If the pump flow pulsatility (Qp2p) value exceeded 4 
L/min and the heart rate was equal or below 70 bpm, 1/4th of the Qp2p value was subtracted 
from the high-pass filtered flow signal before determining the zero-crossing and 
consequently the rising and falling edges that delimited the systolic portion of the flow.  
 
The three features of the systolic portion of the pump flow signal were used for training and testing 
of two different classification algorithms: a) a linear classifier that attempts to express the 
dependent variable, in our case the state of the AV, as a linear combination of the three features 
(13); b) a quadratic classifier that attempts to express the dependent variable as a quadratic 
combination of the three features (13). 
Classification of the AV state based on echocardiography 
Each beat in the M-mode echocardiography was classified according to the AV state by one 
cardiologist and two biomedical engineers. Three levels of certainty were introduced:  
1. If the state of the AV could clearly be identified based on M-mode echocardiography (AV 
opening time could be measured or AV leaflets did not move during systole) the beat was 
classified into a beat with the AV open or closed with 100% certainty.  
2. If the state of the AV could not clearly be identified based on M-mode echocardiography, 
the three evaluators/referees/experts ### classified the beat as AV open or closed basing 
their decision on additional information (e.g. AV leaflet motion in B-Mode 
echocardiography). 
3. If the state of the AV could not clearly be identified based on M-mode echocardiography 
and additional information was not reliable, the beat was rejected and excluded from further 
analysis.  
Beats which were classified into the first two categories were used for the validation of the the 
developed method.  
 
 
!Data analysis 
Three different procedures for data analysis were performed to validate the developed algorithm: 
 
1. Validation of the algorithm with all beats of the entire patient population 
 To validate the ability of the algorithm to discriminate beats with an open and closed AV 
with the entire dataset, the whole sample of classified beats of all patients was divided 
randomly into 5 subsamples. Of the 5 subsamples, 4 subsamples were used as training 
dataset and one as test dataset for the evaluation of the classifiers. This cross-validation 
process was then repeated 5 times, with each of the 5 subsamples used once as the 
validation data. Performance statistics were calculated as an average from the obtained 5 
cross-validation results.  
 
2. Patient specific validation of the algorithm 
a. Beat-wise analysis: To predict the reliability of the classification process for each single 
patient, a cross-validation was performed that used all classified beats from 14 patients 
as training dataset and the beats of one patient as validation dataset. This process was 
repeated 15 times, with each patient data being the test dataset once. 
b. Speed-wise analysis: To quantify the ability of the classification algorithm to determine 
the AV state at a given speed setting, the classifiers were also trained with average 
feature values calculated over each speed setting. The reference AV state during each 
speed setting was considered to be the most frequent AV state occurrence classified by 
echocardiography. Also here a cross-validation was performed that used all speed 
settings from 14 patients as training dataset and the speed settings of one patient as 
validation dataset. This process was repeated 15 times, with each patient data being 
the test dataset once. 
The performance statistics of the classification were expressed as specificity and sensitivity. 
Specificity measured the ability to correctly identify a beat with a closed AV state. Similarly, 
sensitivity measured the ability to correctly identify a beat with an open AV. Negative (NPV) 
and positive predictive values (PPV) were used to represent the likelihood that an AV state 
determined as closed (open) was actually closed (open). The correct classification rate 
measured the proportion of correctly classified samples among all classified samples. 
 
Results: 
The demographics as well as hemodynamic and key echocardiographic parameters of the 15 
patients are summarized in Table 1. 
 
Table& 1& Demographics& as& well& as& hemodanymic& and& echocardiographic&
parameters&at&baseline&pump&speed&of&the&15&patients&enrolled&in&the&study.&&
&Age!(years)! 56.7!±!9.8!(21"75)!Etiology!(DCMP/ICMP)! 6/9!BMI!(kg/m2)! 25.5!±!4.7!(15.8"37.7)!Male!gender!(%)! 80!Time!on!device!(days)! 231!±!221!(19"610)!Baseline!pump!speed!(rpm)!Heart!rate!(bpm)!Mean!pump!flow!(L/min)!Pump!flow!pulsatility!(L/min)!
2721!±!212!(2400"3100)!86!±!13!(67"113)!4.7!±!0.8!(3.0"6.0)!3.5!±!1.0!(2.0"6.0)!LV!end"diastolic!diameter!(mm)! 60!±!14!(35"87)!LV!end"systolic!diameter!(mm)! 51!±!15!(21"76)!Ejection!fraction!(%)! 26!±!7!(15"43)!
!Patients! with! AV! open! at! baseline! speed!(%)!Patients! with! AV! regurgitation! (%! grade!0/1/2/3)!
27!53/40/7/0!
DCMP: Dilated Cardiomyopathy, ICMP: Ischemic Cardiomyopathy, BMI: Body Mass Index, LV: 
Left Ventricle, AV: Aortic Valve. 
 
Figure 1 shows the pump speed signal during a typical experiment. An example of the synchronized 
echocardiographic and pump data used for classification purposes is presented in Figure 2. On the 
left side of Figure 2 the AV is clearly closed (full support) whereas at the right side after second 206 
the AV opens (partial support). Note the difference in shape of the systolic portion of the signal: 
during full support the shape is sharper than in the partial support condition, where the plateau can 
be observed (11). 
 
Figure 1 Time course of the pump speed signal during a typical speed step experiment. The pump speed was stepwise 
reduced from 2700 rpm to the lower speed limit of 1800 rpm. 
 
 
Figure 2 Pump speed (upper panel) flow (middle panel) and synchronized M-mode picture (lower panel) during a speed 
step experiment from 2500 rpm to 1800 rpm. In the right half of the figure the AV opens. 
Validation of the algorithm with all beats of the entire patient population 
From the 15 patients 9757 beats were recorded. 7384 beats could be classified as beats with an AV 
open or closed and were used for further analysis. In 3497 beats the AV was open; in 3887 beats the 
!AV remained closed during the entire cardiac cycle. In Figure 3, the three single-beat features 
extracted from the pump data are plotted for all 15 patients in a three dimensional graph and the 
classification based on the M-mode echocardiography is represented by dots in black and gray. The 
linear discrimination plane determined by the classification procedure is also indicated. The 
specificity/NPV and sensitivity/PPV values achieved in this cross-validation process are presented 
in Table 2.  
 
Figure 3 All beats (n=7384) with an open (black) and closed (gray) AV of 15 patients and the identified linear discrimination plane. 
Table 2 Performance of the two classifiers to distinguish between an open and closed aortic valve tested with clinical 
data. NPV=Negative Predictive Value, PPV=Positive Predictive Value. 
& Specificity/NPV&(%)& Sensitivity/PPV&(%)& Correct!Classification&(%)&Linear!classifier& 91.2/90.3! 91.0/91.8! 91.1!Quadratic!classifier& ! 95.7/85.3! 81.6/94.5! 89!
 
Patient specific validation of the algorithm 
a. Beat-wise analysis 
The correct classification rates of the cross-validation, using the beats of 14 patients as training 
dataset and the beats of one patient as test dataset, are presented in Table 3. The mean correct 
classification rate was 86.9±10.1% and it was greater than 82% in 12 of 15 patients using the linear 
classifier. It must be noted that the results of the statistical analysis are strongly influenced by the 
AV condition at baseline speed: Due to the performed speed step protocol (speed decrease for 20 
seconds followed by 60 seconds of baseline speed) the proportion of beats recorded at baseline 
speed is obviously much higher than in any other speed setting; therefore, if the baseline speed 
setting is in a AV borderline condition between open and closed this may lead to many 
misclassified beats, this has a strong influence on the correct classification rate (indicating the ratio 
between misclassified and correctly classified beats) even if the beats recorded in all other speed 
settings were classified correctly (Patient 1, 14 and 15). Therefore, in the next step, a speed-wise 
analysis was performed. In this analysis the proportion of beats at different speed settings does not 
have an influence on the results. 
 
 
!Table 3 Correct classification rates for each patient for the linear and quadratic classifier. 
& Correct!Classification!(linear!classifier)!(%)& Correct!Classification!(quadratic!calssifier)!(%)&Patient!1& 71.4! 73.9!Patient!2& 84.4! 86.5!Patient!3& 99.5! 99.3!Patient!4& 99.9! 99.9!Patient!5& 82.8! 91.2!Patient!6& 94.4! 94.1!Patient!7& 89.6! 92.0!Patient!8& 92.1! 92.8!Patient!9& 88.9! 91.0!Patient!10& 91.6! 82.4!Patient!11& 83.4! 78.9!Patient!12& 96.3! 94.1!Patient!13& 87.7! 87.8!Patient!14& 63.7! 52.8!Patient!15& 77.9! 76.9!ALL!(Mean±SD)& 86.9±10.1! 86.2±12.1!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. Speed-wise analysis 
The correct classification rates of the cross-validation, using the speed settings of 14 patients as 
training dataset and the speed settings of one patient as test dataset, are presented in Table 4. With 
the linear classifier in two patients (Patients 1 and 2) only one speed setting  was misclassified, in 
the other patients all other 76 speed settings were classified correctly, resulting in a mean correct 
classification rate of 97.4±7.2% of performed speed steps.  
 
Table 4 Number of performed speed steps and percentage of correctly classified speed steps with the linear and 
quadratic classifier. Additionally, the status of the AV at baseline speed is presented. 
& #!of!speed!settings& %!of!correctly!classified!speed!steps!with!linear!classifier&
%!of!correctly!classified!speed!steps!with!quadratic!classifier&Patient!1& 7! 85.7! 100!Patient!2& 4! 75! 75!
!Patient!3& 7! 100! 100!Patient!4& 9! 100! 100!Patient!5& 3! 100! 100!Patient!6& 5! 100! 100!Patient!7& 5! 100! 100!Patient!8& 5! 100! 80!Patient!9& 3! 100! 100!Patient!10& 3! 100! 100!Patient!11& 5! 100! 100!Patient!12& 4! 100! 100!Patient!13& 7! 100! 85.7!Patient!14& 6! 100! 100!Patient!15& 5! 100! 100!ALL!(Mean±SD)& 5.2±1.7! 97.4±7.2! 96.1±8.4!
 
 
 
Discussion: 
In this study a previously developed method (11) was validated in the real clinical setting. It allowed 
the discrimination between beats with an open and closed AV employing an estimated pump flow 
signal with high reliability. In a first validation step, using the entire dataset, the basic ability of the 
algorithm to discriminate between beats with an open and closed AV was proven. In the beat-wise 
analysis both linear and quadratic discrimination analysis showed a correct classification rate of 
approx. 90% of all beats, which is similar to the previously reported performance in animal 
experiments (11). Beside the validation of the algorithm using the entire dataset, also a patient 
specific analysis was performed. The result of such an analysis predicts the performance and 
reliability of the developed algorithm when it is applied to new patients, with completely unknown 
AV state. Whereas the beat-wise analysis indicated a slightly worse result (correct classification 
rate 86.8 ± 10%) compared to the analysis with the entire dataset, in a speed-wise analysis only 2 
out of 78 speed steps (Patient 1 and 2) were misclassified in the 15 patients. However, in this 
analysis the information about the frequency of beats with an open/closed AV is lost; even 
borderline cases of the AV state would be classified as open/closed, losing the information of the 
ratio between open and closed beats. This might be of importance especially in case of arrhythmia 
where each beat is characterized by a different contraction force. Nevertheless, an analysis over a 
time-window of e.g. 20 seconds could indicate accurately whether the AV is currently more 
frequently open or closed within this interval.  
The developed algorithm determines the presence of a plateau in the pump flow signal, which is 
more prominent during the ejection phase. In (11) we found in data derived from a numerical 
hemodynamic model that this plateau could only be detected reliably in case a volume of more 
than 3 ml was ejected via the AV. In this study, from the M-mode echocardiography the ejected 
volume could not be determined, therefore the AV leaftlet motion and the actual ejected volume 
could not be correlated. This might also explain one of the misclassified speed steps in the speed-
wise analysis (Patient 2): The AV was classified as closed by the algorithm even if the AV leaflets 
were opening. However, the volume ejected may had not been relevant because the dynamics of 
the AV leaflet opening was slow and not even complete in most beats. However, since we could 
not measure the volume of ejected blood, this remains speculative.  
The examinations were performed on the laying patient, not reflecting the daily life activities of out-
of-hospital activities; however, different pathologies as well as a wide range of ventricular function, 
heart rate, pump settings, flow pulsatility, waveform and arrhythmia were observed in the 15 
patients (Table 1). This indicates the robustness of the algorithm regarding this diversity but a 
validation during physical activity (e.g. during exercise stress tests) seems important. 
To the authors’ knowledge there is only one study that addresses the assessment of the AV 
opening by using pump data only without any additional intervention. In Bishop et al. (14) this 
!method was clinically evaluated. Their results with 6 patients indicated the ability to discriminate 
between an open and closed AV in 4 out of 6 patients. The two remaining patients suffered from 
mild aortic insufficiency, which might have affected the results in these cases. In the presented 
study with 15 patients various degrees of aortic regurgitation (grade 0 to 2) were observed, 
however, this did not impair the discrimination abilities of the presented algorithm.  
The patient specific validation of the alogrithm provided very good results demonstrating that only 
one single discrimination plane for all patients was required and no patient specific training was 
necessary for correct discrimination. This allows a simple implementation of this algorithm into a 
controller of a RBP system which would be valid for any patient without any additional intervention 
required. Once implemented into the controller of a currently clinically used RBP system this 
method would allow continuous monitoring of the AV opening with a high accuracy. The physician 
could be provided with the long-term trend of the AV opening and could adapt the treatment and 
the pump speed setting accordingly. Frequent AV opening could be especially of importance in 
bridge-to-recovery candidates, where it is obviously beneficial that an aortic stenosis/insufficiency 
is prevented. In this study in 4 out of 15 patients the AV was permanently open at baseline pump 
speed (Table 1), in all other patients a decrease in pump speed was required to force the AV to 
open. In patients with a weak cardiac function it might be disadvantageous and even dangerous to 
decrease the pump speed permanently; therefore, in these patients an intermittent pump speed 
reduction to allow AV opening could be used. To determine for each patient the amount and 
duration of speed reduction a continuous monitoring of the AV status would be necessary to 
achieve a certain ratio between beats with an open and closed AV. It must be however noted that 
because of the lack of continuous monitoring of the AV status the optimal ratio between an open 
and closed AV to prevent adverse events as aortic leaflet fusion, insufficiency and thrombus 
formation in the aortic root is not known yet. 
In conclusion, this study demonstrates that the AV opening can be reliably detected using the 
estimated pump flow signal in RBP patients. Combined with other non-invasive diagnostic methods 
based on intrinsic pump signals as suction detection (15), determination of contractility and 
relaxation properties (16, 17), heart rate and its variability (18), the method of continuous 
monitoring of the AV state could be integrated into an automated patient (tele-) monitoring system. 
This would not only provide important information for the treatment of the patient but detect 
occurrence of adverse events at an early stage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!2.2 Transthoracic echocardiography of 
outpatients with an intrapericardial left 
ventricular assist device implanted: a single 
center experience. 
 
Introduction: 
 
With the increasing number of implants {Kirklin, 2014 #973}}1, the clinical interest about the role of 
transthoracic echocardiography (TTE) in the management of patients with a left ventricular assist 
device (LVAD) in the outclinic setting is growing.  
The two actually most frequently implanted pumps (Heartmate II, Thoratec Inc., Pleasanton, CA 
USA, and HVAD, Heartware Inc., Framingham, MA, USA) while providing both a continuous flow, 
have substancial differences {Slaughter, 2010 #1199}: axial and extrapericardial the first, 
centrifugal and intrapericardial the second.  Both pumps have a monitoring system, providing 
information about pump speed, pump estimated flow, power consumption and pulsatility index; in 
the HVAD monitor these parameters are shown both in real time and in their fluctuations over time, 
as well as different kind of alarms, thus allowing to achieve useful information3,4 for pump setting 
regulations in the outclinic management. To help to discriminate among different causes of 
variations in pump data and alarms, together with physical exam and laboratory exams, 
transthoracic echocardiography plays a key role, helping the Clinician in the patients’ management, 
in optimization of pump settings and in the assessment of some mid or long-term complications 
after LVAD implantation (i.e. aortic regurgitation (AR) and right ventricular (RV) failure). 
However, almost the totality of the patients included in the clinical series and observational 
prospective studies focusing on the role of TTE had been implanted with a Heartmate II pump5,6,7,8. 
Echocardiographic data about the other largely implanted pump, HVAD, are less often 
documented; one possible explanation could be the theoretical difficulty on performing TTE due to 
its intrapericardial placement.  
In the unique, small clinical series (19 patients) focused on TTE on HVAD9, only three kind of 
information are provided: a) the feasibility of visualizing inflow and outflow cannula in most of the 
patients; b) the impossibility to have a Doppler signal inside the inflow cannula, whereas it’s 
possible to be achieved in the outflow cannula; c) the artifacts precluding mitral valve color Doppler 
examination when inlet cannula is included in the screen. Thus, in the current literature there is 
lack of data and reports about the feasibility of performing a comprehensive standard TTE 
examination and measurements in HVAD patients, including Doppler measurements (i.e. PAP 
estimation, mitral inflow pattern, Tissue Doppler) when inlet cannula is not included in the screen. 
Moreover, it has not been reported if non-standard echographic views are needed in HVAD 
patients and there are no data about the possibility of evaluating the flow provided by the pump or 
by the overall circulating system through a TTE exam; there is only one clinical case in which pump 
flow through outflow cannula was evaluated by transesophageal echocardiography (TEE). 
The aim of this clinical series is to provide echocardiographic insights about the feasibility of 
performing standard and pump-specific measurements in patients with HVAD when evaluated in a 
routine, outpatient setting. Herein, we report echocardiographic data of patients with HVAD 
enrolled in a prospective study made in our Clinic validating the ability of a mathematical algorithm 
in predicting aortic valve opening based on pump flow signal; we mainly focus on the feasibility of 
standard TTE measurements, as well as on specific non-standard TTE approaches. 
 
Materials and methods: 
 
Study population  
17 outclinic patients (14 males, 3 females), implanted at Vienna General Hospital (AKH) between 
2011 and 2013 and routinely followed in the outclinic ambulance, were evaluated during 2013, and 
!TTE were performed. The almost totality (n=16) of patients had been enrolled in a study protocol 
evaluating the ability of a mathematical algorithm in predicting aortic valve opening (as assessed 
by TTE) based on pump flow signal at different HVAD speed settings during the exam and 
approved by the local Ethic Review Board; the informed consent to the study protocol was 
collected before TTE exam.  All of them were clinically stable patients. Only in one patient, TTE 
was made by clinical reasons (assess for left ventricular recovery); in this case, pump speeds were 
not changed. Demographic characteristics are shown in table 1; surgical implantation technique 
was mini-invasive in all cases (mini-left thoracotomy and right subclavear incision), except that for 
one patient 
 
Echocardiographic measurements 
TTE was made only once in 15 patients; in 2 patients, TTE was repeated respectively 3 and 2 
times as follow-up; in the first case the TEE was repeated to monitor pump speed reduction after 
the first exam due to left-shifted position of interventricular septum, and in the second case the two 
exams were motivated by medical therapy optimization after implantation. Thus, overall, 20 TTE 
were performed. All TTE were made by the same operator, a Cardiologist trained in 
echocardiography using the ultrasound device iE33 xMATRIX Ultrasound (Philips Medical 
Systems, Andover, MA, USA). During the exams, all standard views and measurements normally 
performed in clinical practice and described by the American Society of Echocardiography (ASE) 
were tried to be achieved. In addition, when an echographic information was not easily achieved by 
standard approaches, additional non-standard views were explored, having the aim, in most of 
cases, to avoid the artifacts related to the pump (especially the ones due to the inflow cannula), or 
to obtain the visualization of inflow and outflow cannula. Images were optimized by modifying the 
gain, brightness, compression, and time-gain compensation settings. Before starting pump speed 
changes, the presence of thrombus in aortic root or left ventricle (LV) was checked. A cardiac 
technician team expert in LVAD management was present during all the examinations. 
 
A standard M-mode examination from parasternal long-axis (PLAX) view as recommended was 
performed. Atria dimensions were measured in apical 4-chambers (4C) view. Aortic valve opening 
status was assessed by M-Mode in parasternal long-axis view putting the sample cursor at the 
level of aortic leaflets and recording the images for more than 5 seconds. LV filling pattern was 
assessed as recommended, and systolic function was assessed by calculating ejection fraction 
from LV end-diastolic and end-systolic volumes (Sympson’s method), when possible, or in 
alternative by integrating visual estimation with Teichholz’s method. Determination of valvular 
regurgitation with color Doppler was attempted first with quantitative methods and than with 
semiquantitative methods (vena contracta for aortic and mitral regurgitation, ratio regurgitant jet/left 
atrium area) made both qualitatively according to the guidelines of ASE (from grade 1 to 4) in all 
views both.  
Regarding RV assessment, in every patient all the RV views were done sistematically:  apical 
(trying to obtain a true, non-foreshortened view) and the parasternal view for RV inflow, PLAX, 
parasternal short-axis (PSAX), and subcostal views, trying to calculate the following parameters, 
following ASE guidelines’ reccomendations: end-diastolic and end-systolic areas and RV diameters 
in the 4C view; RV shortening fraction, two-dimensions lateral tricuspid annular motion (TAPSE), 
RV index of myocardial performance (RIMP), S’ wave at Tissue Doppler (TDI). Then, RV function 
was assessed and qualitatively graded using a four-point grading system (normal, mild, moderate, 
or severly reduced), when at least 2 of the 4 standard predefined RV dysfunction criteria (low 
TAPSE, low RVFAC, low tricuspid s’, or high right ventricular index of myocardial performance, 
using the American Society of Echocardiography cutoffs) were met. Pulmonary artery pressure 
was estimated using the modified Bernoulli formula: [4 (peak systolic tricuspid regurgitation [TR] 
velocity at end-expiration)2] + right atrial pressure estimated by the inferior vena cava diameter as 
well as its response to inspiration, as previously described. Total RV output, (corresponding to the 
sum of HVAD output and the flow ejected by LV) was calculated, as recommended, using the 
formula (RVOT/2) 2 x π x RV flow VTI. RVOT was assessed in the PSAX view at the level of great 
arteries, RV VTI  (velocity-time integral) by pulsed-wave Doppler at the same level. The 
interference of the pump on PW-Doppler signal in the LV outflow tract didn’t allow to calculate LV 
!output. In patients where the aortic valve was closed, as the RV output is supposed to be virtually 
equal to the HVAD output, we compared the RV output with the pump flow estimated by HVAD 
controller, taking in account also eventual valvular regurgitations. 
Inflow cannula was assessed in parasternal long-axis view and apical 4C and 2C views; 
sometimes, off-axis images (i.e. para-longitudinal views) were required.  
Outflow cannula was assessed, to look for the anastomosis with ascending aorta, as previously 
described by others, in right parasternal views (turning the patient to the right side), proceeding 
from the lower to higher intercostal spaces, or by high-left parasternal view; flow velocity in the 
outflow cannula was assessed 1 cm proximal to aortic anastomosis, as previously described in 
Heartmate II-Echo studies. The direction of the flow was also assessed by color-Doppler, and had 
different directions, depending on transducer’s position. 
Pericardial effusion was investigated in all views. 
 
Other data collected 
During the execution of TTE, data from the pump controller were simultaneously collected: flow 
(estimated by considering the hematocrit value of the  day of TTE), power, speed. Blood pressure, 
heart rate were also collected 
 
Study endpoints 
The primary endpoint of this report is the feasibility of performing a measurement normally included 
in a TTE exam; this was defined as the possibility of measuring it and it was verified in every single 
TTE; its values are  expressed as percentage among the total number of  TTE.  
We described also the difficulties encountered in TTE performance across the different 
measurements and the need for specific non standard views. 
The quality of a single measurable echocardiographic parameter was defined using a scale: good 
(grade 2) if the endocardium border was clearly visible in B-mode or if there weren’t significant 
disturbances on Doppler signal; acceptable (grade 1) if myocardium was clearly visible but 
endocardium contour was not completely visible in all wall segments or if significant disturbances 
were present on Doppler signal but allowing data measurement; poor (grade 0) if endocardium 
border was not clearly assessable in most of wall segments or if a Doppler measurement was not 
calculable because of significant interferences.  !
Results: 
 
Feasibility and quality 
The overall exam quality was good in 80% cases. Feasibility was different among various 
echographic parameters, and it is reported in Table 1. In all TTE exams, to calculate some of the 
echocardiographic data, it was necessary to obtain non-standard views; the quality of the data 
achieved is reported in the same Table, evaluated as explained in the Methods’ section. Herein, 
we report insights about the specific need of non standard views. 
 
 
Parameter Feasibility Quality 0 Quality 1 Quality 2 
     
M-Mode of left ventricle 100% 0% 0% 100% 
SAX view 100% 0% 0% 100% 
Left ventricular ejection fraction  
             by Teichholz’s method 
             by Simpson’s method 
 
 
100% 
20% 
 
 
0% 
80% 
 
 
0% 
0% 
 
 
100% 
20% 
Left ventricle filling pattern 100% 0% 50% 50% 
!Aortic valve opening status 100% 0% 0% 100% 
Aortic regurgitation  100% 0% 0% 100% 
Mitral regurgitation (by color 
Doppler) 
100% 0% 0% 100% 
Tricuspidal regurgitation (by 
color Doppler) 
100% 0% 0% 100% 
Systolic pulmonary artery 
pressure 
100% 0% 50% 50% 
Right ventricular areas 100% 0% 30% 70% 
TAPSE 85% 15% 35% 50% 
Right ventricular myocardial 
performance index (MPI) 
85% 15% 40% 60% 
Right ventricular function 100%    
TDI of right ventricle 85% 15% 35% 50% 
PW/CW Doppler of RVOT and 
RV output calculation 
85% 15% 0% 85% 
Inflow cannula visualization 
                 PW Doppler 
100% 
0% 
0% 0% 100% 
Outflow cannula visualization 
                 PW Doppler (when 
visualized) 
95% 
100% 
5% 
0% 
0% 
0% 
95% 
100% 
Left ventricular output  0% 100% 0% 0% 
PW/CW Doppler of aortic valve 0% 100% 0% 0% 
 
Table 1. Feasibility of different echocardiographic parameters 
 
Assessment of parameters of left ventricular unloading.  
Aortic valve opening status (open or closed) was assessable in all patients by B-mode in PLAX 
view; however, given the small openings of the valve observed in some patients and their possible 
underestimation by B-mode, aortic valve status was verified by M-Mode from the PLAX, placing the 
cursor at aortic leaflets’ level (Fig. 1). This allowed to clearly assess valve status (open or closed) 
in all TTE, even if not in all beats (75% overall). Even if aortic valve opening area was not 
calculated, the degree of excursion of the leaflets was, as expected, different among the patients, 
being influenced by mean aortic pressure, pump speed and left ventricular function, thus reflecting 
different support conditions. To assess for support and grade of unloading given by the pump, the 
position of interventricular and interatrial septum were also easily investigated, and than integrated 
with the analysis of pump curves obtainable from HVAD monitor to estimate the degree of pump 
support. In all patients, when pump speed was modified during TTE performance, the change in 
aortic valve opening status (from closed to open or vice versa) and/or in leaflets’ excursion was 
assessed by M-Mode in PLAX view, and corresponding to change in pump flow and curves 
morphology in HVAD monitor.   
 
! 
 
Fig. 1 M-mode analysis of aortic valve: a) assessment of aortic valve opening status by M-
Mode in PLAX, b) continuous aortic regurgitation 
 
 
Doppler examination.  
A comprehensive Doppler assessment (both PW and CW-Doppler) was possible for mitral, 
tricuspid and pulmonary valves in the great majority of cases (Table 1), thus allowing the 
achievement of useful hemodynamic information, such as LV filling pattern and estimated 
pulmonary artery pressure.  
In standard 4C view, a significant “window effect” on color-Doppler signal didn’t allow PW or CW 
Doppler measurements (Fig. 2A).  
 
 
 
Fig. 2 A Standard apical 4 chamber view 
! 
 
 
Fig. 2 B Modified 4 chamber-view 
 
PW-Doppler of mitral valve for evaluation of left ventricle filling pattern was obtained by a 
“modified” 4C view (Fig. 2B), by placing the probe at 1-2 higher intercostal spaces and directed 
more medially than the standard apical approach (1-2 cm from left mid-clavicular line), thus 
allowing filling pattern assessment in 100% of cases (Fig. 3A).  
 
 
 
 
 
Fig. 3 Doppler analysis feasibility: a) filling pattern of left ventricle, b) pulmonary pressure 
assessment c) RV outflow tract Doppler assessment (for RV output calculation) 
 
Figure 3 A. Filling pattern of left ventricle 
 
! 
 
Figure 3 B. Assessment of systolic pulmonary artery pressure 
 
By the same approach, CW Doppler exam of tricuspid valve was possible in 100% of cases, thus 
allowing calculation of estimated systolic pulmonary pressure. 
 
PW and CW Doppler evaluation of aortic valve was not possible in standard fifth-chamber view 
from apical approach. Tilting the probe more upwards from the modified 4-C approach previously 
described, only in a few cases color Doppler evaluation was possible. 
 
Doppler evaluation of pulmonary valve was possible in 85% of cases by the standard PSAX view; 
this allowed to calculate RV acceleration time and right ventricular output (Fig. 3C) . We compared, 
for descriptive purposes, RV output and the pump flow as estimated by the HVAD monitor; results 
are reported in Table 2. As previously described, in patients with a closed aortic valve, without 
significant valvular regurgitations, RV output is theoretically equal to the LVAD output: the two 
values were comparable with a maximal error of 20%.  The greatest differences between the two 
values were more often observed in patients with a concomitant significant valvular regurgitation. 
In the same table, we reported HVAD flow and the RV output estimated by Echo in patients with an 
open aortic valve for descriptive purposes. 
! 
 
Figure 3C. Calculation of right ventricular output through right ventricular outflow tract 
 
 
Patient 
# 
LVAD 
flow 
(l/min) 
RV 
output 
(l/min) 
Aortic 
valve 
status 
AR 
grade 
MR 
grade 
Pump 
speed 
Heart 
rate  
Blood 
pressure 
(mmHg) 
Pump 
power 
(Watts) 
1 4.6 4.8 Closed 1.5 0 2680 71 70 3.9 
2 5.4 5.7 Closed 0 0 2600 95 80 3.8 
3 4.6 4.1 Closed 0 0 2640 62 75 3.7 
4 5.0 3.9 Closed 0 0 2500 72 70 3.4 
5 5.2 5.1 Closed 1.5 2 3000 75 75 5.2 
6 5.3 5.2 Closed 0.5 1 2700 61 80 4.2 
7 6.3 5.2 Closed 1 0 3000 97 90 6.0 
8 5.3 4.8 Closed 2 1 2800 95 88 4.5 
9  5.0 Mostly 
open 
0 0 NA 85 NA NA 
10 4.8 6.6 50% 
open 
0.5 1.5 2800 73 78 4.2 
 
Table 2. Comparison between controller-estimated LVAD-output and right ventricular 
output by Echo 
 
Assessment of valvulopathies.  
Assessment of valvular regurgitations by quantitative methods was never possible. Assessment of 
valvular regurgitation by semiquantitative methods was possible in all cases. Mitral regurgitation 
(MR) was easily visualized by parasternal approaches; however, to avoid interference with inflow 
cannula, it was necessary placing the probe 1-2 intercostal spaces lower than the standard PLAX 
view. At the same way, MR was easier assessed in the “modified” 4C view rather than the 
standard one. 
Aortic regurgitation (AR) assessment  through vena contracta measurement was done in 100% of 
cases by standard PLAX view; by modified 4C view in 50% of cases, AR was assessed. As CW 
and PW Doppler for aortic valve were never possible, quantitative determination of AR was not 
!done. Aortic regurgitation was in most of cases continuous during cardiac cycle (systo-diastolic); 
this could be assessed by color M-mode, and it has been already reported in echocardiographic 
studies involving HM-II (Figures 4A and B). In 4 exams, a flow in red at color Doppler was 
visualized in the medium tract of left ventricle; PW analysis allowed to distinguish if it was due to 
aortic regurgitation or to flow inside inflow cannula. 
Quantification of tricuspidal regurgitation (TR) was made by modified 4C view in 100% of cases; 
when TR was more than mild, it was easily visualized also by projection for right ventricle inflow 
from parasternal view and form short-axis. 
 
 
Fig. 4 A. Aortic regurgitation by PLAX view 
 
 
 
 
Fig. 4 B. Color M Mode of aortic regurgitation 
!Assessment of left ventricular function 
Left ventricular diameters were assessed by standard PLAX in all cases. Clear visualization of 
apical endocardium in standard 4C view was not possible in most cases (80%) , whereas it was 
clearly identifiable in modified 4C view in all cases, even if, in this projection, left ventricular volume 
are probably underestimated. Given the not clear visualization of LV in most of cases, LV ejection 
fraction (LVEF) was calculated by Simpson’s method only in 20% of cases, while in the other 
cases,it was calculated first by Teichholz’s method and then visually estimated.  
 
Assessment of right ventricular function 
All traditional parameters of right ventricular function were calculated from modified 4 C view. Their 
feasibility was high, as reported in Table 2. S wave at Tissue Doppler were easily assessed in 
most cases by 4-chamber view, as well as MPI. The mean value of each parameter is reported in 
Table 3. 
Characterization of overall RV function was possible in 100% of cases; the degree of RV systolic 
impairment was evaluating taking into account all the multiple parameters of RV function possible 
to be measured, as described in the methods section. 
 
 
Visualization of inflow and outflow cannulas 
Inflow cannula was visualized in all patients in PLAX view and in 4-C apical view. A tract of outflow 
cannula was visualized in most patients (95%) anteriorly to right ventricle in the PLAX view or 
anteriorly and laterally to the right ventricle in the 4-C apical view. The anastomosis of outflow 
cannula to ascending aorta was visualized in 80% cases by using or an high-left parasternal view 
(2-3rd intercostal space) or by a right parasternal view, obtained positioning the probe between the  
2nd to the  4th right intercostal space, and turning the patient to right. In all cases in which outflow 
cannula was visualized, it was possible to measure flow velocity by pulsed-wave Doppler. 
Normally, we measured the velocity about 1 cm proximally to the anastomosis between outflow 
cannula and ascending aorta. The velocity spectrum appeared as a negative flow (see Fig.5); 
mean velocity was 135 cm/sec, similar to what declared by Heartware . 
 
 
 
Figure 5A. Visualization of inflow and outflow cannulas by PLAX. Inflow cannula is indicated 
with the circle, outflow cannula with an arrow  
 
 
! 
 
 
Figure 5B. Outflow cannula visualization by right parasternal view  
 
 
 
Figure 5C. Doppler analysis of outflow cannula 
 
Echocardiographic data observed 
For descriptive purposes, we reported in Table 3 the results of echocardiographic measurements 
performed. 
As reported, right ventricular function was impaired in most cases, and aortic regurgitation was 
often present. 
 
  
!Left ventricular M-Mode measurements  
End-diastolic diameter (LVEDD, mm) 
End-systolic diameter (LVESD, mm) 
Septum diastolic thickness (IVSd, mm) 
Septum systolic thickness (IVSs, mm) 
Posterior wall diastolic thickness (LVPWd, mm) 
Posterior wall systolic thickness (LVPWs, mm) 
 
58.8 ± 13.5 
49.0 ± 14.9  
   9.6 ± 1.4 
11.5 ± 2.4 
   9.4 ± 2.8 
13.1 ± 3.2 
Aortic root (mm)    33.8 ± 
Left ventricular ejection fraction (EF,%) 26.1 ± 6.7  
Left ventricle filling pattern 
Normal , n (%) 
Impaired relaxation , n (%) 
Pseudonormal, n  (%) 
Restrictive, n  (%) 
 
  5 (26.3%) 
  3 (15.6%) 
  1 (5.2%) 
10 (52.6%) 
Aortic valve status 
Open (%) 
Mostly open (%) 
Mostly closed (%) 
Closed (%) 
 
  4 (20.8%) 
  1 (5.2%) 
  1 (5.2%) 
13 (67.6%) 
Aortic regurgitation 
None (%) 
Mild (%) 
Moderate (%) 
Severe (%) 
 
12 
5 
2 
0 
Mitral regurgitation 
None (%) 
Mild (%) 
Moderate (%) 
Severe (%) 
 
12 
6 
1 
0 
Tricuspidal regurgitation 
None (%) 
Mild (%) 
Moderate (%) 
Severe (%) 
 
9 
6 
4 
0 
Systolic pulmonary artery pressure (mmHg) 35 ± 10 
Right ventricular end-diastolic area (cm2) 
Increased (%) 
Normal (%) 
 
11 
  8 
TAPSE (mm) 13.3 ± 1.8 
Right ventricular myocardial performance index (MPI)  
Right ventricular function 
Severly reduced , n (%) 
Mildly reduced , n (%) 
Slightly reduced, n (%) 
Normal, n (%) 
 
0 
2 
7 
10 
Pericardial effusion  
No, n (%) 
Mild, n (%) 
 
14 
  5 
 
Table 3. Echocardiographic parameters of the study population 
! 
Discussion: 
This single center small clinical series provides for the first time, to the best of our knowledge, 
insights about the feasibility of a comprehensive transthoracic echocardiographic exam of HVAD, a 
wide implanted intrapericardial pump. Beside the specific echocardiographic data achieved in our 
population, the main information provided by our report is that, even if non-standard views are 
often required to achieve the data normally evaluated in a standard echocardiographic exam, thus 
making overall difficult and perhaps longer its performance, a comprehensive TTE is generally 
possible in patients with an HVAD implanted.  
As already reported in literature, TTE can be helpful in dissecting among the different possible 
causes of complications in LVAD patients, like right ventricular failure or suction. Given the 
considerable information achievable from HVAD monitor system, through analysis of pump flow 
curves and variations over time of flow, power and alarms, the integration of this information with 
TTE data may help in patients’ management.  We could verify that within this cohort of patients, in 
those cases in whom TTE was performed more than one time because of clinical reasons. In one 
case of low flow alarms, with evidence of suction events, TTE confirmed the diagnosis of excessive 
left ventricular unloading, through the visualization of a left-sided interventricular septum and 
dilated right ventricle with a only slightly reduced systolic function, thus excluding a problem of RV 
failure. After a reduction in pump speed and an increase in liquid intake from the patient, a 
subsequent TTE revealed a position of interventricular septum more directed to right, with a 
decrease in RV dimensions and an increase in RV output; accordingly, the pump controller showed 
an increase in estimated flow. In another case, TTE helped in confirming the decision of wean a 
patient from HVAD: monitor has shown an increase in pulsatility and a supposed opening of aortic 
valve in all beats, echocardiography confirmed a permanently open aortic valve and a LV with 
normal diameter and ejection fraction >45%, with trivial mitral regurgitation. Moreover, in most of 
cases the calculation of RV systolic pressure was possible (and well related with RHC?) 
 
In our series, TTE in HVAD achieved the calculation of the standard haemodynamic parameters 
assessing the grade of  the efficacy of LV unloading and the effect of HVAD on pulmonary 
pressures, like left ventricular filling pattern and pulmonary systolic pressure. 
Right ventricle is a crucial player, as recently underlined, in determining the clinical outcome of 
LVAD patients. Clinicians know that RV assessment by TTE is challenging, and of course remains 
so also in this setting of patients. In a recent study (cit.), given the objective difficulty of assessing 
RV function by TTE, it has been suggested to evaluate multiple parameters, like TAPSE, RV 
areas, TEI index. Our study suggests that most of parameters for assessment of RV function can 
be calculated in HVAD patients, thus giving a strong effort in using this technique for specific 
longitudinal studies of RV function along time. Particularly, we stressed the importance of S wave, 
as assessed by TDI, of TAPSE, and of TEI index. In previous larger studies about HM-II patients, S 
wave was found to be one important prognostic marker of RV failure post-LVAD implantation, and 
TEI index may be also affected by the grade of unloading provided by the LVAD. However, their 
prognostic relevance in patients with a centrifugal pump must yet be demonstrated. 
The good relationship between pump-estimated flow and the RV flow calculated by TTE (when the 
aortic valve is closed) also in a centrifugal pump is an important acquisition and may be of interest, 
especially when an evaluation of loading status is needed and a pump controller is not immediately 
available; moreover, one may speculate that it could be useful to calculate RV output even when 
part of the flow is provided through the LV: in this case, the difference between RV output and the 
flow estimated by the controller may give information about the output trough the LV and, indirectly, 
about the residual LV contractility reserve. However, one must also take in account also 
valvulopaties (i.e. aortic regurgitation). 
This study is, to best of our knowledge, the first one assessing the issue of the practice feasibility 
of a complete TTE exam in HVAD. In the literature, most of the available data and studies about 
TTE in patients with an LVAD involve HM-II device. A paper specifically reported a single center 
experience on TTE in HVAD patients, but it provided only information about the visualization of the 
cannulas, and involved 19 patients. Our study provides, with a similar size sample, more detailed 
and comprehensive information.  The lack of reports in literature about TTE feasibility in HVAD is 
difficult to explain. Probably, it could be explained with a general assumption that theoretically one 
!should not expect to observe significant differences are supposed between two continuous-flow 
pumps with respect to echo. However, the intrapericardial implant of HVAD is supposed to 
generate more acoustic problems, and this could explain the scares enrollment of HVAD patients 
into ramp studies. Even if our aim is not to speculate and discuss about TTE differences between 
the two pumps, we observed two main differences with respect to published Echo paper on HM-II: 
the impossibility of achieving a Doppler signal of the inflow cannula and of the aortic valve, thus not 
allowing calculation of left ventricular output, the difficulty in achieving a standard apical 4-C view, 
thus rending necessary a paralongitudinal view. On the other hand, several theoretic similarities 
were also observed: Doppler analysis of outflow cannula, feasibility of achieving hemodynamic 
information. On the other hand, one may speculate a different importance of some TTE parameters 
with respect to the two pumps: an assessment of LV (and/or RV) output by TTE appears to be 
mandatory for HM-II patients, as flow estimation by the controller is less accurate , whereas 
appears to be less important with HVAD, where controller provides a more accurate flow 
estimation.  
 
The artifacts due to the intrapericardial placement of the pump require non-standard 
echocardiographic views, to which the sonographer should become familiar, considering the 
increasing number of ambulatory patients with this device.  
 
Study limitations 
The major study limitations are: limited number of patients, single center study, case-reporting 
design. Moreover, a potentially bias is the patient selection (specifica i criteri di selezione per la 
scelta dei pz nel lavare; guarda anche il lavoro di marcus. However, the aim of our study was 
simply to give a clinical-oriented, practice description of TTE exam in an outpatient setting. Even if 
the number of patients enrolled is small, it is superior to the number of  HVAD patients enrolled in 
single  echocardiographic studies, and  similar to the one reported in another recent 
echocardiographic series about HVAD. 
 
Conclusions: 
This clinical series provides for the first time data about the feasibility of a complete TTE exam in 
HVAD patients, one of the commonly implanted pumps, in a real-world outpatient setting. 
According to our experience, non standard views are required to assess some of the parameters of 
a stan Specific problems and possible tricks are presented. Even if studies enrolling a larger 
sample size are required, we believe that TTE examination of HVAD patients requires pump-
specific expedients, but it is possible and allows complete and useful hemodynamic information in 
the great majority of cases, thus allowing the echo- guided optimization of the pump settings, and 
the study of the complex interaction between the pump, the patient and the heart. 
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